BUPROPION Tablet, Extended Release [Zydus Pharmaceuticals (USA) Inc.]

Updated Date: Feb 18, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Asystole shortly after intravenous fat emulsion for overdose: causation or coincidence?

3 out of 5 stars Asystole Immediately Following Intravenous Fat Emulsion for Overdose. Cole JB et al. J Med Toxicol 2014 Feb 12. [Epub ahead of print] Abstract This case paper describes 2 patients who developed asystolic within 60 seconds of being given intravenous fat emulsion (IFE) bolus for treatment of severe cardiotoxicity. Both patients had return of spontaneous circulation (ROSC) after several minutes of cardiopulmonary resuscitation. Unfortunately, both patients died days after admission from multisystem organ failure. Patient A,  a 50-year-old woman, had ingested an undetermined about of metoprolol and bupropion in a suicide attempt. She seized and then developed bradycardia and hypotension unresponsive to multiple interventions (fluid, glucagon, insulin). Within 30 sec of recei...

Effects of bupropion and pramipexole on cell proliferation in the hippocampus of adrenocorticotropic hormone-treated rats.

In this study, we used the mitotic marker 5-bromo-2'-deoxyridine to investigate the effects of bupropion and pramipexole on cell proliferation in the subgranular zone of the hippocampal dentate gyrus following chronic treatment with ACTH. The ACTH treatment for 14??d decreased adult hippocampal cell proliferation. The chronic administration of bupropion for 14??d blocked the loss of cell proliferation resulting from the chronic treatment with ACTH, whereas pramipexole did not. The administration of bupropion may have treatment-resistant antidepressive properties, which may be partly attributed to the normalization of hippocampal cell proliferation. PMID: 24492730 [PubMed - in process] (Source: Biological and Pharmaceutical Bulletin)

Asystole Immediately Following Intravenous Fat Emulsion for Overdose.

This report adds only case experience, not clarity. We report two cardiac arrests that were temporally associated with IFE. PMID: 24519703 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)

Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors: Crooks PA, Bardo MT, Dwoskin LP Abstract Despite the proven efficacy of current pharmacotherapies for tobacco dependence, relapse rates continue to be high, indicating that novel medications are needed. Currently, several smoking cessation agents are available, including varenicline (Chantix®), bupropion (Zyban®), and cytisine (Tabex®). Varenicline and cytisine are partial agonists at the α4β2* nicotinic acetylcholine receptor (nAChR). Bupropion is an antidepressant but is also an antagonist at α3β2* ganglionic nAChRs. The rewarding effects of nicotine are mediated, in part, by nicotine-evoked dopamine (DA) release leading to sensitization, which is associated with repeated nicotine administration and nicotine addiction. Receptor antagonists that selectivity target ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion and bupropion analogs as treatments for CNS disorders.

Authors: Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI Abstract Bupropion, introduced as an antidepressant in the 1980s, is also effective as a smoking cessation aid and is beneficial in the treatment of methamphetamine addiction, cocaine dependence, addictive behaviors such as pathological gambling, and attention deficit hyperactivity disorder. (2S,3S)-hydroxybupropion is an active metabolite of bupropion produced in humans that contributes to antidepressant and smoking cessation efficacy and perhaps benefits in other CNS disorders. Mechanisms underlying its antidepressant and smoking abstinence remain elusive. However, it seems likely that efficacy is due to a combination of the effects of bupropion and/or its active metabolite (2S,3S)-hydroxybupropion invo...

Smoking Cessation

Cigarette smoking is a major preventable cause of morbidity and mortality. It is the major risk factor for chronic obstructive pulmonary disease in the developed world. Smoking is a chronic relapsing disease. Optimal treatment includes nonpharmacologic support, together with pharmacotherapy. All clinicians should be comfortable with the use of nicotine replacement therapy, bupropion, and varenicline. Second-line therapies can be used by those familiar with their use. Effective use of these medications requires their integration into an effective management plan, which is likely to be a long-term undertaking, involving several cycles of remission and relapse. (Source: Clinics in Chest Medicine)

BUPROPION HYDROCHLORIDE Tablet, Film Coated [BluePoint Laboratories]

Updated Date: Feb 7, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [Jubilant Cadista Pharmaceuticals Inc.]

Updated Date: Feb 3, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [REMEDYREPACK INC. ]

Updated Date: Jan 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [REMEDYREPACK INC. ]

Updated Date: Jan 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The long?term cost?effectiveness of varenicline (12?week standard course and 12 + 12?week extended course) vs. other smoking cessation strategies in Canada

ConclusionsThe standard and extended courses of varenicline are decidedly cost?effective treatment regimes compared with alternative smoking cessation interventions and can provide significant cost savings to the healthcare system. (Source: International Journal of Clinical Practice)

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [Preferred Pharmaceuticals, Inc.]

Updated Date: Jan 29, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL

Title: bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/22/2014 12:00:00 AM (Source: MedicineNet Depression General)

Varenicline may reduce negative effect while aiding smoking cessation

Commentary on: Cinciripini PM, Robinson JD, Karam-Hage M, et al.. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 2013;70:522&ndash;33. Context Cigarette smoking remains the most important cause of preventable morbidity and premature mortality, with projected annual tobacco-attributable deaths worldwide estimated to reach nearly 6.5 million by 2015.1 The most effective treatment for tobacco dependence is combined behavioural and pharmacological therapy, which is widely available yet underemployed. Most attempts to quit smoking are still unaided, and surveys suggest that pharmacological treatment is often n...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Zydus Cadila gets USFDA nod for anti-depressant drug

Drug major Zydus Cadila has received approval from the US health regulator to market Bupropion Hydrochloride extended-release tablets, an anti-depressant medicine, in the American market. (Source: The Economic Times Healthcare and Biotech News)

Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union

Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion may be classified as a dual noradrenaline and dopamine reuptake inhibitor, a difference with potential implications for the treatment of residual sleepiness and fatigue in major depressive disorder (MDD). Post-hoc analysis of subjects with remitted MDD was performed on data pooled from six double-blind, randomized trials comparing the European Union (EU)-approved dose of &le;300 mg/day bupropion with SSRIs (sertraline, paroxetine or escitalopram) for the resolution of sleepiness and fatigue. Hypersomnia score was defined as the sum of scores of the Hamilton Depression Rating Scale (HDRS) items 22, 23, and 24; fatigue score as HDRS item 13 score; and remission as HDRS-17&le;7. Similar proportions of bupropion- and SSRI-treate...

Safety of Varenicline in Patients With Cardiovascular Disease

Smoking cessation lowers the risk of death substantially in patients with cardiovascular disease. Although varenicline is an effective medication for smoking cessation, its safety in this population has been questioned and evaluated in several studies. In 2 randomized controlled trials of patients with cardiovascular disease, the rates of serious cardiovascular events were up to 2% higher in patients receiving varenicline than placebo, though the differences were not statistically significant. In the first meta-analysis of mostly trials involving patients with a history of cardiovascular disease, varenicline was found to significantly increase the risk of cardiovascular events by 72%; however, a second meta-analysis did not find a significant increased risk. In an observational study, vare...

Serotonin Syndrome: Is It a Reason to Avoid the Use of Tramadol With Antidepressants?

Conclusions: Review of the available case reports of tramadol combined with antidepressant drugs in therapeutic doses indicates caution in regard to the potential for SS but does not constitute a contraindication to their use. Tramadol is only contraindicated in combination with MAOIs but not other antidepressants in common use today. These case reports do suggest several factors associated with a greater risk of SS, including increased age, higher dosages, and use of concomitant potent cytochrome P450 2D6 inhibitors. Tramadol can be safely combined with antidepressants; however, monitoring and counseling patients are prudent when starting a new serotonergic agent or when doses are increased. (Source: Journal of Pharmacy Practice)

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [St Marys Medical Park Pharmacy]

Updated Date: Jan 16, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Jan 10, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Drug Combo Boosts Early Quit Rates in SmokersDrug Combo Boosts Early Quit Rates in Smokers

Combining varenicline with bupropion may boost early quit rates compared with varenicline alone; heavier smokers most likely to benefit. Medscape Medical News (Source: Medscape Psychiatry Headlines)

Antidepressants for smoking cessation.

CONCLUSIONS: The antidepressants bupropion and nortriptyline aid long-term smoking cessation. Adverse events with either medication appear to rarely be serious or lead to stopping medication. Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement. Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding. Evidence suggests that neither selective serotonin reuptake inhibitors (e.g. fluoxetine) nor monoamine oxidase inhibitors aid cessation. PMID: 24402784 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

Combined Therapy Benefits Cigarette Smokers Trying to Quit Compared to Monotherapy

ROCHESTER, Minn. ?? Jan. 7, 2014 ?? Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month [...] (Source: Mayo Clinic Research News)

Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration.

This study investigated the ability of agmatine administered orally to abolish the depressive-like behavior induced by the administration of the pro-inflammatory cytokine, tumor necrosis factor (TNF-α) in mice. In control animals, agmatine (0.001, 0.01, 0.1, and 1mg/kg) reduced the immobility time in the tail suspension test (TST). Acute administration of TNF-α (0.001fg/mouse, i.c.v.) increased immobility time in the TST, indicative of a depressive-like behavior, and agmatine (0.0001, 0.1, and 1mg/kg) prevented this effect. Additionally, we examined the effects of the combined administration of sub-effective doses of agmatine with antidepressants, the NMDA receptor antagonist MK-801 and the neuronal nitric oxide synthase inhibitor 7-nitroindazole (7-NI) in mice exposed to either TNF-α o...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDE Tablet, Film Coated, Extended Release [Aidarex Pharmaceuticals LLC]

Updated Date: Jan 2, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE Tablet, Film Coated [Aidarex Pharmaceuticals LLC]

Updated Date: Jan 2, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE SR (SR) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Aidarex Pharmaceuticals LLC]

Updated Date: Jan 2, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Mechanism of an unusual, but clinically significant, digoxin?bupropion drug interaction

This article is protected by copyright. All rights reserved. (Source: Biopharmaceutics and Drug Disposition)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion Linked With Delayed-Onset UrticariaBupropion Linked With Delayed-Onset Urticaria

Bupropion may put patients at risk for delayed-onset urticaria, a nationwide study from Taiwan has shown. Reuters Health Information (Source: Medscape Medical News Headlines)

Naltrexone/Bupropion Combination in Obese Patients With T2DMNaltrexone/Bupropion Combination in Obese Patients With T2DM

Can this antidepressant/opioid receptor antagonist combination product promote weight loss in patients with T2DM? Diabetes Care (Source: Medscape Today Headlines)

A case of hypomania during nicotine cessation treatment with bupropion.

We describe the case of a 67-year-old man known for dysthymic disorder in remission on quetiapine and venlafaxine who experienced a first lifetime episode of hypomania with the introduction of bupropion SR for smoking cessation. To the best of our knowledge, this is the first case report of bupropion-induced mood shift when used specifically for nicotine cessation in a nonbipolar patient. This case highlights the need for clinicians who prescribe bupropion for smoking cessation to perform regular and systematic mood follow-ups during treatment. These follow-ups could even be more important when bupropion is selected to quit smoking in a patient already taking an antidepressant. PMID: 24359680 [PubMed - as supplied by publisher] (Source: Addiction Science and Clinical Practice)

??Real?world?? effectiveness of smoking cessation treatments: a population study

ConclusionsAfter adjusting for major confounding variables such as tobacco dependence, smokers in England who use a combination of behavioural support and pharmacotherapy in their quit attempts have almost three times the odds of success than those who use neither pharmacotherapy nor behavioural support. Smokers who buy nicotine replacement therapy over the counter with no behavioural support have similar odds of success in stopping as those who stop without any aid. (Source: Addiction)

Antidepressant-Induced Liver Injury: A Review for Clinicians.

CONCLUSIONS Although an infrequent event, DILI from antidepressant drugs may be irreversible, and clinicians should be aware of it. Aminotransferase surveillance is the most useful tool for detecting DILI, and prompt discontinuation of the drug responsible is essential. The results of antidepressant liver toxicity in all phases of clinical trials should be available and published. Further research is needed before any new and rigorously founded recommendations can be made. PMID: 24362450 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse.

Conclusions. The issue of bupropion cue generalisation to cocaine needs further elucidation. People with past cocaine addiction need to be informed on the potential of bupropion to elicit cocaine-like cues and be invited to adhere to medical prescription, because bupropion has been associated with fatalities in some cases. PMID: 24334787 [PubMed - in process] (Source: Annali dell'Istituto Superiore di Sanita)

New and Emerging Drug Molecules Against Obesity

Obesity has become a growing pandemic of alarming proportions in the developed and developing countries over the last few decades. The most perturbing fact regarding obesity is the increased predisposition for coronary artery disease, congestive heart failure and sudden cardiac death. The modest efficacy of current anti-obesity agents such as orlistat and the increasing withdrawals of several anti-obesity agents such as sibutramine, rimonabant have led to huge gaps in the pharmacotherapy of obesity. Lorcaserin and Phentermine-topiramate combination (phen-top) are two drugs approved by US FDA in 2012. Lorcaserin, a 5HT2C agonist has moderate efficacy with an acceptable safety profile. Clinical trials with Phen-top have shown a reasonable efficacy but at the cost of risks such as teratogenic...

Serum creatinine elevation caused by bupropion.

Authors: Kinalp C, Kurultak I, Ceri M, Keskinel I PMID: 24343039 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)

'No serious heart risks' linked to smoking cessation therapies

The American Heart Association claims that three different types of smoking cessation therapies do not pose serious heart risks, quashing concerns that certain products may increase the risks of heart attack, stroke or heart-related death.Researchers looked at the results of 63 clinical trials involving 30, 508 people who were quitting smoking using either nicotine replacement gums and patches, the nicotine addiction treatment varenicline (Chantix), or taking the antidepressant bupropion (Wellbutrin), which can reduce cravings and other unwanted withdrawal effects. (Source: Health News from Medical News Today)

Comparison of the Antidepressive Effects of Trans-Resveratrol and 5-Methoxy-7H-dibenzo[de,h]quinolin-7-one.

In this study we evaluate the in vivo antidepressant effect of a natural phenolic compound, trans-resveratrol, and a synthetic derivative from Menispermum dauricum DC (Menispermaceae) 5-methoxy-7H-dibenzo[de,h]quinolin-7-one known as 5-methoxyoxoisoaporphine (OXO 4). The antidepressant-like effect of trans-resveratrol and OXO 4 were evaluated through a Forced Swimming Test (FST), and they were compared with reference antidepressants: imipramine, desipramine, nomifensine, bupropion, nisoxetine, citalopram and moclobemide. Trans-resveratrol (10 mg/kg, intraperitoneally i.p. significantly decreased the immobility time in mouse model of despair test (69.03 ± 8.74 sec) p&lt;0.05, as well as OXO 4 (1mg/kg, i.p. (60.92 ± 11.37 sec); p&lt;0.05. We also evaluate the OXO 4 at 15, 30 and 45 min. af...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Utilization of Evidence-Based Therapy for Acute Coronary Syndrome in High-Income and Low/Middle-Income Countries

In conclusion, patients with ACS in low/middle-income countries were less likely to be revascularized and to receive evidence-based medications at discharge. Further studies are needed to understand the underutilization of procedures and evidence-based medications in low/middle-income countries. (Source: The American Journal of Cardiology)

Cardiovascular Events Associated with Smoking Cessation Pharmacotherapies: A Network Meta-Analysis.

CONCLUSIONS: Smoking cessation therapies do not appear to raise the risk of serious CVD events. PMID: 24323793 [PubMed - as supplied by publisher] (Source: Circulation)

Bupropion response on sleep quality in patients with depression: Implications for increased cardiovascular disease risk

Abstract: Depression could be an independent risk factor for cardiovascular disease. We assessed bupropion response in depressed patients by polysomnography (PSG) and cardiopulmonary coupling (CPC) variables. Nineteen subjects participated in a two-session, two consecutive night PSG protocol. Participants received either placebo or bupropion-SR 150mg, orally, in a randomized, double-blind cross-over fashion on night two. Outcome variables were: sleep stages, REM latency, stable, unstable sleep and very low frequency coupling (VLFC). CPC analysis uses heart rate variability and the electrocardiogram's R-wave amplitude fluctuations associated with respiration to generate frequency maps. Bupropion increased REM latency (p=0.043) but did not impact PSG sleep continuity, architecture and CPC va...

Lipid rescue therapy can interfere with critical lab values

3 out of 5 stars Caution with interpreting laboratory results after lipid rescue therapy. Punja M et al. Am J Emerg Med 2013 Oct;1536.e1-1536.e1 Reference (No abstract available) This case report describes a 54-year-old man who presented to the emergency department after ingesting a suicidal ingestion of diphenhydramine, amitriptyline, and acetaminophen (APAP). On arrival the patient had evidence of cardiotoxicity with unstable vital signs and a prolonged QRS interval (136 msec). His initial aspartate aminotransferase (AST) level was elevated (138 U/L). After treatment with sodium bicarbonate, N-acetylcysteine (NAC), and 20% intravenous lipid rescue therapy (apparently &lt; 2 ml/kg) an AST level was repeated and was undetectable. Based partially on this result, treatment with NAC was st...

[Original Articles] Relationship Between Obesity and Depression: Characteristics and Treatment Outcomes With Antidepressant Medication

Conclusions BMI was related to clinical presentation and prevalence of comorbidities, but not antidepressant outcomes. Lower BMI classes had more psychiatric comorbidities, potentially obscuring the relationship between BMI and antidepressant effects. Trial Registration ClinicalTrials.gov identifier: NCT00590863 (Source: Psychosomatic Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion-SR for Smoking Reduction and Cessation in Alcohol-Dependent Outpatients: A Naturalistic, Open-Label Study.

Conclusion: Bupropion-SR may be helpfulto quit or reduce smoking for recently abstinent AD individuals. PMID: 24218993 [PubMed - as supplied by publisher] (Source: Current Clinical Pharmacology)

Managing tobacco use: the neglected cardiovascular disease risk factor

Cigarette smoking is a major risk factor for cardiovascular disease (CVD) and the leading avoidable cause of death worldwide. Exposure to secondhand smoke (SHS) increases the risk of CVD among non-smokers. Smoking cessation benefits all smokers, regardless of age or amount smoked. The excess risk of CVD is rapidly reversible, and stopping smoking after a myocardial infarction reduces an individual's risk of CVD mortality by 36% over 2 years. Smoking cessation is a key component of primary and secondary CVD prevention strategies, but tobacco use often receives less attention from cardiologists than other risk factors, despite the availability of proven treatments that improve smoking cessation rates. Both psychosocial counselling and pharmacotherapy are effective methods to help smokers qui...

Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study.

Conclusion: Twenty-four weeks of open-label NB32 therapy with dietary and behavioral counseling was associated with improvement in depressive symptoms and reduced body weight in overweight/obese women with MDD. Trial Registration: ClinicalTrials.gov Identifier: NCT00624858. PMID: 24171147 [PubMed] (Source: Primary Care)

Tennessee Health Plan Tobacco Cessation Coverage

ConclusionIn 2012, Tennessee fell short of Healthy People goals for total managed care and comprehensive TennCare coverage of smoking cessation. If Tennessee mandates that all health plans provide full coverage, 481,900 smokers may immediately be in a better position to quit. (Source: Public Health Nursing)

Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.

In this study, the direct inhibitory effect of serum from chronic renal failure (CRF) patients receiving dialysis was evaluated in CYP3A4 (testosterone) and CYP2B6 (bupropion) metabolism assays. Human liver microsomes were incubated with ultrafiltered serum collected pre- and post-hemodialysis from ten CRF patients. Additionally, several uremic toxins were evaluated in the CYP3A4 assay. In only three patients was there a significant decrease or increase in testosterone or bupropion metabolism post-dialysis. Urea, mannitol, guanidine, homocysteine, uridine and creatinine had no effect on CYP3A4 metabolism. CMPF, hippuric acid and p-cresol had IC50 values that fell within CRF patient plasma concentrations. The IC50 values for indoxyl sulfate and indole-3-acetic acid were greater than CRF pla...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes.

CONCLUSIONSNB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes. PMID: 24144653 [PubMed - as supplied by publisher] (Source: Diabetes Care)

bupropion hydrochloride extended release (Forfivo XL)

Title: bupropion hydrochloride extended release (Forfivo XL)Category: MedicationsCreated: 10/16/2013 1:31:00 PMLast Editorial Review: 10/16/2013 1:31:29 PM (Source: MedicineNet Depression General)

Bupropion diversion and misuse in the correctional facility - Hilliard WT, Barloon L, Farley P, Penn JV, Koranek A.

The antidepressant bupropion plays an important role in the treatment of mental health disorders. It is well known that incarcerated individuals are at increased risk of experimenting with psychiatric medications and it is imperative for prescribers and cl... (Source: SafetyLit: All (Unduplicated))

Assessment of Effects of Chronic Hydrogen Sulfide Poisoning on Cytochrome P450 Isoforms Activity of Rats by Cocktail Approach.

Authors: Wang X, Chen X, Chen M, Hu G, Ma J, Pan J, Hu L, Lin G Abstract Hydrogen sulfide (H2S) is one of the neurotoxic gases with suffocating and irritating. Its main target organs of toxic effects are the central nervous system and respiratory system. Cocktail method was used to evaluate the influence of chronic hydrogen sulfide poisoning on the activities of cytochrome P450 (CYP450) isoforms CYP1A2, CYP2C9, CYP2B6 and CYP2D6, which were reflected by the changes of pharmacokinetic parameters of 4 specific probe drugs phenacetin, tolbutamide bupropion and metroprolol, respectively. The experimental rats were randomly divided into two groups, control group and chronic hydrogen sulfide poisoning group. The chronic hydrogen sulfide poisoning group rats were inhaled 20??ppm for 1??...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR?D) trial

This study is a cost-utility analysis (CUA) of different second-line approaches. In a simulated trial outpatients with MDD were treated with citalopram for 13 weeks (level 1), then based on two alternative algorithms implemented from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. : citalopram was continued until study endpoint (week 26). : patients who remitted during level 1 continued citalopram. Those who did not remit could opt for switching to another antidepressant (venlafaxine; sertraline) (b1) or adding bupropion to citalopram treatment (augmentation; b2). increased remission rate by 10.6% over (number needed to treat: 9.9; sensitivity range: 9.1??12.5). As a comparison, differences between active antidepressants and placebo are associated with NNT value...

For smoking cessation in patients with current or past depression varenicline proves safe and effective

Varenicline is safe and effective to help smokers with current or past major depression quit smoking. Approximately half of smokers seeking treatment have a history of depression. This is a clinically important relationship because depression and smoking are among the leading causes of disability and death in the world and having depression makes quitting smoking more difficult. Varenicline has proven more effective than bupropion for smoking cessation, but because of its mechanism of action, there are concerns about the safety of varenicline in patients with psychiatric disorders... (Source: Health News from Medical News Today)

The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders.

CONCLUSIONS Because of limited data, the task force could not make broad statements endorsing antidepressant use but acknowledged that individual bipolar patients may benefit from antidepressants. Regarding safety, serotonin reuptake inhibitors and bupropion may have lower rates of manic switch than tricyclic and tetracyclic antidepressants and norepinephrine-serotonin reuptake inhibitors. The frequency and severity of antidepressant-associated mood elevations appear to be greater in bipolar I than bipolar II disorder. Hence, in bipolar I patients antidepressants should be prescribed only as an adjunct to mood-stabilizing medications. PMID: 24030475 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)

Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events.

CONCLUSIONS This analysis revealed no evidence that varenicline is associated with adverse neuropsychiatric events. The evidence supports the superior efficacy of varenicline relative to both placebo and bupropion, indicating considerable benefit without evidence of risk of serious neuropsychiatric adverse events, in individuals with and without a recent history of a psychiatric disorder. PMID: 24030388 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)

Can E-Cigarettes Help Smokers Quit?

E-cigarettes create controversy and profits - almost equally. New data argue they can help people quit smoking - but will they also promote it?read more (Source: Psychology Today Addiction Center)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The Antidepressants Fluoxetine and Bupropion Differentially Affect Proceptive Behavior in the Naturally Cycling Female Rat

ConclusionsThe motivational components of female sexual behavior are more sensitive than the receptive components to the inhibitory actions of fluoxetine. Bupropion selectively stimulated hopping/darting, while yohimbine lacked an action on female sexual behavior. Ventura?Aquino E and Fernández?Guasti A. The antidepressants fluoxetine and bupropion differentially affect proceptive behavior in the naturally cycling female rat. J Sex Med **;**:**??**. (Source: The Journal of Sexual Medicine)

Pharmacotherapy Effects on Smoking Cessation Vary with Nicotine Metabolism Gene (CYP2A6)

ConclusionsNicotine replacement therapy is effective amongst individuals with fast, but not slow, CYP2A6?defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely affected by nicotine metabolism as estimated from CYP2A6 genotype. The variation in treatment responses amongst smokers with genes may guide future personalized smoking cessation interventions. (Source: Addiction)

Effect of combined naltrexone and bupropion therapy on the brain??s reactivity to food cues

Effect of combined naltrexone and bupropion therapy on the brain&#8217;s reactivity to food cues International Journal of Obesity advance online publication, September 10 2013. doi:10.1038/ijo.2013.145 Authors: G-J Wang, D Tomasi, N D Volkow, R Wang, F Telang, E C Caparelli & E Dunayevich (Source: International Journal of Obesity)

Efficacy of psychostimulant drugs for amphetamine abuse or dependence.

CONCLUSIONS: Results of this review do not support the use of psychostimulant medications at the tested doses as a replacement therapy for amphetamine abuse or dependence. Future research could change this conclusion, as the numbers of included studies and participants are limited and information on relevant outcomes, such as efficacy according to the severity of dependence or craving, is still missing. PMID: 23996457 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice

ConclusionThere is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression. (Source: Addiction)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparison of the behavioral effects of bupropion and psychostimulants.

Authors: Mori T, Shibasaki M, Ogawa Y, Hokazono M, Wang TC, Rahmadi M, Suzuki T Abstract Psychostimulant abuse has been a serious social problem worldwide for a long time. Bupropion, which is used as an antidepressant and to aid smoking cessation in the U.S., is considered to have psychostimulant-like activity. Although activation of the dopaminergic system induces several behavioral effects and bupropion can activate the dopaminergic system, the abuse potential and other behavioral effects of bupropion have not been fully investigated. Therefore, in this study we compared the behavioral effects of bupropion to those of psychostimulants in mice. Both methamphetamine and bupropion induced sensitization to locomotor activity, and cross-sensitized each other. Methamphetamine and bupro...

Tobacco cessation interventions for young people.

CONCLUSIONS: Complex approaches show promise, with some persistence of abstinence (30 days point prevalence abstinence or continuous abstinence at six months), especially those incorporating elements sensitive to stage of change and using motivational enhancement and CBT. Given the episodic nature of adolescent smoking, more data is needed on sustained quitting. There were few trials with evidence about pharmacological interventions (nicotine replacement and bupropion), and none demonstrated effectiveness for adolescent smokers. There is not yet sufficient evidence to recommend widespread implementation of any one model. There continues to be a need for well-designed adequately powered randomized controlled trials of interventions for this population of smokers. PMID: 23975659 [PubMe...

Exploration of 100 commonly used drugs and supplements on cognition in older adults.

CONCLUSIONS: Reported use of common medications is associated with cognitive performance in older adults, but studies are needed to investigate the mechanisms underlying these effects. PMID: 23954027 [PubMed - as supplied by publisher] (Source: The Journal of Alzheimers Association)

Smoking cessation interventions for smokers with current or past depression.

CONCLUSIONS: Evidence suggests that adding a psychosocial mood management component to a standard smoking cessation intervention increases long-term cessation rates in smokers with both current and past depression when compared with the standard intervention alone. Pooled results from four trials suggest that use of bupropion may increase long-term cessation in smokers with past depression. There was no evidence found for the use of bupropion in smokers with current depression. There was not enough evidence to evaluate the effectiveness of the other antidepressants in smokers with current or past depression. There was also not enough evidence to evaluate the group of trials that investigated interventions without specific mood management components for depression, including NRT and psychos...

Relapse prevention interventions for smoking cessation.

CONCLUSIONS: At the moment, there is insufficient evidence to support the use of any specific behavioural intervention to help smokers who have successfully quit for a short time to avoid relapse. The verdict is strongest for interventions focused on identifying and resolving tempting situations, as most studies were concerned with these. Little research is available regarding other behavioural approaches.Extended treatment with varenicline may prevent relapse. Extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed. PMID: 23963584 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Exploration of 100 commonly used drugs and supplements on cognition in older adults

Conclusions: Reported use of common medications is associated with cognitive performance in older adults, but studies are needed to investigate the mechanisms underlying these effects. (Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association)

Understanding the role of cessation fatigue in the smoking cessation process

Abstract: Background: To understand the dynamic process of cessation fatigue (i.e., the tiredness of trying to quit smoking) with respect to its average trend, effect on relapse, time-varying relations with craving and negative affect, and differences among genders and treatment groups.Method: Randomized placebo-controlled clinical trial. Participants received either placebo, monotherapy (bupropion SR, nicotine patch, nicotine lozenge), or combined pharmacotherapy (bupropion SR+nicotine lozenge, nicotine patch+nicotine lozenge). Data were collected from 1504 daily smokers who were motivated to quit smoking. The participants completed baseline assessments and ecological momentary assessments for 2 weeks post-quit.Results: Cessation fatigue reduced the likelihood of 6-month post-quit abstine...

Influence of a Dopamine Pathway Additive Genetic Efficacy Score on Smoking Cessation: Results from Two Randomized Clinical Trials of Bupropion

ConclusionsA score based on functional polymorphisms relating to dopamine pathways appears to predict lapse to smoking following a quit attempt, and the association is mitigated in smokers using bupropion. (Source: Addiction)

Telephone counselling for smoking cessation.

CONCLUSIONS: Proactive telephone counselling aids smokers who seek help from quitlines. Telephone quitlines provide an important route of access to support for smokers, and call-back counselling enhances their usefulness. There is limited evidence about the optimal number of calls. Proactive telephone counselling also helps people who receive it in other settings. There is some evidence of a dose response; one or two brief calls are less likely to provide a measurable benefit. Three or more calls increase the chances of quitting compared to a minimal intervention such as providing standard self-help materials, or brief advice, or compared to pharmacotherapy alone. PMID: 23934971 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

Effects of bupropion on cognitive performance during initial tobacco abstinence

We examined whether bupropion would attenuate abstinence-induced cognitive deficits on the first day of a brief quit attempt, when smokers are most likely to relapse.Methods: Smokers (N=24) with high quit interest were recruited for within-subjects cross-over test of bupropion vs placebo on ability to abstain during separate short-term practice quit smoking attempts. After introduction to working memory (N-back) and sustained attention (continuous performance task; CPT) tasks during the pre-quit smoking baseline, performance on these tasks was assessed after abstaining overnight (CO (Source: Drug and Alcohol Dependence)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Involvement of the monoaminergic system in the antidepressant-like activity of chromium chloride in the forced swim test.

Authors: Piotrowska A, Siwek A, Wolak M, Pochwat B, Szewczyk B, Opoka W, Poleszak E, Nowak G Abstract Bio-metal chromium(III) is a crucial microelement for the proper functioning of living organisms. Previous preclinical and clinical studies reported its potential antidepressant properties. The aim of the present study was to examine the effect of antidepressants and noradrenergic and dopaminergic receptor antagonists on chromium chloride (CrCl3) activity in the forced swim test (FST) in mice and rats. Imipramine (5 mg/kg), fluoxetine (5 mg/kg) and reboxetine (5 mg/kg) but not bupropion (1 mg/kg), administered jointly with CrCl3 at a dose of 6 mg/kg, reduced the immobility time in the FST in mice. The reduction of the immobility time induced by the active dose (12 mg/kg) of CrCl3 w...

[Antidepressants in epilepsy].

Authors: Castano-Monsalve B Abstract Depression is a common condition in patients with epilepsy that entails a deterioration of the quality of life of this population and that, therefore, requires appropriate treatment. The potential risk of antidepressants in relation to the seizure threshold is overestimated by many professionals, and this has an influence when it comes to making the decision to treat them. It sometimes means that the patients do not receive antidepressant drugs. In this regard, the aim of this review is to present the current state of the art in terms of the safety of antidepressants in patients with epilepsy. A search of the medical literature was conducted and, following its analysis, the most significant results are presented. Current information indicates th...

Randomized trial of NRT, bupropion, and NRT plus bupropion for smoking cessation: effectiveness in clinical practice

ConclusionThere is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy (NRT) and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than NRT for smokers with a history of depression. (Source: Addiction)

Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats

Conclusions: The data indicate that the cardiovascular effects of nicotine and nicotine-like agents are mediated through receptor mechanisms that are distinct from those that mediate the central effects of nicotine. (Source: Drug and Alcohol Dependence)

Table of Contents

Abstract Use of valproate while pregnant increases child's autism risk SSRI exposure in utero linked to autism in children Pneumonia risk associated with typical versus atypical antipsychotics in nursing home residents Results conflict with FDA warning on high?dose citalopram Risk of Clostridium difficile infection with antidepressants? Editor's Commentary: DSM?5: Implications for psychopharmacology Benzodiazepine augmentation does not improve schizophrenia symptoms Bupropion effective for smoking treatment nonresponders Aripiprazole once?monthly assessed for schizophrenia d?Cycloserine augments CBT for social anxiety Clonidine improves gating deficits in patients with schizophrenia Psychostimulants for negative symptoms of schizophrenia FDA drug safety communication: Long?acting...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion Reduces the Inflammatory Response and Intestinal Injury Due to Ischemia-Reperfusion

Abstract: Intestinal ischemia-reperfusion (I/R) causes severe organ failure and intense inflammatory responses, which are mediated in part by the cytokine tumor necrosis factor-alpha (TNF-alpha). Bupropion is an antidepressant known to inhibit TNF-alpha production. We sought to examine the protective effects of bupropion on intestinal I/R injury in 15 male Sprague-Dawley rats that were randomized to sham surgery, 45 minutes of intestinal ischemia followed by 180 minutes reperfusion, or bupropion (100 mg/kg) before the intestinal I/R injury. To evaluate the systemic inflammatory response induced by intestinal I/R, we measured serum levels of TNF-alpha, interleukins-1 and -6, lipid peroxidation, and transaminases. Histologic analysis evaluated intestinal injury using the Chiu muscosal injury...

Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery.

CONCLUSIONS: Several variables previously associated with poorer weight loss after RYGB surgery including age, baseline BMI, and type 2 diabetes were replicated. Several others suggest possible clinical interventions for post-operative management of RYGB patients to improve weight loss outcomes. PMID: 23804287 [PubMed - as supplied by publisher] (Source: Obesity)

Bupropion Diversion and Misuse in the Correctional Facility

This article concludes that in the incarcerated population, bupropion is a medication with significant misuse and diversion potential. (Source: Journal of Correctional Health Care)

Sensitivity and Specificity of A Procedure for Early Human Screening of Novel Smoking Cessation Medications

ConclusionsAssessing days abstinent during 1 week of use of medication versus placebo in a cross?over design could be a useful early Phase 2 study design for discriminating between medications useful vs not useful in aiding smoking cessation. (Source: Addiction)

Effect of Repeated Wuniu Early Tea Administration on the CYP450 Activity Using a Cocktail Method

RA Xu, ZS Xu, GY Lin, LF Hu, XQ Wang, JS MaIndian Journal of Pharmaceutical Sciences 2013 75(1):94-98Wuniu early tea (Camellia sinensis) is an important beverage consumed in China. Up to date, a lot of methods for identifying and chemical analysing have been done. However, there is no report on the effects of Wuniu early tea on cytochrome P450 isozymes. Therefore, the present objective of our study was to evaluate the potential effects of Wuniu early tea on cytochrome P450 isozymes P2C9, P1A2, P2C19 and P2B6 in rats with a cocktail approach including, matching probe drugs of tolbutamide, phenacetin, omeprazole and bupropion. These four probe drugs were simultaneously administered to rats after repeated Wuniu early tea administration. The pharmacokinetics of the probes in the plasma was sim...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.

Authors: Bae SH, Kwon MJ, Choi EJ, Zheng YF, Yoon KD, Liu KH, Bae SK Abstract The present study was performed to evaluate the potency and specificity of sibutramine as an inhibitor of the activities of nine human CYP isoforms in liver microsomes. Using a cocktail assay, the effects of sibutramine on specific marker reactions of the nine CYP isoforms were measured in human liver microsomes. Sibutramine showed potent inhibition of CYP2B6-mediated bupropion 6-hydroxylation with an IC50 value of 1.61 μM and Ki value of 0.466 μM in a competitive manner at microsomal protein concentrations of 0.25 mg/ml; this was 3.49-fold more potent than the typical CYP2B6 inhibitor thio-TEPA (Ki = 1.59 μM). In addition, sibutramine slightly inhibited CYP2C19 activity (Ki = 16.6 μM, noncompetitive ...

SSRI-Related Modulation of Sexual Functioning is Predicted by Pre-treatment Resting State Functional Connectivity in Healthy Men.

Authors: Metzger CD, Walter M, Graf H, Abler B Abstract Sexual dysfunction related to treatment with selective serotonin reuptake inhibitors (SSRIs) is a common reason for discontinuation of otherwise effective antidepressant treatment regimens. Thus, identification of subjects at risk for this side effect remains a crucial challenge. After demonstrating task-related neural correlates of impaired sexual functioning under treatment with the SSRI paroxetine (Abler et al., 2011), we studied (1) if resting state brain function before treatment predicts subsequent development of treatment-related modulation of sexual function, and (2) which neural circuits relate to different aspects of the impairment. Effects of paroxetine and bupropion administration over 1 week on subjective sexual ...

Bupropion-induced hyponatremia

Abstract: Although hyponatremia has been reported with the use of various antidepressants, the association of hyponatremia with bupropion has been limited to two case reports. In this case report, we present the case of a 75-year-old man who developed hyponatremia with the use of bupropion, which improved with stoppage of bupropion. (Source: General Hospital Psychiatry)

Bupropion Drug Profile

Bupropion is an antidepressant, also sold as Zyban to help people quit smoking. The brand name of the antidepressant form is Wellbutrin. Here are important facts about bupropion HCl. (Source: About.com Bipolar Disorder)

Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database

Conclusions This novel approach identified sizeable and easily definable groups of patients who are systematically failing to receive support for smoking cessation in primary care. Association rule mining can be used to identify key numerically important groups at high or low risk of receiving treatment and hence potentially to improve healthcare delivery. (Source: Tobacco Control)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Wellbutrin / Zyban / Bupropion Side Effects

Bupropion is marketed under the brand names Wellbutrin (as an antidepressant) and Zyban (for smoking cessation). Common side effects include constipation, loss of appetite, dry mouth, and trembling or shaking. Other side effects may be more severe. (Source: About.com Bipolar Disorder)

Information about Some of the Newer &#039;Atypical&#039;...

Information about some of the newer 'atypical' antidepressants - Buspar buspirone Desyrel trazodone Effexor venlafaxine Remeron mirtazapine Serzone nefazodone Wellbutrin bupropion. (Source: About.com Mental Health)

Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses.

CONCLUSION: The available meta-analytic literature does not cover questions of essential clinical relevance for adults with ADHD. PMID: 23739183 [PubMed - as supplied by publisher] (Source: CNS Spectrums)

Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence

Conclusions: Bupropion and methylphenidate antagonize the effects of methamphetamine in vitro and may be potential candidates for the treatment of stimulant addiction. However, drugs that very potently antagonize the effect of methamphetamine are likely to also exhibit considerable abuse liability (MDPV??>??methylphenidate??>??bupropion). (Source: BMC Research Notes)

Characterizing the interaction between enantiomers of eight psychoactive drugs and highly sulfated-β-cyclodextrin by counter-current capillary electrophoresis.

Authors: Asensi-Bernardi L, Escuder-Gilabert L, Martín-Biosca Y, Sagrado S, Medina-Hernández MJ Abstract The estimation of apparent binding constants and limit mobilities of the complexes of the enantiomers that characterize the interaction of enantiomers with chiral selectors, in this case highly sulfated β-cyclodextrin, was approached using a simple and economic electrophoretic modality, the complete filling technique (CFT) in counter-current mode. The enantiomers of eight psychoactive drugs, four antihistamines (dimethindene, promethazine, orphenadrine and terfenadine) and four antidepressants (bupropion, fluoxetine, nomifensine and viloxazine) were separated for the first time for this cyclodextrin (CD). Estimations of thermodynamic and electrophoretic enantioselectivies wer...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial.

CONCLUSIONS: Bupropion and smoking cessation counseling are underutilized even when provided within the context of a randomized trial. Future research is needed to examine strategies for improving treatment utilization among African American smokers. Trial Registration No. NCT00666978 ( www.clinicaltrials.gov ). PMID: 23733379 [PubMed - as supplied by publisher] (Source: Annals of Behavioral Medicine)

Mechanism of Autoinduction of Methadone N-Demethylation in Human Hepatocytes.

CONCLUSIONS:Methadone caused concentration-dependent autoinduction of methadone N-demethylation in human hepatocytes, related to induction of CYP2B6 and CYP3A4 mRNA expression, protein expression, and catalytic activity. Induction was related to pregnane X receptor but not constitutive androstane receptor activation. These in vitro findings provide mechanistic insights into clinical autoinduction of methadone metabolism and clearance. PMID: 23733841 [PubMed - as supplied by publisher] (Source: Anesthesia and Analgesia)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

Updated Date: May 30, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pharmacological means of reducing human drug dependence: A selective and narrative review of the clinical literature

Abstract Substance abuse or addictive disorder is a global problem. A greater understanding of the associated changes in brain pathophysiology support the notion that pharmacological treatments are part of the necessary treatment options. Craving is a core symptom of addictive disorder; it refers to a strong desire to use drugs again either to re?experience positive effects or to diminish negative experiences. Currently there are a number of medicines that are effective in the treatment of addictive disorders. These medications can either be for substitution (same pharmacological effect as the abused substance) or anticraving (decrease the craving of the abused substance). In this MEDLNE based review, we select specific compounds (naltrexone, acamprosate, topiramate, disulfiram, baclofen...

Behavioral characteristics and pharmacological manipulations of a nicotine-entrainable circadian oscillator.

Authors: Gillman AG, Leffel JK, Kosobud AE, Timberlake W Abstract Chronic daily administration of nicotine and other drugs of abuse has been found to entrain pre- and post-drug circadian locomotor activity episodes that oscillate on a 24-h schedule and persist for several days after administration ceases. This drug-entrainable oscillator system could conceivably lead to circadian rhythms of drug seeking and drug use in human drug addicts. The present study (1) characterizes the ability of daily nicotine administration to entrain circadian wheel-running activity episodes in rats across a range of doses, lighting schedules, and food access; and (2) tests whether pre- and post-nicotine episodes can be altered through pharmacological manipulations. Adult female rats were housed in whee...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Managing depression in patients with advanced heart failure awaiting transplantation.

CONCLUSION: Key considerations in antidepressant selection in the context of advanced HF include HF-related changes in drug pharmacokinetics that may affect initial dosing or dosage adjustment, possible drug interactions, adverse effects that may potentiate those induced by immunosuppressants added after transplantation, and tolerability issues. PMID: 23640347 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

Characterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system

Conclusions: This suggests that the B0AT3 transporter have a role in regulation of monoaminergic as well as glutamatergic synapses. (Source: BMC Neuroscience - Latest articles)

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals]

Updated Date: May 3, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch.

CONCLUSIONS It is possible to rescue a significant portion of smokers who would have failed to achieve abstinence if left on nicotine patch alone by identifying these smokers before their quit date and implementing adaptive changes in treatment. PMID: 23640009 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)

Intravenous lipid emulsion to reverse acute drug toxicity in pediatric patients.

CONCLUSIONS: There is an increasing interest in use of intravenous lipid emulsions to treat life-threatening toxicity from several lipophilic drugs in adults and children. Although most of the literature describes adult cases, intravenous lipid emulsion has been used in neonates and adolescents, with generally positive outcomes. Given the life-threatening, sometimes near-death situations in which an intravenous lipid emulsion is typically used after conventional resuscitation is unsuccessful and the dramatic positive response to this therapy in most published cases, its use likely will continue. Continued reporting of pediatric cases will guide the optimal use and safety profile of intravenous lipid emulsion for the emergent reversal of drug toxicity. PMID: 23613099 [PubMed - in proces...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Serotonergic drugs for depression and beyond.

Authors: Stahl SM, Lee-Zimmerman C, Cartwright S, Ann Morrissette D Abstract The current generation of antidepressant drugs acts predominantly by targeting the serotonin transporter (SERT). The original trend to do this selectively (e.g., with SSRIs or selective serotonin reuptake inhibitors) has given way to combining various additional pharmacologic mechanisms with SERT inhibition, including dual actions by single drugs (e.g., SNRIs or serotonin norepinephrine reuptake inhibitors), or by augmenting SSRIs with a second drug of a different mechanism (e.g., bupropion with dopamine and norepinephrine reuptake inhibition; trazodone with 5HT2A antagonism; mirtazapine with 5HT2A/5HT2C/5HT3/alpha2 antagonism; buspirone or some atypical antipsychotics with 5HT1A partial agonism; other aty...

Coping with urges to smoke: what is a clinician to do?

Authors: Modesto-Lowe V, Chmielewska A Abstract Cigarette smoking is a public-health problem associated with significant morbidity and mortality. Effective medications such as nicotine replacement therapy (NRT), bupropion, and varenicline can assistwith nicotine withdrawal and facilitate smoking cessation. In order to sustain abstinence, however, a smoker must also disrupt strong behavioral associations with smoking. Behavioral strategies complement pharmacotherapy by enhancing the smoker's motivation to quit and teaching quitting skills such as managing relapse triggers (e.g. negative emotions, urges to smoke). Despite these therapies, long-term cigarette abstinence rates are modest for each attempt to quit. However, many smokers who are persistent in their efforts eventually quit...

Teen girls less successful than boys at quitting meth in UCLA pilot research study

A UCLA-led study of adolescents receiving treatment for methamphetamine dependence has found that girls are more likely to continue using the drug during treatment than boys, suggesting that new approaches are needed for treating meth abuse among teen girls. &nbsp; Results from the study, conducted by the UCLA Center for Behavioral and Addiction Medicine and the community-based substance abuse treatment program Behavioral Health Services Inc., are published in the April edition of the Journal of Adolescent Health.&nbsp; &nbsp; "The greater severity of methamphetamine problems in adolescent girls compared to boys, combined with results of studies in adults that also found women to be more susceptible to methamphetamine than men, suggests that the gender differences in methamphetamine addict...

A Non-Epileptiform Event in the Course of rTMS: A Case for Close Physician Monitoring

We present the following case to demonstrate the importance of having physician supervision of patients undergoing repetitive transcranial magnetic stimulation (rTMS) treatments. The patient was a married 60-year-old male with a diagnosis of Major Depressive Disorder and Generalized Anxiety Disorder who had continuous symptoms of depression since the early 1980s despite receiving at least 7 adequate antidepressant treatments. The patient had several comorbid medical conditions. The patient did not have any previous history of seizure, stroke, an abnormal EEG, head injury, neurosurgical procedure, implanted devices, frequent headaches, or a neurologic illness. In addition, there was no family history of epilepsy. The patient's medications included bupropion XL 300 mg, diazepam 10 mg every...

Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits

Conclusions: Our results suggest that this model is a relevant tool to study the pathophysiology of motor and non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease. (Source: Molecular Neurodegeneration)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Genotoxicity of 2-bromo-3'-chloropropiophenone.

Authors: Meng F, Yan J, Li Y, Fu PP, Fossom LH, Sood RK, Mans DJ, Chu PI, Moore MM, Chen T Abstract Impurities are present in any drug substance or drug product. They can be process-related impurities that are not completely removed during purification or are formed due to the degradation of the drug substance over the product shelf-life. Unlike the drug substance, impurities generally do not have beneficial effects and may present a risk without associated benefit. Therefore, their amount should be minimized. 2-Bromo-3'-chloropropiophenone (BCP) is an impurity of bupropion, a second-generation antidepressant and a smoking cessation aid. The United States Pharmacopeia recommends an acceptable level for BCP that is not more than 0.1% of the bupropion. Because exposure to genotoxic i...

Pharmacotherapy of amphetamine?type stimulant dependence: An update

Conclusion.After over 20 years of efforts worldwide to develop a broadly effective medication for dependence on methamphetamine? or amphetamine?type stimulants, no candidate has emerged. This highlights the need for new compounds, consistent and stringent research methods, better integration between preclinical and clinical stages of medication development, and improved collaboration between government, industry and researchers. [Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine?type stimulant dependence: An update. Drug Alcohol Rev 2013] (Source: Drug and Alcohol Review)

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Dispensing Solutions, Inc.]

Updated Date: Apr 9, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

Updated Date: Apr 8, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

The effects of combination naltrexone/bupropion therapy on body composition and visceral adipose tissue (VAT) mass were examined in a subset (n??=??107) of obese subjects from a Phase 2 trial that compared the efficacy and safety of placebo, naltrexone monotherapy, bupropion monotherapy or one of three naltrexone/bupropion dose combinations for 24??weeks. Body composition data were obtained using dual?energy X?ray absorptiometry and computed tomography. Eighty subjects completed the substudy. Naltrexone/bupropion resulted in weight loss and a greater reduction in body fat (??14.0??±??1.3%) than placebo (??4.0??±??2.0%), naltrexone monotherapy (??3.2??±??2.5%) and bupropion monotherapy (??4.1??±??2.9%; all p??&lt;??0.01). Reduction in VAT mass was also greater with ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity.

CONCLUSIONS Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments. PMID: 23558394 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)

Use of varenicline versus bupropion and risk of psychiatric adverse events

ConclusionsIn Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in?patient admission was not significantly higher with varenicline use compared with bupropion. (Source: Addiction)

High-performance liquid chromatographic enantioseparation of (RS)-bupropion using isothiocyanate-based chiral derivatizing reagents.

Authors: Bhushan R, Batra S Abstract A high-performance liquid chromatographic (HPLC) method for enantioseparation of bupropion was developed using two isothiocyanate-based chiral derivatizing reagents, (S)-1-(1-naphthyl) ethyl isothiocyanate, (S)-NEIT, and (R)-α-methyl benzyl isothiocyanate, (R)-MBIT. The diastereomers synthesized with (S)-NEIT were enantioseparated by reversed-phase HPLC using gradient elution with mobile phase containing water and acetonitrile, whereas diastereomers synthesized with (R)-MBIT were enantioseparated using triethyl amine phosphate buffer and methanol. Derivatization conditions were optimized and the method was validated for accuracy, precision and limit of detection. The limit of detection was found to be 0.040-0.043 µg/mL for each of the diastere...

Stop-Smoking Drugs Not Equal in Real Life (CME/CE)

(MedPage Today) -- Varenicline (Chantix) may hold some longer-term advantages for smoking cessation compared with bupropion (Zyban, others), according to a community-based trial. (Source: MedPage Today Psychiatry)

Treatment for Tobacco Dependence: Effect on Brain Nicotinic Acetylcholine Receptor Density

Authors: Arthur L Brody, Alexey G Mukhin, Stephanie Shulenberger, Michael S Mamoun, Maggie Kozman, Jonathan Phuong, Meaghan Neary, Trinh Luu & Mark A Mandelkern Keywords: Addiction & Substance Abuse; Biological Psychiatry; Bupropion; Cognitive-Behavioral Therapy; Imaging; Clinical or Preclinical; Nicotine; Nicotinic Acetylcholine Receptor; Psychiatry & Behavioral Sciences; Tobacco Dependence (Source: Neuropsychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

An increased rate of smoking among subjects with schizophrenia contributes to multiple negative health effects including higher rates of coronary heart disease, hypertension, respiratory disease and lung cancer than the general population (). Studies of nicotine cessation or reduction in schizophrenia have focused on a limited armamentarium of pharmacologic agents showing modest effects. Varenicline is a recent smoking cessation agent with potent partial agonism of the α4β2 and full agonism of the α7 nicotinic acetylcholine receptor; it may also activate the β4 nicotinic acetylcholine receptor (). Despite early reports of varenicline's exacerbation of psychiatric symptoms () leading to FDA issuance of black box warning, several recent studies provide evidence for its safety and effecti...

Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice

Abstract Strategies for assisting smoking cessation include behavioural counselling to enhance motivation and to support attempts to quit and pharmacological intervention to reduce nicotine reinforcement and withdrawal from nicotine. Three drugs are currently used as first?line pharmacotherapy for smoking cessation: nicotine replacement therapy, bupropion, and varenicline. Compared to placebo, the drug effect varies from 2.27 (95% CI 2.02?2.55) for varenicline, to 1.69 (95% CI 1.53?1.85) for bupropion, and to 1.60 (95% CI 1.53?1.68) for any form of nicotine replacement therapy. Despite some controversy regarding the safety of bupropion and varenicline, regulatory agencies consider these drugs as having a favourable benefit/risk profile. However, given the high rate of psychiatric c...

Combined antidepressants: clinical experience.

CONCLUSION: Adding or combining antidepressant medications has advantages for the speed of onset and maintaining the existing response. More rigorous clinical trials comparing combination therapy with monotherapy and for the development of rational treatment guidelines are required. PMID: 16307617 [PubMed - indexed for MEDLINE] (Source: Acta Psychiatrica Scandinavica Supplementum)

Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange

We present a pediatric case of DRESS syndrome associated with either lamotrigine or bupropion, leading to multiorgan involvement and life-threatening complications of respiratory failure and cardiac arrest. After failing to improve with removal of these medications and administration of systemic corticosteroids, our patient showed dramatic, sustained clinical response to therapeutic plasma exchange. To our knowledge, this is the first reported case of therapeutic plasma exchange used for life-threatening DRESS syndrome in a pediatric patient. This case suggests needed research for this therapeutic option in life-threatening DRESS syndrome resistant to high-dose steroids. (Source: PEDIATRICS)

Use of Varenicline vs Bupropion and Risk of Psychiatric Adverse Events

ConclusionsIn Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or inpatient admission is not significantly higher with varenicline use compared with bupropion. (Source: Addiction)

Intranasal bupropion abuse: case report.

Authors: Yoon G, Westermeyer J PMID: 23414507 [PubMed - in process] (Source: American Journal on Addictions)

An Unusual Case of Chronic Diarrhea

Question: An 80-year-old man with a history of Henoch??Schonlein purpura at the age of 59 requiring partial jejunal resection, coronary artery disease, chronic kidney disease, gout, gastroesophageal reflux disease, and prior cholecystectomy was admitted for 2 weeks of guaiac-positive watery brown diarrhea and dehydration. Medications included aspirin 81 mg/d, clopidogrel, aldactazide, furosemide, hydralazine, isosorbide mononitrate, metoprolol, simvastatin, lansoprazole, allopurinol, trazodone, and tamsulosin. He had switched from citalopram to bupropion 2 weeks prior. He was afebrile and hemodynamically stable. His abdomen was distended and tympanitic, with normal bowel sounds and tenderness to palpation over the epigastrium and periumbilical area, but no peritoneal signs. Laboratory eva...

pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery.

Authors: Balogh GT, Müller J, Könczöl A Abstract In the present study we validated a widely used, high-throughput in vitro permeability model (PAMPA) to be used at the early stage of drug discovery for the phospholipidosis (PLD) prediction of drug-like compounds. Regarding the mechanism of action of PLD, our pH-gradient PAMPA system is the first noncell based model to mimic one-way transport of cationic amphiphilic drugs (CADs) from cytosol to the lysosome. Moreover, due to the fact that PLD can mainly occur in lung, liver, brain, kidney and heart, we have used similar commercially available original tissue-derived lipid fractions (heart, liver, brain), and in the case mimicking membrane of kidney and lung tissue we prepared tissue-mimetic artificial lipid mixtures in house. Met...

Hypokalemia Secondary to Bupropion Sustained Release Overdose

Journal of Child and Adolescent Psychopharmacology Feb 2013, Vol. 23, No. 1: 57-60. (Source: Journal of Child and Adolescent Psychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUDEPRION (Bupropion Hydrochloride) Tablet, Extended Release [Bryant Ranch Prepack]

Updated Date: Feb 8, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Preferred Pharmaceuticals, Inc]

Updated Date: Feb 6, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Reward responsiveness and fatigue in multiple sclerosis

Discussion: Reward responsiveness was linked with MS-related fatigue and might represent one of its key cognitive underpinnings. Our results suggest that evaluation of reward responsiveness could provide useful information to guide individualized therapy of MS-related fatigue. (Source: Multiple Sclerosis)

Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions.

Authors: Mayumi K, Hanioka N, Masuda K, Koeda A, Naito S, Miyata A, Narimatsu S Abstract The common marmoset is a promising species for evaluating the safety of drug candidates. To further understand the capacity for drug metabolism in marmosets, a cDNA encoding a CYP2B enzyme was cloned from the total RNA fraction of marmoset liver by 3'- and 5'-RACE methods. Nucleotide and deduced amino acid sequences showed 90.8 and 86.2% identity, respectively, with human CYP2B6. The marmoset CYP2B6 (marCYP2B6) protein was expressed in insect cells, and its enzymatic properties were compared with those of human (humCYP2B6) and cynomolgus monkey (cynCYP2B6) orthologs in liver and insect cell microsomes. Enzymatic functions were examined for the oxidation of 7-ethoxy-4-(trifluoromethyl)coumarin (...

Choosing a Generic AntidepressantChoosing a Generic Antidepressant

With one generic bupropion formulation recently withdrawn, how can clinicians best select from among the remaining options? FDA on Medscape (Source: Medscape Today Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Novel CYP2B6 Enzyme Variants in a Rwandese Population: Functional Characterization and Assessment of in silico Prediction Tools

Abstract Cytochrome P450 CYP2B6 is a highly polymorphic enzyme that metabolizes numerous drugs, pesticides, and environmental toxins. Sequence analysis of a Rwandese population identified eight functionally uncharacterized non?synonymous variants c.329G&gt;T (p.G110V), c.341T&gt;C (p.I114T), c.444G&gt;T (p.E148D), c.548T&gt;G (p.V183G), c.637T&gt;C (p.F213L), c.758G&gt;A (p.R253H), c.835G&gt;C (p.A279P), c.1459C&gt;A (p.R487S) and five novel alleles termed CYP2B6*33 to CYP2B6*37 were assigned. Recombinant expression in COS?1 cells and functional characterization using the antidepressant bupropion and the antiretroviral efavirenz as substrates demonstrated complete or almost complete loss?of?function for variants p.G110V, p.I114T, p.V183G, and p.F213L, while p.E148D, p.R253H, p.A279...

Antidepressant link to heart changes confirmed

Conclusion This study shows a link between three antidepressants (two SSRIs and one tricyclic) and prolonged QT interval (a risk factor for rare but serious heart rhythm problems). The study did not assess the risk of these heart rhythm problems directly (which is difficult to measure because of their rarity). The researchers point out that the recent FDA warning over the risks of citalopram was based on its association with prolonged QT interval only, and ??in spite of the epidemiological data showing no difference in risk for arrhythmia [heart rhythm abnormality]?. The researchers say that certain SSRIs were not significantly associated with risk of prolonged QT interval, and that these medications may be preferable treatment options for people with other cardiac risk factors. Althoug...

Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction: A Randomized, Placebo-Controlled Trial

Conclusions: Two-thirds of patients return to smoking by 12 months after AMI. Bupropion is well tolerated and seems to be safe to use in the immediate post-AMI period. However, bupropion is not effective for smoking cessation in patients post-AMI. (Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial; NCT00689611) (Source: Journal of the American College of Cardiology)

Smoking-Cessation Drug Not Effective in the Post-AMI SettingSmoking-Cessation Drug Not Effective in the Post-AMI Setting

Although safe and well tolerated in the immediate post-AMI period, treatment with bupropion failed to halt cigarette smoking, as more than two-thirds returned to smoking by 12 months after their AMI. Heartwire (Source: Medscape Today Headlines)

BUDEPRION SR (Bupropion Hydrochloride) Tablet, Extended Release [Bryant Ranch Prepack]

Updated Date: Jan 29, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction A Randomized, Placebo-Controlled Trial

ConclusionsTwo-thirds of patients return to smoking by 12 months after AMI. Bupropion is well tolerated and seems to be safe to use in the immediate post-AMI period. However, bupropion is not effective for smoking cessation in patients post-AMI. (Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial; NCT00689611) (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)

Smoking-cessation drug bupropion not effective in the post-AMI setting

Although safe and well tolerated in the immediate post-AMI period, treatment with bupropion failed to halt cigarette smoking, as more than two-thirds returned to smoking by 12 months after their AMI. (Source: theHeart.org)

Stop-Smoking Drug No Help After MI (CME/CE)

(MedPage Today) -- Taking bupropion (Zyban) right after a heart attack won't help smokers quit, researchers found. (Source: MedPage Today Cardiovascular)

Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task

Previous studies have shown that drugs which block the reuptake of catecholamine neurotransmitters improve impulse control in diseases such as attention deficit hyperactivity disorder (ADHD). Serotonin-specific reuptake inhibitors (SSRI) lack efficacy in ADHD and have been linked to increased suicide risk. The present study investigated drugs with affinity for one or more of the monoamine reuptake transporters using the 5-choice serial reaction time task, a model of attention and impulsivity in rodents. We also tested the effects of the alpha2-adreoceptor antagonist, idazoxan and novel antidepressant, agomelatine, which both increase cortical noradrenaline concentrations through non-reuptake mechanisms. Improvements in impulse control were observed with venlafaxine, a serotonin and noradre...

Bupropion: Visual hallucinations: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Pilot Randomized Trial of Bupropion for Adolescent Methamphetamine Abuse/Dependence

Conclusions: Results do not support the feasibility of additional trials of bupropion for adolescent methamphetamine abuse/dependence. Future studies should investigate the influence of gender on adolescent methamphetamine abuse and treatment outcomes. (Source: Journal of Adolescent Health)

Table of Contents

Abstract Discontinuing Risperidone Linked to Agitation in Alzheimer's Prenatal Antidepressant Exposure Not Linked to Intellectual, Behavioral Effects Rhabdomyolysis Linked to Pregabalin and Simvastatin Bipolar Patients at Higher Risk for Adverse Pregnancy Outcomes FDA: Benefits of New Obesity Drugs Greater than Risks Study Examines Risk for Cardiovascular Events of Varenicline vs. Bupropion Scopolamine Augmentation for Moderate to Severe Depression N?acetylcysteine as an Add?On Treatment for OCD Memantine Augmentation for Moderate to Severe OCD Discontinuation Paxil Labeling Revision (Source: The Brown University Psychopharmacology Update)

Bupropion/gabapentin overdose: Burst suppression, seizures and cardiovascular disorders: case report

(Source: Reactions)

Predictors of success in smoking cessation among Italian adults motivated to quit

In conclusion, we found that a steady attendance of the cognitive behavioral program, as well as the addition of pharmacologic interventions to counseling, remarkably increased the probability of the smoking cessation behavior to be determined. Nevertheless, FTQ was a valid measure in predicting the smoking cessation, and women revealed to be more likely to keep the smoking behavior, as well as subjects who declared an age of onset less than 17years. (Source: Journal of Substance Abuse Treatment)

Bupropion Med Profile

Bupropion is an antidepressant, also sold as Zyban to help people quit smoking. The brand name of the antidepressant form is Wellbutrin. Here are important facts about bupropion HCl. (Source: About.com Bipolar Disorder)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Taking Bupropion, Wellbutrin or Zyban? Facts You Need

Here are important things you should know if you're taking one of these three drugs in any form. For example, people with a history of anorexia or bulimia shouldn't take ...Read Full Post (Source: About.com Bipolar Disorder)

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.

Authors: Clapper JR, Athanacio J, Wittmer C, Griffin PS, D'Souza L, Parkes DG, Roth JD Abstract Antagonism of opioid systems (e.g., with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e.g., bupropion). Previously, we demonstrated that amylin enhances the food intake lowering and weight loss effects of neurohormonal (e.g., leptin, cholecystokinin, melanocortins) and small molecule (e.g., phentermine, sibutramine) agents. Here, we sought to characterize the interaction of amylin with naltrexone/bupropion on energy balance. Wild-type and amylin knockout mice were similarly responsive to the food intake lowering effects of either naltrexone (1mg/kg, subcutaneous)...

Pharmacotherapy Considerations in Patients with HIV and Psychiatric Disorders: Focus on Antidepressants and Antipsychotics.

CONCLUSIONS: Larger controlled studies are needed to validate the current findings as well as expand knowledge for non-SSRI antidepressants and second-generation antipsychotics for use in HIV-infected patients. PMID: 23341158 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

Cardiovascular effects of pharmacologic therapies for smoking cessation

Abstract: Tobacco dependence is a potent risk factor for cardiovascular (CV) diseases and, despite known harms of smoking and benefits associated with smoking cessation, approximately 20% of the adult population with CV diseases or hypertension continue to smoke. Extensive research has demonstrated that nicotine replacement, varenicline, and bupropion sustained-release are superior to placebo for short- and intermediate-term smoking cessation. Because of their mechanisms of action, some smoking cessation therapies have been thought to have the potential to increase CV risk, particularly if the pharmacotherapies are taken while individuals are still smoking. Hence, we have analytically reviewed the literature describing the CV effects of therapies for smoking cessation, particularly as th...

Increased oxidative stress in patients with depression and its relationship to treatment

In conclusion, oxidative stress is increased in patients with depression. However, although treatment with either bupropion or sertraline reduces the symptoms of depression, it may increase F2 isoprostane excretion. These results suggest that alternative mechanisms, beyond oxidative stress, may be involved in the development of depression and subsequent responses to treatment. (Source: Psychiatry Research)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O??Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. ?Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. ?Bipolar Disord 2012: 00: 000??000. © 2012 John Wiley & Sons A/S.Published by Blackwell Publishing Ltd. The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorder...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Institutional Inc.]

Updated Date: Dec 12, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Sandoz Inc]

Updated Date: Dec 12, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Primary Care-Relevant Interventions for Tobacco Use Prevention and Cessation in Children and Adolescents: A Systematic Evidence Review for the U.S. Preventive Services Task Force.

CONCLUSION: Primary care-relevant interventions may prevent smoking initiation over 12 months in children and adolescents. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality. PMID: 23229625 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)

Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report.

CONCLUSIONS: Although early-onset chronic/recurrent MDD is associated with a more severe clinical picture, it does not seem to be useful for predicting differential treatment response to antidepressant medication. Clinicians should remain alert to an increased risk of suicidality in this population. PMID: 23228340 [PubMed - as supplied by publisher] (Source: Psychological Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The Pharmacist "Toolbox" for Smoking Cessation: A Review of Methods, Medicines, and Novel Means to Help Patients Along the Path of Smoking Reduction to Smoking Cessation

Annually there are 500 000 preventable deaths in the United States caused by smoking; as health care professionals, pharmacists have a unique opportunity to advise, assess, and assist patients to quit smoking. This review article provides pharmacists with a "toolbox" containing an overview of pharmacologic and nonpharmacologic methods for smoking cessation. Currently approved over-the-counter (OTC) and prescription medications (nicotine replacement therapy, varenicline, and bupropion) are summarized, and nonpharmacologic therapies discussed include cognitive therapy and hypnosis. In addition to traditional therapies some potential approaches to smoking cessation are addressed, including nicotine immunizations and electronic cigarettes. (Source: Journal of Pharmacy Practice)

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Dec 5, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN SR (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Dec 4, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Global Pharmaceuticals, Division Of Impax Laboratories Inc.]

Updated Date: Dec 4, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of TSHAC on Human Cytochrome P450 Activity, and Transport Mediated by P-Glycoprotein.

Authors: Im Y, Kim YW, Song IS, Joo J, Shin JH, Wu Z, Lee HS, Park KH, Liu KH Abstract TSAHC [4'-(p-toluenesulfonylamido)-4-hydroxychalcone] is a promising antitumorigenic chalcone compound, especially against TM4SF5 (four-transmembrane L6 family member 5)-mediated hepatocarcinoma. We evaluated the potential of TSAHC to inhibit the catalytic activities of nine cytochrome P450 isoforms and of P-glycoprotein (Pgp). The abilities of TSAHC to inhibit phenacetin Odeethylation (CYP1A2), coumarin 6-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), amodiaquine Ndeethylation (CYP2C8), diclofenac 4-hydroxylation (CYP2C9), omeprazole 5-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and midazolam 1'-hydroxylation (CYP3A) were...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Treatment of depression in cardiovascular disease

ConclusionsThere is considerable evidence from randomized controlled clinical trials that antidepressants, especially SSRIs, are safe in the treatment of major depression in patients with CVD. Although efficacy has been demonstrated in some, but not all, trials for both antidepressants and certain psychotherapies, large, well?powered trials are urgently needed. There are virtually no data available on predictors of antidepressant response in depressed patients with CVD. Whether successful treatment of depression is associated with a reduction in cardiac morbidity and mortality remains unknown. (Source: Depression and Anxiety)

Nicotine replacement therapy for smoking cessation.

CONCLUSIONS: All of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) can help people who make a quit attempt to increase their chances of successfully stopping smoking. NRTs increase the rate of quitting by 50 to 70%, regardless of setting. The effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the individual. Provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT. PMID: 23152200 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Nicotine receptor partial agonists for smoking cessation.

CONCLUSIONS: Cytisine increases the chances of quitting, although absolute quit rates were modest in two recent trials. Varenicline at standard dose increased the chances of successful long-term smoking cessation between two- and threefold compared with pharmacologically unassisted quit attempts. Lower dose regimens also conferred benefits for cessation, while reducing the incidence of adverse events. More participants quit successfully with varenicline than with bupropion. Two open-label trials of varenicline versus NRT suggested a modest benefit of varenicline but confidence intervals did not rule out equivalence. Limited evidence suggests that varenicline may have a role to play in relapse prevention. The main adverse effect of varenicline is nausea, but mostly at mild to moderate level...

CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion.

Authors: Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF Abstract Bupropion is indicated to promote smoking cessation. Animal studies suggest that the pharmacologic activity of bupropion can be mediated by its major metabolite, hydroxybupropion. We measured plasma bupropion and its metabolite levels in a double-blind, placebo controlled, randomized smoking-cessation trial. Among the treatment-adherent individuals, higher hydroxybupropion concentrations (per μg/ml) resulted in better smoking-cessation outcomes (week 3, 7, and 26 odds ratio (OR) = 2.82, 2.96, and 2.37, respectively, P = 0.005-0.040); this was not observed with bupropion levels (OR = 1.00-1.03, P = 0.59-0.90). Genetic variation in CYP2B6, the enzyme that metabolizes bupropion to ...

BUPROPION HYDROCHLORIDE (XL) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Wockhardt Limited]

Updated Date: Nov 26, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDE (XL) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Wockhardt USA LLC.]

Updated Date: Nov 26, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Nov 16, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy.

Authors: Gerin B, Dell'aiera S, Richert L, Smith S, Chanteux H Abstract 1.??A fast, straightforward and cost-effective assay was validated for the assessment of CYP induction in cryopreserved human hepatocytes cultured in 48-well plates. The cocktail strategy (in situ incubation) was used to assess the induction of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 by using the recommended probe substrate, i.e. phenacetin, bupropion, diclofenac and midazolam, respectively. 2.??Cryopreserved human hepatocytes were treated for 72??h with prototypical reference inducers, β-naphthoflavone (25 µM), phenobarbital (500 µM) and rifampicin (10 µM) as positive controls for CYP induction. The use of a cocktail strategy has been validated and compared to the classical approach (single incubation). The ...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Nov 13, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Antidepressant therapy in epilepsy ?? can treating the comorbidities affect the underlying disorder?

Summary There is a high incidence of psychiatric comorbidity in people with epilepsy (PWE), particularly depression. The manifold adverse consequences of comorbid depression have been more clearly mapped in recent years. Accordingly, considerable efforts have been made to improve detection and diagnosis, with the result that many PWE are treated with antidepressant drugs, medications with the potential to influence both epilepsy and depression. Exposure to older generations of antidepressants (notably tricyclic antidepressants and bupropion) can increase seizure frequency. However, a growing body of evidence suggests that newer (??second generation??) antidepressants, such as selective serotonin reuptake inhibitors or serotonin?noradrenaline reuptake inhibitors, have markedly less effe...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study

Source: BMJ Area: News Against the background of increasing worldwide use of varenicline, postmarketing surveillance and other research have identified and investigated several safety concerns, including psychiatric effects, suicide and suicidal ideation, and cardiovascular effects. However a meta-analysis of RCTs has reported no significantly increased risk of cardiovascular events in patients taking varenicline compared with those taking placebo. The debate about a causal effect thus continues. &#160; A paper in the BMJ further explores the association between use of varenicline and the occurrence of serious cardiovascular events, including myocardial infarction, unstable angina, ischaemic stroke, and death from cardiovascular disease. &#160; It reports the findings of a Danish ...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Bryant Ranch Prepack]

Updated Date: Nov 6, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combined pharmacotherapy and behavioural interventions for smoking cessation

Source: Cochrane Area: Evidence &#62; Disease Focused Reviews Background Both behavioural support (including brief advice and counselling) and pharmacotherapies (including nicotine replacement therapy (NRT), varenicline and bupropion) are effective in helping people to stop smoking. Combining both treatment approaches is recommended where possible, but the size of the treatment effect with different combinations and in different settings and populations is unclear. &#160; Objectives To assess the effect of combining behavioural support and medication to aid smoking cessation, compared to a minimal intervention or usual care, and to identify whether there are different effects depending on characteristics of the treatment setting, intervention, population treated, or take-up of treatm...

The Antidepressant Drug Best for Sex

Compared with the SSRIs, Wellbutrin treats depression just as well but causes far fewer sexual side effects.read more (Source: Psychology Today Depression Center)

QTC Prolongation and Torsades in Bupropion Overdoses Presenting to United States Emergency Departments

Bupropion is an atypical antidepressant commonly used for depression and smoking cessation. It is structurally dissimilar to other antidepressants and is an inhibitor of norepinephrine and dopamine uptake. It is associated with QTc prolongation in therapeutic use and in overdose. There are limited data assessing QTc prolongation and torsades de points (TDP) in cases of overdose. The purpose of this study is to assess the incidence of QTc prolongation and the development of TDP in cases of bupropion overdose presenting to Emergency Departments (EDs). (Source: The Journal of Emergency Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Combined pharmacotherapy and behavioural interventions for smoking cessation.

CONCLUSIONS: Interventions that combine pharmacotherapy and behavioural support increase smoking cessation success compared to a minimal intervention or usual care. Further trials would be unlikely to change this conclusion. We did not find strong evidence from indirect comparisons that offering more intensive behavioural support was associated with larger treatment effects but this could be because intensive interventions are less likely to be delivered in full. PMID: 23076944 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)

Conclusions Dose reduction in CKD3-5 is necessary for selegiline, amitriptylinoxide, venlafaxine, desvenlafaxine, milnacipran, bupropion, reboxetine and tianeptine. The evidence on effectiveness of antidepressants versus placebo in patients with CKD3-5, and with the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)-defined depression is insufficient, and in view of the high prevalence, a well-designed RCT is greatly needed. (Source: Nephrology Dialysis Transplantation)

Dilated and Unreactive Pupils and Burst-Suppression on Electroencephalography due to Buproprion Overdose

We report a case of a 29-year-old female thought to be brain dead based on initial physical examination and EEG findings of burst-suppression, who was later found to have supratherapeutic serum levels of bupropion. This is the second documented case of burst-suppression pattern on EEG in a patient who overdosed on bupropion. We propose that burst-suppression in the setting of bupropion toxicity may revert with drug clearance. (Source: Journal of Intensive Care Medicine)

Statistics on NHS Stop Smoking Services: England, April 2012 to June 2012

Source: NHS Information Centre Area: News This quarterly report presents provisional results from the monitoring of the NHS Stop Smoking Services (NHS SSS) in England during the period 1 April 2012 to 30 June 2012. &#160; The reports noted some of the following findings: &#160; .&#160;176,945 people set a quit date through NHS Stop Smoking Services. .&#160;At the 4 week follow-up, 86,341 people had successfully quit (based on self-report), 49% of those setting a quit date. .&#160;The majority of those setting a quit date received nicotine replacement therapy (NRT) only (64%). A further 26% received varenicline only, 1% received bupropion only, 2% received both NRT and varenicline and less than 1% received both NRT and bupropion. .&#160;Of those who used varenicline only, 60%...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Bryant Ranch Prepack]

Updated Date: Oct 17, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Question Question: What is the risk of suicide death for people with depression on antidepressants? People: 502&nbsp;179 adults in the Veterans Affairs (VA) Health System with depression (identified using implantable cardioverter defibrillator (ICD) coding), who started taking any of the most commonly used antidepressants between April 1999 and September 2004. A new antidepressant start (index date) was defined as filling of a prescription for any of the antidepressants after at least 6&nbsp;months with no observed antidepressant prescription fills. Exclusion criteria: diagnosis of bipolar I, schizophrenia or schizoaffective disorder. Setting: Department of VA Health System, USA; 1999&ndash;2004. Risk factors: New start on one of the antidepressants (27.0% started sertraline, 26.1% citalop...

Why Quitting Smoking Without Help Is So Hard

Quitting smoking is hard, and although most people quit alone, many need help. Focusing on motivation and other personality factors might be key.read more (Source: Psychology Today Addiction Center)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Oct 15, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Therapeutic equivalence of bupropion generics in question

(Source: Reactions)

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Oct 12, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antidepressant-like effect of creatine in mice involves dopaminergic activation

This study investigated the effect of creatine (p.o.) in the tail suspension test, a predictive test of antidepressant activity. Creatine reduced the immobility time in the tail suspension test (0.1&ndash;1000 mg/kg, male and female mice), without affecting locomotor activity. Furthermore, the involvement of the dopaminergic system in creatine-induced antidepressant-like effect in male mice in the tail suspension test was investigated. The anti-immobility effect of creatine (1 mg/kg) was prevented by the pre-treatment of mice with haloperidol (0.2 mg/kg, intraperitoneal (i.p.) route, non-selective dopamine receptor antagonist), (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390; 0.05 mg/kg, subcutaneous (s.c.) route, dopamine D1 recepto...

Bupropion pre-treatment of endotoxin-induced depressive symptoms.

Authors: Dellagioia N, Devine L, Pittman B, Hannestad J Abstract Increased levels of inflammatory cytokines may play a role in depression. Depressive symptoms can be induced in humans with administration of low-dose lipopolysaccharide (LPS; endotoxin), which activates the innate immune system and causes release of inflammatory cytokines. We previously found that pre-treatment with the serotonin reuptake inhibitor citalopram reduced LPS-induced fatigue and anhedonia. This is a follow-up study to determine whether LPS-induced symptoms could be reduced by pre-treatment with bupropion, a norepinephrine and dopamine reuptake inhibitor. In this double-blind, randomized, placebo-controlled, cross-over study, 10 healthy subjects received intravenous LPS (0.8 ng/kg) after oral pre-treatment...

Once-Daily Antidepressant Now Available in the USOnce-Daily Antidepressant Now Available in the US

Forfivo XL, a new extended-release formulation of bupropion hydrochloride, is now available in the US for the treatment of major depressive disorder. Medscape Medical News (Source: Medscape Today Headlines)

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Oct 9, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Oct 9, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Oct 9, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155)

Conclusion&nbsp;&nbsp;Although it may not share all the properties of stimulant drugs, the effect profile of bupropion presents a number of similarities with that of methylphenidate over a 2-week treatment period. Content Type Journal ArticleCategory Clinical TrialPages 1-9DOI 10.1007/s00228-012-1418-zAuthors Hugues Chevassus, CHRU Montpellier, Centre d??Investigation Clinique, Montpellier, FranceAnne Farret, CHRU Montpellier, Centre d??Investigation Clinique, Montpellier, FranceJean-Pierre Gagnol, CHRU Montpellier, Centre d??Investigation Clinique, Montpellier, FranceClaire-Anne Ponçon, CHRU Montpellier, Centre d??Investigation Clinique, Montpellier, FranceFrançoise Costa, CHRU Montpellier, Centre d??Investigation Clinique, Montpellier, FranceClarisse Roux, CHRU Montpel...

FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg

October 3, 2012 -- The U.S. Food and Drug Administration (FDA) has reviewed new data that indicate Budeprion XL 300 mg (bupropion hydrochloride extended-release tablets), manufactured by Impax Laboratories, Inc., and marketed by Teva Pharmaceuticals... (Source: Drugs.com - Pharma News)

FDA Withdraws Approval of Generic AntidepressantFDA Withdraws Approval of Generic Antidepressant

The antidepressant Budeprion XL 300 mg, a generic form of the extended-release bupropion hydrochloride, is not therapeutically equivalent to Wellbutrin XL 300 mg, the brand-name drug, says the FDA. News Alerts (Source: Medscape Today Headlines)

FDA stops production of generic anti-depressant Budeprion XL 300

Teva Pharmaceuticals has been asked by the US Food and Drug Administration to stop shipping a generic version of a bupropion anti-depressant, after analysis revealed it does not work properly. (Source: Pharmaceutical Technology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The interaction between dopamine transporter function, gender differences, and possible laterality in depression

Abstract: The Dopamine Transporter (DAT) can reflect the general state of striatal dopamine activity. This current study examined the role of DAT in depressed patients before and after bupropion treatment. Twenty-three patients with major depression were treated with bupropion for 8 weeks. Before and after the treatment, they and 20 normal subjects received the radioligand 99mTc-TRODAT-1 single photon emission tomography scan (SPECT). Subjects were assessed with the Hamilton Depression Rating Scale. All DAT images were spatially normalized to an averaged brain template, and the specific binding ratios of the striatum, caudate, and putamen were calculated according the formulae of: [region counts] / [occipital counts] - 1. Depressed patients had greater DAT availability on both sides of the...

FORFIVO XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Edgemont Pharmaceuticals, LLC]

Updated Date: Oct 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

FDA Withdraws Approval for High-Dose Generic Wellbutrin XL

The FDA has withdrawn its approval for a high-dose extended-release generic bupropion pill called Budeprion XL due to the fact that it was found to be not therapeutically equivalent to the brand name version....Read Full Post (Source: About.com Depression)

Bupropion: Visual hallucinations: case report

(Source: Reactions)

Bupropion/sertraline interaction: Hypersexuality: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial

Conclusion: Compared with placebo, bupropion did not control HFs in this group of BC survivors. (Source: Journal of Pain and Symptom Management)

The Genetics of Quitting Smoking

The argument of whether biology has something to do with addiction is silly??the interaction between nicotine metabolism, bupropion, and quitting smoking can show you why.read more (Source: Psychology Today Addiction Center)

Pharmacological interventions for promoting smoking cessation during pregnancy

Source: Cochrane Area: Evidence &#62; Disease Focused Reviews Background Smoking in pregnancy is a substantial public health problem. When used by non-pregnant smokers, pharmacotherapies [nicotine replacement therapy (NRT), bupropion and varenicline] are effective treatments for smoking cessation, however, their efficacy and safety in pregnancy remains unknown. &#160; &#160; Objectives To determine the efficacy and safety of smoking cessation pharmacotherapies, including NRT, varenicline and bupropion (or any other medications) when used to support smoking cessation in pregnancy. &#160; Search methods We searched the Pregnancy and Childbirth Group's Trials Register (5 March 2012), checked references of retrieved studies and contacted authors in the field. &#160; &#160; ...

Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

Conclusion: Combinations of antidepressants (SSRI, mirtazapine, venlafaxine) with mood stabilizers (lithium, valproic acid, lamotrigine) and / or atypical antipsychotics (quetiapine, olanzapine) are common. Of most of those combinations the efficacy has not been studied. The use of aripiprazole and the concomitant use of two or three antidepressants contrast the guidelines. (Source: BMC Psychiatry - Latest articles)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Major Pharmaceuticals]

Updated Date: Sep 19, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults.

CONCLUSIONS Varenicline is better than placebo or bupropion and does not differ from the nicotine patch for smoking abstinence. Varenicline increases serious adverse events compared with placebo.Varenicline for smoking cessation in adults*OutcomesComparisonNumber of trials (n)Weighted event ratesRBI (95% CI)NNT (CI)Continuous or sustained abstinence at ? 24 wkStandard-dose varenicline? vs placebo14 (6166)27% vs 12%127% (102 to 155)7 (6 to 8)Point prevalence abstinence at 24 wkStandard-dose varenicline vs nicotine patch2 (778)38% vs 34%13% (-6 to 35)Not significantContinuous abstinence at 52 wkStandard-dose varenicline vs bupropion3 (1622)21% vs 14%52% (22 to 88)15 (10 to 25)Abstinence at 52 wkLower-dose varenicline vs placebo4 (1272)21% vs 10%109% (56 to 178)10 (8 to 15)Standard vs lo...

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: Sep 13, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Medications help adults quit smoking

Adults are more likely to successfully quit smoking if they take bupropion, varenicline (Chantix), or a nicotine patch, than those who attempt to quit without medication, according to the results of an ongoing prospective cohort survey published by the journal Addiction. (Source: Drug Topics - Top News)

A case of bupropion-induced stuttering

Conclusion: Neuroimaging and pharmacological studies have implicated dopamine in the pathophysiology of stuttering. Bupropion's ability to increase dopamine in the frontal cortex was suspected to have been involved in this patient's stuttering. However, further research is needed before causality can be assured. (Source: General Hospital Psychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Sep 5, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

E-cigarettes 'may damage lungs'

Conclusion The preliminary findings of this small study suggest the potential harmful effects of e-cigarettes on a person??s lung function. However, limited conclusions can be drawn from this press release and conference abstract. Scientific research is often presented first at conferences. It gives researchers a chance to speak about their results and discuss them with their peers. However, the results they present are often preliminary, and don??t have to go through the same peer-review quality assurance process that is needed for publication in a journal. Also, as conference presentations are summarised in very brief ??abstracts? for the public, very limited details are usually available on the study??s methods and results. This makes it difficult to judge the study??s strengths ...

Bilateral pallidal necrosis and cardiac toxicity in a patient with venlafaxine and bupropion overdose.

Authors: Lin YH, Huang E, Chien YL PMID: 22952082 [PubMed - in process] (Source: The American Journal of Psychiatry)

BUPROPION HYDROCHLORIDE (SR) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Wockhardt Limited]

Updated Date: Aug 31, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE (SR) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Wockhardt USA LLC.]

Updated Date: Aug 31, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Use of Bupropion in the Treatment of Sexual Dysfunction

ACS Medicinal Chemistry LettersDOI: 10.1021/ml300244w (Source: ACS Medicinal Chemistry Letters)

The effect of smoking cessation pharmacotherapies on pancreatic beta cell function.

Authors: Woynillowicz AK, Raha S, Nicholson CJ, Holloway AC Abstract The goal of our study was to evaluate whether drugs currently used for smoking cessation (i.e., nicotine replacement therapy, varenicline [a partial agonist at nicotinic acetylcholine receptors (nAChR)] and bupropion [which acts in part as a nAChR antagonist]) can affect beta cell function and determine the mechanism(s) of this effect. INS-1E cells, a rat beta cell line, were treated with nicotine, varenicline and bupropion to determine their effects on beta cell function, mitochondrial electron transport chain enzyme activity and cellular/oxidative stress. Treatment of INS-1E cells with equimolar concentrations (1μM) of three test compounds resulted in an ablation of normal glucose-stimulated insulin secretion b...

Bupropion/lithium: Feeding problems? and hypotonia, after in utero exposure: 2 case reports

(Source: Reactions)

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [STAT Rx USA LLC]

Updated Date: Aug 24, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pharmacokinetic Interaction between Prasugrel and Ritonavir in Healthy Volunteers

Abstract The new anti?aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor. The aim of this open?label cross?over study was to assess the effect of ritonavir on prasugrel active metabolite (prasugrel?AM) pharmacokinetics in healthy volunteers. Ten healthy male volunteers received 10 mg prasugrel. After at least a week washout, they received 100 mg ritonavir, followed by 10 mg prasugrel 2 hr later. We used dried blood spot sampling method to monitor prasugrel?AM pharmocokinetics (Cmax, t1/2, tmax, AUC0?6h) at 0, 0.25, 0.5, 1, 1.5, 2, 4 and 6 hr after prasugrel administration. A ??cocktail? approach was used to measure CYP2B6, 2C9, 2C19 and 3A activities. In the pres...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effectiveness of stop?smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey

ConclusionsConsistent with evidence from randomized controlled trials, smokers in the United Kingdom, Canada, Australia and the United States are more likely to succeed in quit attempts if they use varenicline, bupropion or nicotine patch. Previous population studies that failed to find an effect failed to control adequately for important sources of bias. (Source: Addiction)

A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation

Discussion: The findings provide preliminary evidence to guide clinical decisions for moderate MA users receiving bupropion. The results are consistent with data from the smoking cessation literature and may highlight the importance of early response in addiction treatment. (Source: Drug and Alcohol Dependence)

Cognitive evaluation of bupropion sustained release in heavy tobacco smokers using event-related potentials.

CONCLUSIONS. The reduction of P3a in the frontal area may be due to the decreased distractibility of task-irrelevant novel events, which may mean an augmentation of focused attention to task-relevant target events. The increases in the P3b and P2 amplitudes for target events in the parietal area are very suggestive of this hypothesis, since these components reflect the response to task-relevant target events. Meanwhile, the increased P2 latency for standard events may reflect reduced attention resources for the processing of standard events due to increased attention resources allocated for task-relevant target events. Decreased distractibility and increased attention are believed to be caused by bupropion. PMID: 22864270 [PubMed - in process] (Source: Medicina (Kaunas))

CADTH Rapid Response Report: Pharmacological smoking cessation interventions for patients with cardiovascular conditions- review of safety and guidelines

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News The rapid review by the Canadian Agency for Drugs and Technologies in Health (CADTH) summarises the available safety evidence for varenicline, bupropion, and nicotine replacement therapy) NRT in patients with cardiovascular disease (CVD). This noted that the efficacy of these agents in patients with CVD has been assessed in well-conducted RCTs and systematic reviews. However, the majority of these studies were not specifically designed to fully assess the safety of smoking cessation pharmacotherapy. There were no head-to-head trials or indirect comparisons of different active treatments for smoking cessation. Therefore, uncertainty remains regarding the comparative safety of these agents in patients with vario...

CADTH Rapid Response Report: Pharmacological smoking cessation interventions for patients with cardiovascular conditions

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News The rapid review by the Canadian Agency for Drugs and Technologies in Health (CADTH) summarises the available safety evidence for varenicline, bupropion, and nicotine replacement therapy (NRT) in patients with cardiovascular disease (CVD). This noted that the efficacy of these agents in patients with CVD has been assessed in well-conducted RCTs and systematic reviews. However, the majority of these studies were not specifically designed to fully assess the safety of smoking cessation pharmacotherapy. There were no head-to-head trials or indirect comparisons of different active treatments for smoking cessation. Therefore, uncertainty remains regarding the comparative safety of these agents in patients with vari...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants:

A Review for Primary Care Physicians Mehrul Hasnain, MD; R. Vieweg W. Victor, MD; Bruce Hollett, MD DOI: 10.3810/pgm.2012.07.2577 Abstract: Second-generation antipsychotics (SGAPs) and second-generation antidepressants (SGADs) have multiple US Food and Drug Administration&ndash;approved indications and are frequently prescribed by primary care physicians. We review the relative potential of these drugs to cause weight gain and glucose dysregulation, and offer clinical guidance to minimize and manage this risk. Among SGAPs, clozapine and olanzapine have a high risk for causing weight gain and glucose dysregulation; iloperidone, paliperidone, quetiapine, and risperidone have a medium risk; and aripiprazole, asenapine, lurasidone, and ziprasidone have a low risk. Young, drug-na&iu...

BUDEPRION SR (Bupropion Hydrochloride) Tablet, Extended Release [Teva Pharmaceuticals USA Inc]

Updated Date: Aug 8, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

Updated Date: Aug 7, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Preferred Pharmaceuticals,Inc.]

Updated Date: Aug 6, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

A comparison of three smokeless tobacco dependence measures.

Authors: Ebbert JO, Severson HH, Danaher BG, Schroeder DR, Glover ED Abstract Smokeless tobacco (ST) use is associated with tobacco dependence and long-term adverse health consequences. Clinical and research tools that can accurately assess ST dependence are needed to improve research and treatment of ST users. Measures of ST dependence have been developed to address this need. We used data from a study evaluating the effectiveness of bupropion sustained release for the treatment of ST use (N=225) to compare the Fagerström Tolerance Questionnaire for Smokeless Tobacco (FTQ-ST) users, the Severson Smokeless Tobacco Dependency Scale (SSTDS), and the Glover-Nilsson Smokeless Tobacco Behavioral Questionnaire (GN-STBQ). We observed that despite the intention of the scale: (1) all scale...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

Updated Date: Aug 2, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

Updated Date: Aug 2, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Teva Pharmaceuticals USA Inc]

Updated Date: Aug 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Intravenous lipid emulsions for treating toxicoses

Intravenous lipid emulsion (ILE) is commonly used in veterinary medicine as a fat component for parenteral nutrition (PN), but new information indicates that it may be a promising new treatment for some toxicoses. The first work was performed in the human arena where ILE was used to treat local anesthetic overdoses. More recent literature on humans has shown ILE to help in the treatment of tricyclic antidepressants, calcium channel blockers, beta blockers, bupropion, haloperidol, hydrochloroquin, flecanide, and carbamazepine toxicoses. In human medicine, ILE is reserved for life-threatening toxicoses or after conventional therapies have not worked. In veterinary medicine, there is no ??standard of care? that has to be followed, and many animals are treated with ILE much earlier in the d...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Lipid emulsion therapy for poisonings: a review

This article reviews the history of intravenous lipid emulsion (ILE) as a treatment for poisoning, proposed mechanisms, laboratory and clinical evidence relating to ILE, dosing, and potential side effects. Interest in ILE as therapy for poisoning began with the serendipitous discovery that pretreatment with lipid emulsion protected animals from the effects of systemic bupivacaine toxicity. Although the exact mechanism responsible for this protective effect, possibly explanations include: the &#8220;lipid sink&#8221; or portioning mechanism, increased levels of myocardial fatty acid fuel, and direct isotopic effect. Multiple mechanisms may be active. Although laboratory data to date are not totally conclusive ?? and case reports are difficult to interpret because of numerous confounding v...

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [Valeant Pharmaceuticals North America LLC]

Updated Date: Jul 30, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

A dopamine/noradrenaline reuptake inhibitor improves performance in the heat, but only at the maximum therapeutic dose

A maximal dose of bupropion has enabled subjects to maintain a higher power output than reported during the placebo session in the heat. Because this drug is taken in different doses it is important to know if there is a dose??response relationship with regard to exercise at high ambient temperature. Ten well?trained male cyclists ingested placebo (pla; 200??mg) or bupropion (50%, 75%, 100% of maximal dose: bup50: 150??mg; bup75: 225??mg; bup100: 300??mg) the evening before and morning of the experimental trial. Trials were conducted in 30??°C (humidity 48%). Subjects cycled for 60??min at 55% Wmax, immediately followed by a time trial to measure performance. Bup100 improved performance (pla: 33'42???±??2'06?; bup100: 32'06???±??1'54?; P??=??0.035). Bupropion incr...

Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients

The objective of the present study was to evaluate changes in platelet counts on three different kinds of antidepressant. All subjects (n??=??131) in their drug?naïve state had been diagnosed with depression. Escitalopram (n??=??42), venlafaxine (n??=??50) and bupropion (n??=??39) were prescribed, and platelet count was measured before and after 1??month of treatment and compared. Decrease in platelet count on escitalopram was significant, while the others were not. These findings suggest that escitalopram may be associated with decreased platelet count, and bupropion is less likely to exert an influence on platelet count. (Source: Psychiatry and Clinical Neurosciences)

Cost-Effectiveness of Varenicline Versus Bupropion, Nicotine-Replacement Therapy, and Unaided Cessation in Greece.

CONCLUSION: The findings from the present study suggest that, compared with the widely used treatment options bupropion and NRT, as well as unaided cessation, varenicline may enhance smoking-cessation treatment outcomes while substantially reducing the overall costs of smoking to the health care system. PMID: 22818870 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3

Abstract&nbsp;&nbsp;Besides the three antidepressant-sensitive, Na+- and Cl??-dependent monoamine transporters, Na+-independent organic cation transporters (OCTs) are known to transport monoamines. However, little is known about the interactions of psychotropic drugs with human (h) OCTs. In the present study, a series of diverse antidepressant and antipsychotic drugs were examined for their inhibitory potency at hOCT1, hOCT2 and hOCT3 by measuring inhibition of [3H]-MPP+ uptake into HEK293 cells stably expressing one of the three hOCTs. The inhibitory potencies (IC50s) ranged from 1 to 900&nbsp;μM. Most of the examined drugs showed highest inhibitory potency at hOCT1 which is very sparsely expressed in the brain and mainly involved in renal and hepatic clearance of cationic drugs. At ...

Bupropion versus methylphenidate in the treatment of children with attention?deficit/hyperactivity disorder: randomized double?blind study

ConclusionsBupropion has a comparable safety and efficacy profile with methylphenidate in children and adolescents with ADHD. Copyright © 2012 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)

Dietary intake after smoking cessation among weight-concerned women smokers.

This study is the first documentation of energy and macronutrient intake during smoking cessation treatment using a validated 24-hr dietary recall methodology. Although cessation was associated with overall increases in energy intake among women, neither bupropion nor weight concerns treatment affected energy or macronutrient intake. Future research to understand the relation between cessation and dietary intake needs to replicate and extend these findings to elucidate how, if at all, smoking cessation affects dietary intake. (PsycINFO Database Record (c) 2013 APA, all rights reserved) (Source: Psychology of Addictive Behaviors)

Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs.

CONCLUSIONS: All drug classes studied-first- and second-generation antipsychotics and antidepressants-were associated with an increased risk of hip fracture in predominantly older adult populations. PMID: 22811347 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [NCS HealthCare Of KY, Inc Dba Vangard Labs]

Updated Date: Jun 22, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: Jun 19, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Uterine Blood Flow in a Psychiatric Population: Impact of Maternal Depression, Anxiety, and Psychotropic Medication

Conclusions: Contrary to a popular hypothesis, depression and anxiety-associated reductions in UBF may not be a pathway by which risk is conferred during prenatal development. However, while requiring replication, our findings suggest that prenatal bupropion exposure may be associated with reductions in UBF. (Source: Biological Psychiatry)

The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review

This article provides a systematic review of published studies (1980??2011) on commonly prescribed newer antidepressants and driving performance. A total of 21 studies could be included in the review, indicating that there is a lack of controlled patient studies. Investigations on newer antidepressants were frequently undertaken in healthy subjects focusing on acute or subchronic effects of application, predominately in young male participants, with dosages usually given in an ambulatory setting. No data, according to selection criteria, were found with respect to agomelatine, duloxetine, bupropion and viloxazine. There is evidence that the SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine) and the SNRI venlafaxine have no deleterious effects on drivin...

Carbonyl reduction of bupropion in human liver.

The objective of this study was to examine the enzyme kinetics of bupropion reduction in human liver. In human liver cytosol, the reduction of bupropion to erythro-and threohydrobupropion was NADPH dependent with Cl(int) values of 0.08 and 0.60 µL·min(-1)mg(-1) protein, respectively. Bupropion reduction in liver microsomes was also NADPH dependent with Cl(int) values of 10.4 and 280 µL·min(-1)mg(-1) protein, respectively. Formation of erythro-and threohydrobupropion in microsomes exceeded that in cytosol by 70 and 170 fold, respectively. Menadione, an inhibitor of cytosolic carbonyl reducing enzymes (e.g. CBRs), inhibited erythro-and threohydrobupropion formation in cytosol with IC(50) of 30 and 54 µM, respectively. In microsomes 18β-glycyrrhetinic acid, an inhibitor of microso...

Bupropion in the treatment of problematic online game play in patients with major depressive disorder

As one of the problematic behaviors in patients with major depressive disorder (MDD), excessive online game play (EOP) has been reported in a number of recent studies. Bupropion has been evaluated as a potential treatment for MDD and substance dependence. We hypothesized that bupropion treatment would reduce the severity of EOP as well as depressive symptoms. Fifty male subjects with comorbid EOP and MDD were randomly assigned to bupropion + education for internet use (EDU) or placebo + EDU groups. The current study consisted in a 12-week, prospective, randomized, double-blind clinical trial, including an eight-week active treatment phase and a four-week post treatment follow-up period. During the active treatment period, Young Internet Addiction Scale (YIAS) scores and the mean time of on...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Extended Release [Unit Dose Services]

Updated Date: May 29, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Unit Dose Services]

Updated Date: May 29, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Unit Dose Services]

Updated Date: May 29, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Escitalopram-induced word finding difficulty

Abstract: Escitalopram is the most selective serotonin reuptake inhibitor used for treatment of major depressive disorder and generalized anxiety disorder. No available report indicating escitalopram may induce word finding difficulty. Here we are presenting a 50-year-old patient who suffered from escitalopram-induced word finding difficulty and the symptom resolved after replacing with bupropion. Carefully monitoring word finding difficulty and speech fluency during antidepressant treatment is important in clinical practice when using selective serotonin reuptake inhibitors, especially escitalopram. (Source: General Hospital Psychiatry)

High smoking cessation rate in Crohn's disease patients after physician advice ?? The TABACROHN Study

Conclusion: Our results underline that an anti-tobacco strategy mostly based on CD patients´s education and counseling is feasible and effective in helping patients reach complete abstinence. (Source: Journal of Critical Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [Cardinal Health]

Updated Date: May 17, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Rebel Distributors Corp]

Updated Date: May 11, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [PD-Rx Pharmaceuticals, Inc.]

Updated Date: May 10, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion: Angioedema presenting as knee monoarthritis: case report

(Source: Reactions)

The association between antidepressant dosage titration and medication adherence among patients with depression

ConclusionsUpward dose titration on antidepressant treatments was associated with improved medication adherence and persistence. For clinicians initiating antidepressant treatment, titrating antidepressant doses may improve patient outcomes. (Source: Depression and Anxiety)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparative effectiveness of second?generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review

ConclusionsEvidence guiding the selection of an SGA based on accompanying symptoms of depression is limited. Very few trials were designed and adequately powered to answer questions about accompanying symptoms; analyses were generally of subgroups in larger MDD trials. (Source: Depression and Anxiety)

BUPROPION HYDROCHLORIDE (SR) (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [NorthStar RX LLC]

Updated Date: May 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Smoking and depression - a review.

This article examines the relationship between smoking and depression, and reviews the evidence for the use of specific therapies in general practice. Discussion All patients with depression should be asked if they smoke. Smokers with depression have higher nicotine dependence and, after quitting, experience more severe negative moods and are at increased risk of major depression. However, they are motivated to quit and many achieve long term abstinence. Effective strategies for smoking cessation in this population include cognitive behavioural mood management, nicotine replacement therapy, varenicline and bupropion. Additional support and longer courses of treatment may be needed. Smokers with depression should be monitored for mood changes after quitting. Preventive antidepressants may h...

Smoking cessation therapy during pregnancy.

Authors: Cressman AM, Pupco A, Kim E, Koren G, Bozzo P Abstract Question Despite being highly motivated to quit, many of my patients struggle with smoking cessation during pregnancy. Can you comment on the current treatment options and discuss their safety and efficacy during pregnancy? Answer Given the considerable and well-documented adverse effects of antenatal smoking on mother and fetus, pharmacotherapy for smoking cessation should be considered. Available medications include nicotine replacement therapy, sustained-release bupropion, and varenicline. Nicotine replacement therapy and bupropion do not appear to increase the risk of major malformations; however, there is currently limited evidence on the use of varenicline during pregnancy. Given that these agents are only margin...

A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial.

Authors: McCann DJ, Li SH Abstract A multisite, double-blind, placebo-controlled trial of bupropion for methamphetamine dependence was reanalyzed using a novel, nonbinary method of evaluating success and failure. The original analysis focused on a group response endpoint (the change in percentage of participants with methamphetamine-free urines each week over the course of the trial) and no significant bupropion effect was observed in the total population of study participants. In this reanalysis, individual participants were regarded as treatment success if they achieved multiple weeks of abstinence lasting through the end of the study, and their degree of success was quantified by calculating the number of beyond-threshold weeks of success (NOBWOS). Thus, setting the threshold at...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Apr 27, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion

We report a case of serotonin syndrome during general anesthesia in a patient requiring mastectomy. (Source: Journal of Clinical Anesthesia)

The effects of varenicline on attention and inhibitory control among treatment-seeking smokers

Conclusions&nbsp;&nbsp;The present study demonstrated that varenicline improves lapses in attention among treatment-seeking smokers preparing to make a quit attempt. These findings suggest that the domain of attention may be a good candidate for larger studies of the role of improved cognition in understanding the mechanisms of varenicline treatment for smoking cessation. Content Type Journal ArticleCategory Original InvestigationPages 1-8DOI 10.1007/s00213-012-2700-6Authors Jessica D. Rhodes, Department of Psychology, University at Buffalo, 230 Park Hall, Box 604110, Buffalo, NY 14260, USALarry W. Hawk, Department of Psychology, University at Buffalo, 230 Park Hall, Box 604110, Buffalo, NY 14260, USARebecca L. Ashare, Department of Psychology, University at Buffalo, 230 Park ...

Rapid Clinical Induction of Bupropion Hydroxylation by Metamizole in Healthy Chinese Men

Conclusions: Four?day oral administration of metamizole significantly altered the pharmacokinetics of both bupropion and its active metabolite 4?hydroxybupropion, and significantly increased the CYP2B6?catalyzed bupropion hydroxylation in all of the subjects. Cautions should be made when metamizole was co?administered with CYP2B6 substrate drugs.© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society (Source: British Journal of Clinical Pharmacology)

Nicotine receptor partial agonists for smoking cessation.

CONCLUSIONS: Cytisine increases the chances of quitting, although absolute quit rates were modest in two recent trials. Varenicline at standard dose increased the chances of successful long-term smoking cessation between two- and threefold compared with pharmacologically unassisted quit attempts. Lower dose regimens also conferred benefits for cessation, while reducing the incidence of adverse events. More participants quit successfully with varenicline than with bupropion. Two open-label trials of varenicline versus NRT suggested a modest benefit of varenicline but confidence intervals did not rule out equivalence. Limited evidence suggests that varenicline may have a role to play in relapse prevention. The main adverse effect of varenicline is nausea, but mostly at mild to moderate level...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

CADTH rapid review: Clinical and cost effectiveness of funding smoking cessation pharmacotherapy in the workplace

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News This rapid review from the Canadian Agency for Drugs and Technologies in Health (CADTH) examines the clinical and cost effectiveness of funding smoking cessation pharmacotherapy in the workplace for adult smokers to increase smoking cessation rates? &#160; Evidence from one clinical study and three economic evaluations suggests that funding smoking cessation pharmacotherapy in the workplace results in increased smoking cessation rates and cost savings due to decreased absenteeism and increased productivity, at a low cost to employers. Varenicline appears to be more effective and cost-effective than other smoking-cessation aids such as bupropion and nicotine patches, according to results from two studies. ...

Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex.

Authors: Hudson AL, Lalies MD, Silverstone P Abstract Venlafaxine is recognised as an effective treatment for depression and is known to inhibit the reuptake of serotonin (5-HT) and noradrenaline (NA). Another antidepressant, bupropion, acts to inhibit dopamine (DA) and NA reuptake and is commonly co-administered with other antidepressants to improve the efficacy of the antidepressant effect. The present study was designed to investigate the acute effect of combining the 2 drugs on extracellular levels of 5-HT, DA, and NA in rat frontal cortex using brain microdialysis, with the drugs being administered by intraperitoneal injection (i.p). Bupropion (10 mg/kg body mass, i.p.) alone had no effect on extracellular 5-HT levels, whereas venlafaxine (10 mg/kg, i.p.) alone significantly...

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [Lake Erie Medical Surgical Supply DBA Quality Care Products LLC]

Updated Date: Apr 16, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Cochrane Quality and Productivity topic: Relapse prevention interventions for smoking cessation

Source: NHS Evidence Area: News Cochrane quality and productivity topics highlight potential disinvestment opportunities that can be used by the NHS to meet its overall QIPP targets, and include calculations of potential cost savings if implemented. The focus of this topic is a Cochrane review of 54 studies that examined the various options available to prevent relapse in people who had given up smoking. &#160; The majority of the studies examined behavioural methods in patients who had achieved abstinence for circumstantial reasons such as being pregnant, an inpatient or being recruited into the military. There was little evidence to show that any benefit was gained from the behavioural interventions studied and little evidence to support the use of bupropion or nicotine replacement ...

Changes in health-related quality of life with smoking cessation treatment

Conclusion: Treatment with varenicline and bupropion SR for smoking cessation resulted in improved self-control and health transition that was mediated in large part by continuous smoking abstinence. (Source: The European Journal of Public Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion overdose: Ventricular tachycardia, QT interval prolongation and status epilepticus, treated with charcoal haemoperfusion: case report

(Source: Reactions)

Recent advances in the pathophysiology and pharmacological treatment of obesity

Conclusion:?? Despite recent setbacks in the pharmacotherapy of obesity (withdrawal of rimonabant and sibutramine), many compounds are in phase II/III trials. The future holds promise for a new drug that alone or in combination with an existing agent could target the initial pathophysiology and morbidities associated with obesity. (Source: Journal of Clinical Pharmacy and Therapeutics)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Aphena Pharma Solutions - Tennessee, Inc.]

Updated Date: Mar 29, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Recent advances in the pathophysiology and pharmacological treatment of obesity

Conclusion:?? Despite recent setbacks in the pharmacotherapy of obesity (withdrawal of rimonabant and sibutramine), many compounds are in phase II/III trials. The future holds promise for a new drug that alone or in combination with an existing agent could target the initial pathophysiology and morbidities associated with obesity. (Source: Journal of Clinical Pharmacy and Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Diplopia: case report

(Source: Reactions)

Bupropion: First report of uveal effusion and angle closure glaucoma: case report

(Source: Reactions)

Promoting smoking cessation.

Authors: Larzelere MM, Williams DE Abstract Cigarette smoking causes significant morbidity and mortality in the United States. Physicians can use the five A's framework (ask, advise, assess, assist, arrange) to promote smoking cessation. All patients should be asked about tobacco use and assessed for motivation to quit at every clinical encounter. Physicians should strongly advise patients to quit smoking, and use motivational interviewing techniques for patients who are not yet willing to stop smoking. Clinical contacts with unmotivated patients should emphasize the rewards and relevance of quitting, as well as the risks of smoking and anticipated barriers to abstinence. These messages should be repeated at every opportunity. Appropriate patients should be offered pharmacologic as...

BUPROPION HYDROCHLORIDEtablet, Extended Release [REMEDYREPACK INC. ]

Updated Date: Mar 12, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Par Pharmaceutical, Inc.]

Updated Date: Mar 8, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Par Pharmaceuticals, Inc.]

Updated Date: Mar 7, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment

Conclusions.Initial smoking status did not impact treatment outcomes. Among smokers, results suggest that bupropion may dissociate cigarette and MA use. The effect was modest and a precise pharmacological mechanism remains elusive. Cholinergic systems may be relevant for MA use outcomes. Future studies should continue to assess the role of smoking in MA treatment outcomes.[Brensilver M, Heinzerling KG, Swanson A?N, Telesca D, Furst BA, Shoptaw SJ. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev 2012] (Source: Drug and Alcohol Review)

BUPROPION HYDROCHLORIDEtablet, Extended Release [American Health Packaging]

Updated Date: Mar 2, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [APHENA PHARMA SOLUTIONS - TENNESSEE, INC.]

Updated Date: Mar 2, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion After Nonresponse or Partial Response to an SSRI or SNRI?

This is the third in a series of occasional columns that aim to help clinicians interpret research related to a clinical question. (Source: Psychiatric Times)

Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys

Conclusions&nbsp;&nbsp;Dopamine release and/or inhibition of dopamine transport blocks detection of ?9-THC and is potentially the mechanism by which some therapeutics (e.g., bupropion) reduce the subjective effects of marijuana and enhance the subjective effects of marijuana withdrawal. Content Type Journal ArticleCategory Original InvestigationPages 1-14DOI 10.1007/s00213-012-2661-9Authors David R. Schulze, Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USAF. Ivy Carroll, Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, Durham, NC, USALance R. McMahon, Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 F...

Brief opportunistic smoking cessation interventions: a systematic review and meta?analysis to compare advice to quit and offer of assistance

Conclusions?? Physicians may be more effective in promoting attempts to stop smoking by offering assistance to all smokers than by advising smokers to quit and offering assistance only to those who express an interest in doing so. (Source: Addiction)

Assessment of Depression among African American Light Smokers

Given the relationship between depression and smoking, we compared the two-item Patient Health Questionnaire (PHQ-2) and 10-item Center for Epidemiological Studies Depression Scale (CESD-10) in assessing depressive symptoms among African American light smokers in a clinical trial of bupropion. Of 539 participants, 21.3 percent reported significant depressive symptoms on the PHQ-2, 31.0 percent screened positive per CESD-10, 36.8 percent reported symptoms on either, and 15.6 percent screened positive on both (r = 0.47, p &lt; .001). Having depressive symptoms was associated with less education, decreased positive affect and social support, and greater levels of negative affect and perceived stress. Cessation treatment should assess depression and address these symptoms. (Source: Journal of ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

Updated Date: Feb 27, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Table of Contents

AbstractStudy Looks at How Mania Drugs Differentially Act on Young BrainsRisperidone Superior to Lithium, Divalproex for Bipolar; Some Adverse EventsWhat is the Evidence for the Use of Bupropion in the Treatment of Attention?Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents?Brain Activity Changes in Depressed Youths Taking FluoxetineParent Training in Combination With Risperidone Shows BenefitTreating Preschool OCD With FluoxetineFrequency, Patterns of Use for Antipsychotic Medications in Canadian YouthRisperidone and Parent Training for PDDSertraline Examined for PTSD in Burned ChildrenRisperidone Linked to Incontinence in a Child With AutismNew Warning and Adverse Events for ChantixNew Precaution Listed for Zyban Sustained?Release (Source: The Brown University Child a...

Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial

Conclusions Bupropion SR was effective in promoting smoking cessation during the medication phase of treatment but showed no effect on long-term smoking cessation among African American light smokers. More research is needed to identify strategies for sustaining abstinence among African American light smokers. (Source: JNCI)

Reversal of SSRI-Associated Apathy Syndrome by Discontinuation of Therapy (March).

CONCLUSIONS:In some patients SSRIs may cause an apathy syndrome that can be reversed through discontinuation of the agent. When evaluating patients being treated with an SSRI, clinicians should have a high degree of suspicion and specifically inquire for this iatrogenic form of apathy syndrome. PMID: 22353235 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Carbonyl reduction of bupropion in human liver.

The objective of this study was to examine the enzyme kinetics of bupropion reduction in human liver. 2.??In human liver cytosol, the reduction of bupropion to erythro-and threohydrobupropion was NADPH dependent with Cl(int) values of 0.08 and 0.60 µL·min(-1)mg(-1) protein, respectively. Bupropion reduction in liver microsomes was also NADPH dependent with Cl(int) values of 10.4 and 280 µL·min(-1)mg(-1)protein, respectively. Formation of erythro-and threohydrobupropion in microsomes exceeded that in cytosol by 70 and 170 fold, respectively. 3.??Menadione, an inhibitor of cytosolic carbonyl reducing enzymes (e.g. CBRs), inhibited erythro-and threohydrobupropion formation in cytosol with IC(50) of 30 and 54 µM, respectively. In microsomes 18β-glycyrrhetinic acid, an inhibitor of micr...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Association between polymorphism SLC6A3 3&#8217;UTR VNTR and response to treatment of nicotine dependence

Conclusion: More studies are needed to assess whether the presence of polymorphism SLC6A3 3?UTR VNTR could be associated with a better response to treatment of nicotine dependence. (Source: Jornal Brasileiro de Psiquiatria)

Influence of acute bupropion pre?treatment on the effects of intranasal cocaine

Conclusions?? The atypical antidepressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug. (Source: Addiction)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Par Pharmaceutical, Inc.]

Updated Date: Feb 10, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Comparative Dynamics of Four Smoking Withdrawal Symptom Scales

Conclusion:?? Among a number of different withdrawal symptoms (urge?to?smoke, negative affect, physical symptoms, and hunger) urge?to?smoke trajectory parameters (level, slope, and volatility) over the first 7 days of smoking cessation show the strongest prediction of both short and long term relapse. Other withdrawal symptoms increase the predictive ability by negligible amounts. (Source: Addiction)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [American Health Packaging]

Updated Date: Feb 8, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion: Partial status epilepticus: case report

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Cardinal Health]

Updated Date: Feb 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Antidepressants and the risk of abnormal bleeding during spinal surgery: a case??control study

Conclusion&nbsp;&nbsp;Clinicians treating patients who are planning to undergo elective spinal surgery and are on an antidepressant medication should be aware of this potential effect and should consider tapering off the serotonergic antidepressant prior to surgery. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00586-011-2132-8Authors Amirali Sayadipour, Division of Spinal Surgery, Department of Orthopaedic Surgery, The Rothman Institute, Thomas Jefferson University, 925 Chestnut St, 5th floor, Philadelphia, PA 19107, USARajnish Mago, Department of Psychiatry, Thomas Jefferson University, Philadelphia, USAChristopher K. Kepler, Division of Spinal Surgery, Department of Orthopaedic Surgery, The Rothman Institute, Thomas Jefferson University, 925 Ches...

Neuromodulators for pain management in rheumatoid arthritis

Source: Cochrane Library Area: Evidence &#62; Drug Class Focused Reviews Background Pain management is a high priority for patients with rheumatoid arthritis (RA). Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the management of patients with chronic musculoskeletal pain. &#160; &#160; Objectives The aim of this review was to determine the efficacy and safety of neuromodulators in pain management in patients with RA. Neuromodulators included in this review were anticonvulsants (gabapentin, pregabalin, phenytoin, sodium valproate, lamotrigine, carbamazepine, levetiracetam, oxcarbazepine, tiagabine and topiramate), ketamine, bupropion, methylphenidate, nefopam, capsaicin and the cannabinoids. &#160; Search ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes

Abstract&nbsp;&nbsp;Many smokers attempt to quit smoking but few are successful in the long term. The heritability of nicotine addiction and smoking relapse have been documented, and research is focused on identifying specific genetic influences on the ability to quit smoking and response to specific medications. Research in genetically modified cell lines and mice has identified nicotine acetylcholine receptor subtypes that mediate the pharmacological and behavioral effects of nicotine sensitivity and withdrawal. Human genetic association studies have identified single nucleotide polymorphisms (SNPs) in genes encoding nicotine acetylcholine receptor subunits and nicotine metabolizing enzymes that influence smoking cessation phenotypes. There is initial promising evidence for a role ...

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jan 27, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Neuromodulators for pain management in rheumatoid arthritis.

CONCLUSIONS: There is currently weak evidence that oral nefopam, topical capsaicin and oromucosal cannabis are all superior to placebo in reducing pain in patients with RA. However, each agent is associated with a significant side effect profile. The confidence in our estimates is not strong given the difficulties with blinding, the small numbers of participants evaluated and the lack of adverse event data. In some patients, however, even a small degree of pain relief may be considered worthwhile. Until further research is available, given the relatively mild nature of the adverse events, capsaicin could be considered as an add-on therapy for patients with persistent local pain and inadequate response or intolerance to other treatments. Oral nefopam and oromucosal cannabis have more signif...

Interventions for preventing weight gain after smoking cessation.

CONCLUSIONS: Although some pharmacotherapies tested to limit PCWG show evidence of short-term success, other problems with them and the lack of data on long-term efficacy limits their use. Weight management education only, is not effective and may reduce abstinence. Personalised weight management support may be effective and not reduce abstinence, but there are too few data to be sure. One study showed a VLCD increased abstinence but did not prevent WG in the longer term. CBT to accept WG did not limit PCWG and may not promote abstinence in the long term. Exercise interventions significantly reduced weight in the long term, but not the short term. More studies are needed to clarify whether this is an effect of treatment or a chance finding. Bupropion, fluoxetine, NRT and varenicline reduce...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Global Pharmaceuticals, Division Of Impax Laboratories, Inc.]

Updated Date: Jan 26, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion/alcohol interaction: Aggressive behaviour: case report

(Source: Reactions)

Systematic review of the cost?effectiveness of varenicline vs. bupropion for smoking cessation

Conclusions regarding the cost?effectives were changed upon sensitivity analysis with the following variables: time horizon, cost of bupropion, efficacy of either drug, age and the incidence of smoking related disease. Varenicline dominated bupropion in most cost?effectiveness models. However, applicability of models to clinical practice and variables which changed conclusion of cost?effectiveness should be considered in the interpretation of results. (Source: International Journal of Clinical Practice)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [H.J. Harkins Company, Inc.]

Updated Date: Jan 20, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Treatments for Methamphetamine Abuse: A Literature Review for the Clinician

The objective of this article is to critically review the literature of METH treatment options. Preclinical research and human research with compounds not yet available commercially in the United States will not be included. A literature review was conducted for research on pharmacological treatments for METH use and addiction. Trial information on the use of sertraline, bupropion, mirtazapine, modafinil, dextroamphetamine, ondansetron, risperidone, aripiprazole, baclofen, and gabapentin was reviewed. Aripiprazole trials appeared in the reviewed literature more frequently than the other medications. Based on the findings of this review, no single medication demonstrated consistent efficacy and each trial contained a variety of methodological limitations. (Source: Journal of Pharmacy Practi...

Baclofen/bupropion overdose: Various toxicities: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Hyperinsulinism (first report) and seizures in a neonate after in utero exposure: case report

(Source: Reactions)

Bilateral Uveal Effusion and Angle-Closure Glaucoma Associated With Bupropion Use [Research Letters]

(Source: Archives of Opthalmology)

Pilot Randomized Clinical Trial of an SSRI vs Bupropion: Effects on Suicidal Behavior, Ideation, and Mood in Major Depression. - Grunebaum MF, Ellis SP, Duan N, Burke AK, Oquendo MA, John Mann J.

This study compared a serotonin reuptake inhibitor with a noradrenergic/dopam... (Source: SafetyLit: All (Unduplicated))

Real world evaluation of three models of NHS smoking cessation service in England

Conclusion: The results suggest that service structure, method of support, healthcare professional involved and pharmacotherapy all play a role in a successful quit. Services must be tailored to support individual needs with patient choice and access to varied services being key factors. (Source: BMC Research Notes)

BUPROPION HYDROCHLORIDE EXTENDED RELEASE SR (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Jan 5, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Unexpected aggressive behaviour: Interaction of bupropion and alcohol. - Chandler P, Herxheimer A.

[Abstract unavailable] Language: Eng... (Source: SafetyLit: All (Unduplicated))

Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial.

CONCLUSIONS Patients with general medical conditions can be safely and effectively treated for MDD with antidepressants with no additional adverse effect or tolerability burden relative to their counterparts without such conditions. Combination therapy is not associated with an increased treatment response beyond that found with traditional monotherapy in patients with MDD, regardless of the presence and number of general medical conditions. PMID: 22230827 [PubMed - in process] (Source: Annals of Family Medicine)

Charcoal hemoperfusion for bupropion overdose with ventricular tachycardia and status epilepticus.

Authors: Chao CT, Wu VC, Wang WJ PMID: 22333014 [PubMed - in process] (Source: J Formos Med Assoc)

BUPROPION HYDROCHLORIDEtablet, Extended Release [REMEDYREPACK INC. ]

Updated Date: Dec 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses

Conclusions Sympathetic activity mainly increases the severity of acute episodes of immune-mediated arthritis. Therapeutic reduction of sympathetic activity at acute stages attenuates inflammation, hyperalgesia and proinflammatory immune parameters. (Source: Annals of the Rheumatic Diseases)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

Updated Date: Dec 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Brief opportunistic smoking cessation interventions: a systematic review and meta?analysis to compare advice to quit and offer of assistance

Conclusions?? Physicians may be more effective in promoting attempts to stop smoking by offering assistance to all smokers than by advising smokers to quit and only offering assistance to those that express an interest in doing so. (Source: Addiction)

Rates of 5 Common Antidepressant Side Effects Among New Adult and Adolescent Cases of Depression: A Retrospective US Claims Study.

CONCLUSIONS: Prevalence and risk of the 5 side effects varied across types of antidepressants for both adults and adolescents. Results from this study were consistent with prior clinical trials, suggesting that variation in side effect profiles exists in a more generalized managed care population. PMID: 22177545 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Influence of Acute Bupropion Pretreatment on the Effects of Intranasal Cocaine

Conclusions: The atypical anti?depressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug. (Source: Addiction)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

Updated Date: Dec 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Influence of acute bupropion pre?treatment on the effects of intranasal cocaine

Conclusions?? The atypical antidepressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug. (Source: Addiction)

BUPROPION HYDROCHLORIDE EXTENDED-RELEASE (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

Updated Date: Dec 12, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Dec 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: A promising new molecular pattern for the development of antidepressant drugs.

In this study we have demonstrated that cyclohexane extract of Hypericum polyanthemum (POL) and its main phloroglucinol derivative uliginosin B (ULI) present antidepressant-like activity in rodent forced swimming test (FST). The involvement of monoaminergic neurotransmission on the antidepressant-like activity of ULI was evaluated in vivo and in vitro. POL 90mg/kg (p.o.) and ULI 10mg/kg (p.o.) reduced the immobility time in the mice FST without altering locomotion activity in the open-field test. The combination of sub-effective doses of POL (45mg/kg, p.o.) and ULI (5mg/kg, p.o.) with sub-effective doses of imipramine (10mg/kg, p.o.), bupropion (3mg/kg, p.o.) and fluoxetine (15mg/kg, p.o.) induced a significant reduction on immobility time in FST. The pretreatment with SCH 23390 (15μg/kg,...

A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression

Conclusions: These preliminary results seem to support the hypothesis that in patients unresponsive to SSRIs the administration of antidepressants with different mechanisms of action is an effective switching strategy. Further studies are needed in light of the challenge posed by resistant depression. (Source: Journal of Affective Disorders)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition

There is a need for antidepressants with novel mechanisms of action. One approach has been to develop compounds that inhibit reuptake of all three monoamines in the central nervous system, for example DOV216,303. Differential reinforcement of low-rate (72-s) responding is a behavioral test that is predictive of antidepressant-like properties. The effects of antidepressant compounds belonging to multiple classes, the anxiolytic diazepam and the antipsychotic haloperidol, were assessed in the DRL-72s task. Subsequently, the antidepressant-like properties of acute DOV216,303 were assessed. The selective serotonin reuptake inhibitor fluvoxamine, the preferential norepinephrine reuptake inhibitor desipramine and the tricyclic antidepressant imipramine exhibited antidepressant-like properties in...

Bupropion for adults with attention?deficit hyperactivity disorder: Meta?analysis of randomized, placebo?controlled trials

Conclusion:?? The evidence suggests that bupropion is superior to placebo and effective for the treatment of ADHD in adults. However, its acceptability and tolerability were not significantly higher than those of placebo. (Source: Psychiatry and Clinical Neurosciences)

Forfivo XL (Bupropion Hydrochloride) - updated on RxList

Forfivo XL (Bupropion Hydrochloride) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Antihypertensives/bupropion/insulin/soya oil emulsion: Cardiogenic shock and bradyasystolic arrest: 2 case reports

(Source: Reactions)

Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking

DiscussionCytisine appears to be effective compared with placebo, and given its (current) relative low cost may be an acceptable smoking cessation treatment for smokers, particularly those in low- and middle-income countries. Cytisine's 'natural' product status may also increase its acceptability and use among certain groups of smokers, such as indigenous people, smokers in countries where the use of natural medicines is widespread (e.g. China, India), and in those people who do not want to use NRT or anti-depressants to help them quit smoking. However it is important to ascertain the effectiveness of cytisine compared with that of existing cessation treatments.Trial registrationAustralian New Zealand Clinical Trials Registry (ACTRN12610000590066) (Source: BMC Public Health - Latest articl...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Why two smoking cessation agents work better than one: Role of craving suppression.

Conclusion: Suppression of craving on the quit day significantly mediates the clinical effects of monotherapies and combination smoking pharmacotherapies, and the higher abstinence rates for combination therapy versus monotherapies appear primarily due to greater craving suppression. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (Source: Journal of Consulting and Clinical Psychology)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals ]

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Suicidal behavior and depression in smoking cessation treatments. - Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S.

BACKGROUND: Two treatments for smoking cessation-varenicline and bupropion-carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increase... (Source: SafetyLit: All (Unduplicated))

Outcomes on the pharmacopsychometric triangle in bupropion?SR vs. buspirone augmentation of citalopram in the STAR*D trial

Conclusion:?? In all domains of the pharmacopsychometric triangle, bupropion?SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram. (Source: Acta Psychiatrica Scandinavica)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

High-Dose Bupropion Wins FDA Nod

(MedPage Today) -- The FDA has approved a new, high-dose formulation of the antidepressant drug bupropion, a pill containing 450 mg of the drug, according to its manufacturer. (Source: MedPage Today Psychiatry)

IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300

SAINT LAURENT, Quebec, Nov. 11, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced that the U.S. Food and Drug Administration (FDA) has approved IntelGenx' lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA. (Source: Medical News (via PRIMEZONE))

Bupropion: Hyponatraemia: case report

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

Updated Date: Nov 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation.

This study evaluated a treatment combining bupropion with a novel acceptance and relationship focused behavioral intervention based on the acceptance and relationship context (ARC) model. Three hundred and three smokers from a community sample were randomly assigned to bupropion, a widely used smoking cessation medication, or bupropion plus functional analytic psychotherapy (FAP) and acceptance and commitment therapy (ACT). Objective measures of smoking outcomes and self-report measures of acceptance and relationship processes were taken at pretreatment, posttreatment, 6-month, and 1-year follow-up. The combined treatment was significantly better than bupropion alone at 1-year follow-up with 7-day point prevalence quit rates of 31.6% in the combined condition versus 17.5% in the medication...

Another cessation aid goes up in smoke

Two drugs used to help people stop smoking &mdash; varenicline (Chantix) and bupropion (Zyban) &mdash; carry a significantly increased risk of depression and suicidal or self-injurious behavior, according to a new study published in the Public Library of Science. (Source: Health Facts and Fears)

Suicide risk higher with varenicline than other stop-smoking meds

Chantix should not be a first-line choice for smoking cessation, authors of a new paper say. Their study found significantly more cases of suicidal behavior and depression with varenicline than with bupropion or nicotine replacements. (Source: theHeart.org)

Analysis investigates risks of suicidal behavior and depression with smoking cessation treatments

Source: PLoS One Area: News The findings of this American study suggest that varenicline is associated with a significantly increased risk for suicidal behavior and depression. Bupropion, for smoking cessation, was found to be associated with smaller increased risks. &#160; The researchers note that both varenicline and bupropion are treatments for smoking cessation and both carry Boxed Warnings from the United States Food and Drug Administration (U.S FDA) relating to suicidal/self-injurious behavior and depression. They examined the comparative neuropsychiatric safety profiles of varenicline and bupropion with regard to suicidal/self-injurious behavior and depression as reflected in adverse drug event data. Data for serious injury case reports between 1998 and September 2010 from the...

Greater Suicide Risk With Varenicline vs Other Cessation MedsGreater Suicide Risk With Varenicline vs Other Cessation Meds

A comparison study of smoking cessation medications shows that varenicline was associated with significantly more cases of suicidal behavior and depression than bupropion or nicotine replacement therapy. Medscape Medical News (Source: Medscape Today Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials

Authors: David P King, Sara Paciga, Eve Pickering, Neal L Benowitz, Laura J Bierut, David V Conti, Jaakko Kaprio, Caryn Lerman & Peter W Park Keywords: pharmacogenetics&#47;pharmacogenomics; addiction and substance abuse; clinical pharmacology&#47;clinical trials; neuropharmacology; varenicline; bupropion; nicotine; smoking cessation; nicotinic receptors (Source: Neuropsychopharmacology)

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.

CONCLUSIONS: Although our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that could mediate adverse effects of antidepressant medication. PMID: 22041458 [PubMed - as supplied by publisher] (Source: Psychological Medicine)

Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals

Abstract: Cigarette smoking is prevalent in cocaine/methamphetamine-dependent patients and associated with significant morbidity and mortality, yet, the provision of smoking cessation treatment in conjunction with substance use disorder (SUD) treatment is not standard practice. This is due, in part, to clinician concern that combining smoking cessation treatment with SUD treatment could lead to poorer SUD outcomes. The NIDA Clinical Trials Network is conducting a 10-week, two-group, randomized trial to evaluate the impact of providing smoking cessation treatment (SCT) with SUD treatment as usual (TAU), compared to TAU alone, in smokers who are in outpatient treatment for cocaine or methamphetamine dependence. Approximately 528 participants, recruited from 12 community treatment programs, w...

Bupropion No 'Magic Bullet' in Post-MI SmokersBupropion No 'Magic Bullet' in Post-MI Smokers

A trial of bupropion in long-time smokers immediately post-AMI found no benefits of the drug at 1 year, suggesting that despite a 'life-changing event,' smokers struggle to kick the habit. Heartwire (Source: Medscape Today Headlines)

A Novel, Nonbinary Evaluation of Success and Failure Reveals Bupropion Efficacy Versus Methamphetamine Dependence: Reanalysis of a Multisite Trial.

Authors: McCann DJ, Li SH Abstract A multisite, double-blind, placebo-controlled trial of bupropion for methamphetamine dependence was reanalyzed using a novel, nonbinary method of evaluating success and failure. The original analysis focused on a group response endpoint (the change in percentage of participants with methamphetamine-free urines each week over the course of the trial) and no significant bupropion effect was observed in the total population of study participants. In this reanalysis, individual participants were regarded as treatment success if they achieved multiple weeks of abstinence lasting through the end of the study, and their degree of success was quantified by calculating the number of beyond-threshold weeks of success (NOBWOS). Thus, setting the threshold at...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of heart disease on depression treatment: results from the COMED study

Abstract: Objective: To determine the impact of self-reported heart disease (HD) on major depressive disorder (MDD) treatment outcomes.Method: This single-blind, 7-month prospective randomized trial enrolled 665 participants, 18??75 years old, from six primary and nine psychiatric care sites across the USA. Participants had at least moderately severe (baseline 17-item Hamilton Rating Scale of Depression ?16), nonpsychotic chronic and/or recurrent MDD. Participants with and without self-reported HD were randomized into three treatment groups (1:1:1 ratio): escitalopram plus placebo, bupropion sustained-release plus escitalopram or venlafaxine extended-release plus mirtazapine. The primary outcome (remission) was defined by the last two consecutive 16-item Quick Inventory of Depressive Sy...

Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges in a 13-Year-Old Girl After an Overdose and Respiratory Arrest

Paramedics found a 13-year-old, previously healthy girl with depression at home and unresponsive after overdosing on bupropion and baclofen. She was observed to be in respiratory arrest and bradycardic, with a Glasgow Coma Scale score of 3. Chest compressions were required, and she was intubated. During transport, she was hypothermic with decerebrate posturing, and manifested a 1-minute, self-terminating, generalized tonic-clonic seizure. In the pediatric intensive care unit, she received intermittent doses of lorazepam and fentanyl for sedation. She remained comatose, and continuous video-electroencephalogram monitoring was initiated to evaluate her for nonconvulsive seizures. (Source: Pediatric Neurology)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pilot Randomized Clinical Trial of an SSRI vs Bupropion: Effects on Suicidal Behavior, Ideation, and Mood in Major Depression

Authors: Michael F Grunebaum, Steven P Ellis, Naihua Duan, Ainsley K Burke, Maria A Oquendo & J John Mann Keywords: depression; unipolar; bipolar; psychopharmacology; clinical pharmacology; clinical trials; mood; anxiety; stress disorders; suicidal behavior; suicidal ideation (Source: Neuropsychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Application of the conditioned taste aversion paradigm to assess discriminative stimulus properties of psychostimulants in rats

Conclusion: These results suggest that discriminative stimulus properties of psychostimulants can be evaluated using the CTA paradigm. (Source: Drug and Alcohol Dependence)

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: Results from a randomized, double-blind, placebo-controlled study

Conclusions: Findings do not support combining nicotine patch and bupropion for smoking cessation in this population. However, findings support previous studies suggesting the importance of assessing the blind in smoking cessation studies and its possible moderating effect on medication efficacy. Future directions for enhancing smoking cessation outcome in these smokers include investigations of intensive behavioral and pharmacological interventions, including studies of potential interactions between individual genetic differences and medication efficacy. (Source: Drug and Alcohol Dependence)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Eon Labs, Inc.]

Updated Date: Oct 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

OBESITY: CVD Risk Cut With Rejected Weight-Loss Drug (CME/CE)

ORLANDO (MedPage Today) -- It appears that the investigational weight-loss combination of naltrexone standard release and bupropion standard release (Contrave) reduces the predicted 10-year risk of cardiovascular events, an analysis of four phase III trials showed. (Source: MedPage Today Pediatrics)

Partial Status Epilepticus after Electroconvulsive Therapy and Medical Treatment with Bupropion

We report a patient who received right unilateral ECT under concomitant treatment with bupropion, a selective noradrenaline- and dopamine-reuptake inhibitor. After the fourth session, a focal status epilepticus occurred, which was pharmacoresistant for the duration of 12 days. We assume that the induction of a status may be facilitated by a lowering of the seizure threshold due to bupropion. An evaluation of drug therapy and control of EEG before and during ECT are recommended, especially when the drug treatment has an influence on the seizure threshold.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents  |  Abstract  |  Full text (Source: Pharmacopsychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Manipulation of Cigarette Craving with Transcranial Magnetic Stimulation

The health risks and societal costs of cigarette smoking are well documented, but the prevalence of smoking among American adults remains high at approximately 20%. Most smokers endorse a desire to quit, but very few (only about 4??7%) will actually do so in a given year without treatment. Current commonly used treatments for tobacco dependence include nicotine replacement therapy (e.g., patch, gum, and lozenge), varenicline HCl (Chantix), bupropion HCl (Zyban), and group and/or individual psychotherapy. These treatments result in roughly 20??25% abstinence rates in smokers at 6 months or more after treatment initiation and are therefore considerably better than attempting abstinence without treatment. However, there continues to be a vital need to improve treatments for cigarette smoker...

Bupropion: Aphthous ulcers: case report

(Source: Reactions)

Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial [Articles]

Conclusions: Despite differences in sociodemographic characteristics and comorbidities, when measurement-based care was used, members of different minority groups had similar outcomes when treated with one antidepressant or a combination of two antidepressants. Black participants had the highest attrition rate, an important issue to address in clinical care. (Psychiatric Services 62:1167&ndash;1179, 2011) (Source: Psychiatr Serv)

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

Conclusion: These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action. PMID: 21951371 [PubMed - in process] (Source: CNS Neuroscience and Therapeutics)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Dispensing Solutions, Inc.]

Updated Date: Sep 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion hydrobromide propanol hemisolvate

The title compound {systematic name: N-[1-(3-chlorophenyl)-1-oxopropan-2-yl]-tert-butanaminium bromide propanol hemisolvate}, C13H19ClNO+·Br??·0.5C3H8O, crystallizes with two independent bupropion hydrobromide ion pairs and a solvent 1-propanol molecule in the asymmetric unit. In both molecules, the expected proton transfer from HBr to the amino group of the bupropion molecule is observed, and intra- and intermolecular N??H...Br hydrogen-bond interactions are formed. These interactions link the molecules into hydrogen-bond dimers. The side chains of the two cations have slightly different orientations. The 1-propanol solvent molecule is linked to a bromide ion by an O??H...Br hydrogen bond. (Source: Acta Crystallographica Section E)

NEJM drops the ball on smoking cessation

A lengthy article in this week??s New England Journal of Medicine catalogues a variety of approaches to helping smokers quit within the healthcare setting, including counseling, smoking cessation medications such as bupropion and varenicline, as well as conventional nicotine replacement modalities like gum, inhalers, and patches. (Source: Health Facts and Fears)

Can??t teach an old anti-smoking drug new tricks

A lengthy article in this week??s New England Journal of Medicine catalogues a variety of approaches to helping smokers quit within the healthcare setting, including counseling, smoking cessation medications such as bupropion and varenicline, as well as conventional nicotine replacement modalities like gum, inhalers, and patches. (Source: Health Facts and Fears)

Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models.

Authors: Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, Michotte Y, Crawford AD, Esguerra CV, de Witte PA, Smolders I, Clinckers R Abstract In the past, antidepressants have been thought to possess proconvulsant properties. This assumption remains controversial, however, because anticonvulsant effects have been attributed to certain antidepressants. To date, it remains unclear which antidepressants can be used for the treatment of patients with epilepsy with depression. The present study was designed to determine the anticonvulsant and/or proconvulsant effects of three antidepressants (citalopram, reboxetine, bupropion) against pilocarpine- and pentylenetetrazole-induced acute seizures in larval zebrafish and mice. In zebrafish, all antidepressants were ant...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Apotex Corp]

Updated Date: Sep 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Nicotine deprivation is associated with craving, negative affect, and difficulty concentrating, which may contribute to subsequent relapse. Bupropion and varenicline are both effective treatments for smoking cessation, and evidence from clinical trials suggests that these treatments increase abstinence rates. However, the mechanism by which these medications reduce relapse remains unclear. Recent research has focused on cognitive processes, such as attention and working memory, which may predict relapse. In addition, there may also be sex differences in cognitive-related deficits during nicotine deprivation. The current sample consisted of 58 (22 females) daily smokers (at least 10 cigarettes per day) randomized to receive bupropion (300 mg/day), varenicline (2 mg/day), or placebo. After a...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Dispensing Solutions, Inc.]

Updated Date: Sep 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet [Dispensing Solutions, Inc.]

Updated Date: Sep 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Diet Drugs Get a New Slim Chance at Approval

Contrave, the investigational diet pill combination of naltrexone and bupropion, has been granted a possible new lease on life by the FDA. In January of this year the FDA issued a complete response letter to Orexigen, the drug's sponsor. Now Orexigen says that it has received guidance from the FDA that could lead to approval of the drug in 2014. (Source: Forbes.com Healthcare News)

[Interactions between metoprolol and antidepressants].

Conclusion. Metoprolol should not be used concomitantly with paroxetine, fluoxetine or bupropion due to extensive interactions and the risk of serious adverse effects. Dose reductions of metoprolol should be considered for combined treatment with citalopram, escitalopram or duloxetine, while concurrent use with sertraline, venlafaxine, mianserin and mirtazapine should be safe. PMID: 21946596 [PubMed - in process] (Source: Tidsskrift for den Norske Laegeforening)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial

The objective of this manuscript is to report associations between baseline depressive severity and (1) baseline sociodemographic and clinical characteristics, (2) treatment outcomes, and (3) differential outcomes for three treatment groups. Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine). For purposes of these analyses, participants were divided into four groups based on baseline severity by the 16-item Quick Inventory of Depressive Symptomatology ?? Self-Report (...

Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study

This study sought to compare Bupropion versus Sertraline in the treatment of depressed patients with Binge Eating Disorder (BED) prescribed off-label. Medical records of outpatients with diagnosis of BED and Depression (DSM-IV-TR criteria) were selected: 15 patients were treated with bupropion 150&nbsp;mg/per day, and 15 with sertraline 200&nbsp;mg/per day. During the screening and control visits (2°??6°??14°??24°&nbsp;week), the selected patients were first weighed and then evaluated using the following questionnaires: Binge Eating Disorder-Clinical Interview (BEDCI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory X (STAI-X) and Arizona Sexual Experience Scale (ASEX). Both drugs reduced anxious-depressive symptoms and binge frequency: Bupropion showed a better...

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: Sep 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Brain energy metabolism is increased by chronic administration of bupropion

Conclusions: Our results demonstrated that bupropion increased some enzymes of brain energy metabolism. These findings are in accordance with other studies which showed that some antidepressants may improve energy metabolism. The present results reinforce the hypothesis that antidepressants modulate brain energy metabolism. (Source: Acta Neuropsychiatrica)

Sociodemographic and clinical factors associated with antidepressant type in a national sample of the home health care elderly

Conclusion: Race/ethnicity and age differences by AD type ?? including blacks' increased TCA use, Hispanics' decreased SNRI and ??Other? AD use, and older elderly's increased tricyclic use ?? suggest systematic differences in prescribing practice variations including differences by geography, patient preferences or access to care in the HHC elderly. (Source: General Hospital Psychiatry)

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet [REMEDYREPACK INC. ]

Updated Date: Sep 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

Updated Date: Sep 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disorders

AbstractWe have demonstrated that neonatal exposure to selective serotonin reuptake inhibitors has lasting effects on behavior and serotonergic neurons in Long Evans rats. Hyperserotoninemia and altered sensory processing are reported in autistic spectrum disorders (ASD). We hypothesized that early life exposure to SSRIs alters sensory processing, disrupts responses to novelty, and impairs social interactions in a manner similar to that observed in ASD. Male and female Long?Evans rat pups were administered citalopram, buproprion, fluoxetine, or saline from postnatal day (P) 8??21. Rats were tested for response to a novel tone before weaning (P25). Later, rats were tested 2? for response to a novel object (P39), and to a novel conspecific (P78, P101). In addition, rats were assessed for...

Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disorders.

Authors: Rodriguez-Porcel F, Green D, Khatri N, Harris SS, May WL, Lin RC, Paul IA Abstract We have demonstrated that neonatal exposure to selective serotonin reuptake inhibitors has lasting effects on behavior and serotonergic neurons in Long Evans rats. Hyperserotoninemia and altered sensory processing are reported in autistic spectrum disorders (ASD). We hypothesized that early life exposure to SSRIs alters sensory processing, disrupts responses to novelty, and impairs social interactions in a manner similar to that observed in ASD. Male and female Long-Evans rat pups were administered citalopram, buproprion, fluoxetine, or saline from postnatal day (P) 8-21. Rats were tested for response to a novel tone before weaning (P25). Later, rats were tested 2? for response to a novel o...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes.

Authors: Jacobsen JK, Jensen B, Skonberg C, Hansen SH, Badolo L Abstract The organic cation transporter 1 (Oct1) has been shown to be one of the most abundant uptake transporters responsible for the uptake of xenobiotics from the sinusoidal blood across the basolateral membrane of hepatocytes. On the same membrane the multidrug resistance-associated protein 3 (Mrp3) mediates the efflux of xenobiotics or their metabolites from the hepatocytes to the blood allowing their systemic exposure. In the present study we investigated the expression and activity of Oct1 and Mrp3 in suspensions and in monolayer- and sandwich cultures, and activities of CYP2B1/2, 2D1, and 3A1 in monolayer- and sandwich cultures of cryopreserved rat hepatocytes. Oct1-mediated active uptake of 10μM [(3)H]-1-meth...

Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second?line medication strategies for treating depression?

Conclusions: Remission and response rates following initial antidepressant treatment failure did not differ by treatment strategy for patients with coexisting atypical symptoms or insomnia. However, some second?step treatments for depression may be more effective than others in the presence of coexisting low energy. Subsequent prospective testing is necessary to confirm these initial findings. Depression and Anxiety 0:1??10, 2011. © 2011 Wiley?Liss, Inc. (Source: Depression and Anxiety)

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Sep 1, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Sep 1, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion as an Augmenting Agent in Patients of Depression with Partial Response

In conclusion, bupropion add?on can act as augmenting agent in patients of depression with partial response to SSRIs. (Source: Basic and Clinical Pharmacology and Toxicology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [H.J. Harkins Company, Inc.]

Updated Date: Aug 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet [REMEDYREPACK INC. ]

Updated Date: Aug 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Aug 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature

Conclusions: The literature is incomplete and in some cases contradictory. In selected cases, bupropion appears to be associated with the induction of psychotic symptoms in addition to the precipitation or worsening of an existing psychotic syndrome. Further research including controlled studies is required to clarify the risk of bupropion precipitating a psychotic illness in vulnerable populations. (Source: General Hospital Psychiatry)

Bupropion: Oromandibular dyskinesia: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

A Prospective Single-arm Open-label Study of Baclofen and Bupropion SR Combination Therapy for Smoking Cessation

Conclusions: Combination of baclofen and bupropion SR seems safe and well tolerated with preliminary efficacy for smoking cessation comparing favorably with current first-line smoking cessation aids. The combination of baclofen and bupropion SR may provide an additional treatment option to varenicline or bupropion SR monotherapy. (Health Canada Clinical Trial Registration Control number: 105226). (Source: Addictive Disorders and Their Treatment)

Cost?effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support

Conclusions:?? Physician brief advice is a cost?effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost?effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future. (Source: Addiction)

Using the Internet to Understand Smokers&#8217; Treatment Preferences: Informing Strategies to Increase Demand

Conclusions: Smokers accessing the Internet for information on quitting appear to differentiate cessation treatments by how much interpersonal interaction or support the treatment entails. Quitting date, smoking level, and sociodemographic variables can identify smokers with varying levels of interest in the 3 classes of cessation methods identified. These results can potentially be used to more effectively target and increase demand for these treatments among smokers searching the Internet for cessation information. (Source: Journal of Medical Internet Research)

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report

Conclusions: We found no evidence of differential remission or response rates to antidepressant combination or monotherapy between melancholic/non-melancholic MDD patients, or according to antidepressant treatment group, after 12 and 28weeks. Melancholic features may not be a valid predictor of more favorable response to antidepressant combination therapy as initial treatment. (Source: Journal of Affective Disorders)

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

Updated Date: Aug 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

[Snus and cardiovascular risk.]

Authors: Underner M, Perriot J, Sosner P, Herpin D Abstract The use of "snus" (smokeless tobacco) can be detrimental to health. Snus delivers rapidly high doses of nicotine which can lead to addiction. The use of snus increases the risk of myocardial infarction and stroke. Nicotine substitution therapy as well as bupropion and varenicline reduce withdrawal symptoms and tobacco craving during snus cessation. However, they have been shown not to assist in long-term abstinence. Information concerning potential cardiovascular hazards of snus must be incorporated into health educational programs in order to discourage its use. Snus is not a recommended product to help stop smoking. PMID: 21872211 [PubMed - as supplied by publisher] (Source: Annales de Cardiologie et d'Angeiologie)

Bupropion and Restless Legs SyndromeBupropion and Restless Legs Syndrome

Many antidepressants seem to exacerbate restless leg syndrome, but buproprion may prove to be an exception. Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)

Hyphenating the curtius rearrangement with Morita-Baylis-Hillman adducts: synthesis of biologically active acyloins and vicinal aminoalcohols

Using Morita-Baylis-Hillman adducts as substrates, the Curtius rearrangement was performed in a sequence that allowed the synthesis of several hydroxy-ketones (acyloins) with great structural diversity and in good overall yields. These acyloins in turn were easily transformed into 1,2-anti aminoalcohols through a highly diastereoselective reductive amination step. The synthetic utility of these approaches was exemplified by performing the syntheses of (±)-bupropion, a drug used to treat the abstinence syndrome of smoker and (±)-spisulosine, a potent anti-tumoral compound originally isolated from a marine source.Um rearranjo de Curtius, utilizando adutos de Morita-Baylis-Hillman como substrato, foi realizado em uma sequência que permitiu a síntese de várias hidroxi-cetonas (aciloínas)...

---

Presse Med. 2011 Aug 11; Authors: Underner M, Perriot J, Peiffer G Abstract The use of snus (smokeless tobacco) can be detrimental to health. Containing carcinogenic nitrosamines (Swedish snus do not contain nitrosamine). Snus delivers rapidly high doses of nicotine which can lead to dependence. It do not induce bronchial carcinoma differently smoked tobacco. Lesions usually develop in the area of the mouth where the snus is placed. Non-malignant oral lesions include leukoedema, hyperkeratotic lesions of the oral mucosa and localised periodontal disease. The most frequently occurring premalignant lesion is leukoplakia. Studies reveal conflicting evidence about the risk of oral and gastroesophageal cancer with regard to snus users. However, the use of snus has proved to be a ris...

APPBUTAMONE (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

Updated Date: Aug 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

APPBUTAMONE-D (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

Updated Date: Aug 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [UDL Laboratories, Inc.]

Updated Date: Aug 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion-SR for Smoking Cessation in Early Recovery from Alcohol Dependence: A Placebo-Controlled, Double-Blind Pilot Study.

Authors: Karam-Hage M, Strobbe S, Robinson JD, Brower KJ We conducted a double-blind pilot study involving 11 alcohol- and nicotine-dependent patients randomized to receive either bupropion or placebo. Four of six patients on bupropion and one of five patients on placebo were abstinent from smoking at the end of medication phase. Those in the bupropion group reported significantly less craving (p &lt; .02) and less exposure to cigarette smoke over time (expired carbon monoxide; p &lt; .01). There were no serious adverse events and no main effects of medication group on either per subject or total number of adverse events. All those who completed treatment remained abstinent from alcohol. PMID: 21797811 [PubMed - as supplied by publisher] (Source: The American Journal of Drug and Al...

Treatment of Apathy in Huntington??s Disease and Other Movement Disorders

Opinion statement&nbsp;&nbsp;Apathy is one of the most prevalent neurobehavioral symptoms in Huntington??s disease (HD), occurring in approximately 70% of the symptomatic HD population. Apathy scores in patients with HD are highly correlated with duration of illness, suggesting that apathy is an inevitable consequence of advanced disease. Although less distressing than symptoms like depression and less disruptive than irritability or aggression, apathy has a considerable adverse impact on those affected with HD because it leads to a decrease of the goal-directed behaviors that contribute much to the day-to-day quality of life. As a neuropsychiatric syndrome, apathy is also common in patients with other neuropsychiatric disorders such as Parkinson??s disease, traumatic brain injury,...

Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia

ConclusionsOf antidepressants studied, only mirtazapine had a statistically significantly greater SD/VA risk versus paroxetine. However, baseline differences between these users suggest that this finding may be attributable to residual confounding. Eleven other antidepressants had SD/VA risks no greater than that of paroxetine, thereby providing reassurance regarding the comparative cardiovascular safety of antidepressants. Copyright © 2011 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)

BUPROPION HYDROCHLORIDEtablet, Film Coated [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Jul 26, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Interaction of bupropion and zinc with neuronal nicotinic acetylcholine receptors.

Authors: García-Colunga J, Godoy-García U, Vázquez-Gómez E Zinc is known to exert antidepressant-like actions and to make the effects of some antidepressants more efficient in animal models of depression. Both zinc and bupropion interact with nicotinic acetylcholine receptors (nAChRs) which are related with depression. Here we examined the effects of bupropion, in the absence and presence of zinc, on the ion current elicited by acetylcholine (ACh-current) in Xenopus oocytes expressing neuronal α4β4 nAChRs. We found that bupropion-inhibited ACh-currents depending on ACh and bupropion concentrations. Thus, the IC(50) of bupropion was lower with a higher ACh concentration: 3.51 and 2.27 μM for the current elicited with 0.5 and 2 μM ACh, respectively. The inhibitory effect of bup...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion overdose: Generalised seizure, sinus tachycardia and ST segment elevation: case report

(Source: Reactions)

Factors associated with smoking menthol cigarettes among treatment-seeking African American light smokers.

CONCLUSIONS: Among AA light smokers, younger individuals and females were more likely to smoke menthol cigarettes and may be more susceptible to the health effects of smoking. Appropriately targeted health education campaigns are needed to prevent smoking uptake in this high-risk population. PMID: 21816543 [PubMed - as supplied by publisher] (Source: Addictive Behaviors)

BUPROPION HYDROCHLORIDEtablet, Film Coated [STAT RX USA LLC]

Updated Date: Jul 21, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion: First report of acute generalised exanthematous pustulosis: case report

(Source: Reactions)

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Jul 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect

Context Cigarette smoking is the leading cause of preventable premature death in the world, with an estimated 5 million smoking-related deaths worldwide. Quitting substantially reduces the health risk associated with smoking. Treatments available for smoking cessation include nicotine replacement therapies (NRTs), bupropion and the most recently marketed, varenicline. Varenicline, an analogue of cytisine, is a partial agonist for the &alpha;4&beta;2 subtype of nicotinic cholinergic receptors, which are associated with the addictive effects of nicotine. Varenicline may help smokers quit smoking by reducing the rewarding effects of nicotine as well as attenuating the withdrawal symptoms.1 This meta-analysis evaluated the efficacy and safety of partial nicotine agonists, varenicline or cytisi...

Disseminated eruption of ectopic sebaceous glands following Stevens-Johnson syndrome

To the Editor: An 18-year-old white woman presented with a 1-year history of numerous asymptomatic, yellowish and skin-colored papules and plaques diffusely involving her face and chest. She reported that these lesions had developed approximately 4 months after an episode of lamotrigine-induced Stevens-Johnson syndrome (SJS). She had received only supportive care during her hospitalization for SJS; she had not received skin grafts to the face or chest. The patient was otherwise healthy except for history of a mood disorder, which was well controlled with bupropion and aripiprazole. She also periodically used eye drops (loteprednol and cyclosporine) for chronic eye irritation secondary to SJS. (Source: Journal of the American Academy of Dermatology)

Bupropion: Exacerbation of psoriasis and drug eruption: case report

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [American Health Packaging]

Updated Date: Jul 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion ??safe but ineffective?? in ACS smokers

Israeli researchers report that bupropion is safe for acute coronary syndrome patients, but it is not an effective smoking cessation aid. (Source: MedWire News - Cardiology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Life?Threatening Bupropion Ingestion: Is There a Role for Intravenous Fat Emulsion?

We present a 51?year?old woman with severe bupropion toxicity whose haemodynamic status transiently improved following intravenous fat emulsion. Serum analysis demonstrated an increase of serum concentration of hydroxybupropion, an active metabolite of bupropion, following IFE administration, lending support to one of the proposed mechanisms of IFE.Case report:?? A 51?year?old woman presented to the emergency department with generalized tonic?clonic convulsions lasting approximately 30 sec., and a wide complex rhythm on her ECG that was suggestive of myocardial sodium channel blockade. Despite sodium bicarbonate therapy, the patient developed profound hypotension refractory to high?dose norepinephrine. Intravenous fat emulsion (IFE) was administered with haemodynamic improveme...

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study [Articles]

Conclusions: Neither medication combination outperformed monotherapy. The combination of extended-release venlafaxine plus mirtazapine may have a greater risk of adverse events. (Source: Am J Psychiatry)

Clinical Inquiry: Which smoking cessation interventions work best?

Authors: Mahvan T, Namdar R, Voorhees K, Smith PC, Flake D Nicotine replacement therapy, bupropion, nortriptyline, clonidine, and varenicline are all effective, although insufficient evidence exists to recommend one intervention over another. Effective nonpharmacologic interventions include brief physician advice and more intensive counseling, such as proactive telephone counseling, group and individual counseling, and use of quit lines. PMID: 21731922 [PubMed - in process] (Source: The Journal of Family Practice)

Reversibility of impaired nasal mucociliary clearance in smokers following a smoking cessation programme

Conclusions:?? A SC programme contributed to improvement in MC among smokers from the 15th day after cessation of smoking, and these beneficial effects persisted for 180??days. (Source: Respirology)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Preferred Pharmaceuticals, Inc]

Updated Date: Jun 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

Updated Date: Jun 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

Updated Date: Jun 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome [Original Investigation]

Conclusion&nbsp; In hospitalized patients with ACS who received continuous, intensive nurse counseling about smoking cessation, bupropion did not increase the rates of smoking abstinence. (Source: Archives of Internal Medicine)

Diet Drug Combination Sheds Weight in Obese Diabetic WomenDiet Drug Combination Sheds Weight in Obese Diabetic Women

Combination therapy with naltrexone plus bupropion is shown to reduce body weight and glycosylated hemoglobin in overweight and obese women with type 2 diabetes. Medscape Medical News (Source: Medscape Today Headlines)

Diet drug combo sheds weight in obese diabetic women

Combination therapy with naltrexone SR/bupropion SR is shown to reduce body weight and HbA1c in overweight/obese women with type 2 diabetes. For complete story visit theheart.org. (Source: theHeart.org)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [Rebel Distributors Corp]

Updated Date: Jun 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combination therapy with naltrexone and bupropion for obesity

Expert Opinion on Pharmacotherapy, Volume 0, Issue 0, Page 1-14, Early Online. (Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Golden State Medical Supply, Inc]

Updated Date: Jun 21, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

Updated Date: Jun 20, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [Golden State Medical Supply, Inc]

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Bryant Ranch Prepack]

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion and Panic Disorder: Case Report and Review of the Literature [LETTERS TO THE EDITOR]

(Source: J Neuropsychiatry Clin Neurosci)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion-Induced Mania and Hypomania: A Report of Two Cases [LETTERS TO THE EDITOR]

(Source: J Neuropsychiatry Clin Neurosci)

Gustatory and Olfactory Hallucinations Under Therapeutic Dosing of Bupropion [LETTERS TO THE EDITOR]

(Source: J Neuropsychiatry Clin Neurosci)

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jun 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation

Conclusions:?? Bupropion and nortriptyline seem to be more effective in smoking cessation among SLC6A4 high?activity variant carriers, probably by blocking the increased serotonin transporter activity, thereby increasing serotonin levels. Prospective studies have to assess if this can improve cessation rates when treatment is targeted at individuals based on their genotypes. (Source: Addiction)

BUPROPION HYDROCHLORIDEtablet, Film Coated [NCS HealthCare Of KY, Inc Dba Vangard Labs]

Updated Date: Jun 9, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Drug Maker Drops US Approval Efforts for Contrave

The drug maker whose new drug application for its combination naltrexone/bupropion diet drug was rejected by the FDA says it is shelving plans to seek approval in the US "until a clear and feasible path to regulatory approval is identified." Heartwire (Source: Medscape Medical News Headlines)

Drug Maker Drops US Approval Efforts for ContraveDrug Maker Drops US Approval Efforts for Contrave

The drug maker whose new drug application for its combination naltrexone/bupropion diet drug was rejected by the FDA says it is shelving plans to seek approval in the US "until a clear and feasible path to regulatory approval is identified." Heartwire (Source: Medscape Cardiology Headlines)

Diet drug maker drops US approval efforts, protesting FDA's insistence on CV data

The drug maker whose new drug application for its combination naltrexone/bupropion diet drug was rejected by the FDA says it is shelving plans to seek approval in the US "until a clear and feasible... For complete story visit theheart.org. (Source: theHeart.org)

Diet Drug Won't Make It to Market in U.S., Company Says

WASHINGTON (MedPage Today) -- The makers of the last potentially promising diet drug announced that its naltrexone/bupropion combination pill won't be marketed in the U.S. because of overly burdensome requests for data from the FDA. (Source: MedPage Today State Required CME)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Bruxism: case report

(Source: Reactions)

Orexigen Therapeutics Provides a Regulatory Update on Contrave NDA

SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen Therapeutics, Inc. announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave (naltrexone HCl/bupropion HCl)... (Source: Drugs.com - New Drug Applications)

Women who smoke - A review of the evidence.

This article presents a summary of the evidence and a range of gender specific strategies that general practitioners can use to optimise the support they give to female smokers. DISCUSSION Women may need more intensive behavioural and pharmacological support when quitting. Particular emphasis should be placed on addressing stress, social support, smoking cues and concerns about weight gain. Nicotine replacement therapy is less effective in women. However, it is still useful if used in adequate doses and can be used in pregnancy if the woman is unlikely to quit without it. Varenicline and bupropion are not approved in pregnancy or in lactation. PMID: 21655488 [PubMed - in process] (Source: Australian Family Physician)

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: May 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile

The objectives were to elucidate its cardiac electrophysiological properties. Patch?clamp technique was used to assess the IKr?, IKs?, and INa?blocking effects of bupropion. Langendorff retroperfusion technique on isolated guinea?pig hearts was used to evaluate the MAPD90?, MAP amplitude?, phase 0 dV/dt?, and ECG?modulating effects of bupropion and of two gap junction intercellular communication inhibitors: glycyrrhetinic acid and heptanol. To evaluate their effects on cardiac intercellular communication, fluorescence recovery after photobleaching (FRAP) technique was used. Bupropion is an IKr blocker. IC50 was estimated at 34??μm. In contrast, bupropion had hardly any effect on IKs and INa. Bupropion had no significant MAPD90?modulating effect. However, as glycyrrhet...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: May 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet, Film Coated [REMEDYREPACK INC. ]

Updated Date: May 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence

Conclusions&nbsp;&nbsp;The evidence that the ratio is related to smoking behaviours and to cigarette dependence is limited, but the ratio seems to influence treatment response to two stop smoking medications. Further studies of the relationship between the ratio and cigarette dependence and trials of ratio-guided pharmacotherapy are needed. Content Type Journal ArticlePages 1-10DOI 10.1007/s00213-011-2341-1Authors Oliver West, UK Centre for Tobacco Control Studies, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AD UKPeter Hajek, UK Centre for Tobacco Control Studies, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University...

Pharmacotherapeutic Management of Nicotine Dependence in Pregnancy

Smoking in pregnancy can cause serious adverse antenatal and postnatal morbidities, and a significant number of women continue to smoke in pregnancy despite these consequences. Early intervention in the form counseling from their physicians, pregnancy-specific self-help materials, counseling sessions with a health educator, and/or continued follow-up can result in better pregnancy outcomes and possibly long-term cessation. If a woman cannot quit despite these measures, pharmacotherapy can be considered. Currently, nicotine replacement therapy (NRT), transdermal patches, and bupropion are used in pregnancy, but data on the safety and efficacy are largely lacking. (Source: Obstetrics and Gynecology Clinics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: May 17, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [REMEDYREPACK INC. ]

Updated Date: May 12, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: May 11, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

APPBUTAMONE (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

Updated Date: May 11, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The dynamics of the urge?to?smoke following smoking cessation via pharmacotherapy

Conclusion: Higher urge?to?smoke trajectory parameters of level, slope, and volatility (measured over 7 days) predict continuous and 7 day point prevalence at EOT and 6 months. Although there were some associations of trajectory parameters with demographics and smoking history, the associations of trajectory parameters with relapse were relatively uninfluenced by demographics and smoking history. (Source: Addiction)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The impact of the introduction of smokefree legislation on prescribing of stop?smoking medications in England

Conclusions: Numbers of primary care prescriptions for smoking cessation medications increased prior to the introduction of smokefree legislation but decreased afterwards, suggesting a temporal displacement in prescribing activity rather than a change in the overall volume of prescribing. Effects observed were consistent across all population subgroups, suggesting that the changes in prescribing will neither widen nor reduce smoking?related health inequalities. (Source: Addiction)

Cost Effectiveness of Interventions to Reduce Relapse to Smoking Following Smoking Cessation

Conclusions: Bupropion, NRT and varenicline appear cost effective at preventing relapse to smoking by smokers who are in quit attempts and have recently become abstinent; they have comparable cost effectiveness to smoking cessation interventions. Widespread use of these effective relapse prevention treatments could promote substantial health gain at an acceptable cost to health providers. (Source: Addiction)

The impact of the introduction of smoke?free legislation on prescribing of stop?smoking medications in England

Conclusions?? Numbers of primary care prescriptions for smoking cessation medications increased prior to the introduction of smoke?free legislation but decreased afterwards, suggesting a temporal displacement in prescribing activity rather than a change in the overall volume of prescribing. Effects observed were consistent across all population subgroups, suggesting that the changes in prescribing will neither widen nor reduce smoking?related health inequalities. (Source: Addiction)

Naltrexone/Bupropion Combo Increases Women's Weight Loss

Two phase 3 studies have found that a combination of naltrexone SR/bupropion SR can produce significant weight loss in overweight and obese women, regardless of menopausal status. Reuters Health Information (Source: Medscape Diabetes Headlines)

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

Updated Date: May 10, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Naltrexone/bupropion combo increases women's weight loss

NEW YORK (Reuters Health) - Two phase 3 studies have found that a combination of naltrexone SR/bupropion SR can produce significant weight loss in overweight and obese women, regardless of menopausal status. (Source: Modern Medicine)

Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging

Conclusion&nbsp;&nbsp;In summary, this study demonstrates that reboxetine and bupropion evoke a significant increase in BOLD functional activity in specific regions of the brain, including the hypothalamus, hippocampus, prefrontal cortex and amygdala. Furthermore, the study illustrates the potential value of pharmacological MRI in rodents to delineate pharmacologically induced changes in regional brain function. Content Type Journal ArticlePages 1-9DOI 10.1007/s00213-011-2311-7Authors Sakthivel Sekar, Psychobiology Research Group, Institute of Neuroscience, Newcastle University, Newcastle, UKJ. Van Audekerke, Bio-Imaging Lab, University of Antwerp, Campus Drie Eiken: U-c; Universiteitsplein, 1, 2610 Wilrijk, Antwerp, BelgiumG. Vanhoutte, Bio-Imaging Lab, University of Antwerp...

APPBUTAMONE-D (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

Updated Date: May 6, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUDEPRION (Bupropion Hydrochloride) Tablet, Extended Release [Cardinal Health]

Updated Date: May 6, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion

Authors: Birgit Abler, Angela Seeringer, Antonie Hartmann, Georg Gr&#246;n, Coraline Metzger, Martin Walter & Julia Stingl Keywords: imaging; clinical or preclinical; psychopharmacology; sexual behavior&#47;related disorders; psychiatry & behavioral sciences; fMRI; sexual dysfunction; Bupropion; erotic stimulation; Paroxetine (Source: Neuropsychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Reversibility of impaired nasal mucociliary clearance in smokers following a smoking cessation program

Conclusions:?? A SC program contributed to improvement in MC among smokers from the fifteenth day after cessation of smoking, and these beneficial effects persisted for 180 days. (Source: Respirology)

Bupropion aids smoking cessation in patients with schizophrenia

NEW YORK (Reuters Health) - Bupropion sustained release (Wellbutrin SR) contributes to smoking cessation efforts in patients with schizophrenia, according to a report in the April 5th online Journal of Clinical Psychiatry. (Source: Modern Medicine)

BUPROPION HYDROCLORIDE (Bupropion Hydrochloride) Tablet, Film Coated [REMEDYREPACK INC. ]

Updated Date: May 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [REMEDYREPACK INC. ]

Updated Date: May 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers [Original Article]

Conclusions&nbsp; Treatment with bupropion is associated with improved ability to resist cue-induced craving and a reduction in cue-induced activation of limbic and prefrontal brain regions, while a reduction in craving, regardless of treatment type, is associated with reduced activation in prefrontal brain regions. (Source: Archives of General Psychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study.

Conclusions: Neither medication combination outperformed monotherapy. The combination of extended-release venlafaxine plus mirtazapine may have a greater risk of adverse events. PMID: 21536692 [PubMed - as supplied by publisher] (Source: The American Journal of Psychiatry)

[Smoking cessation in patients with cardiopulmonary diseases.]

CONCLUSION: Results of this analysis confirm that, tobacco dependence is still a severe but necessary condition for the patients with cardiopulmonary diseases. Additionally neither of the treatment protocols was superior to the others. PMID: 21466992 [PubMed - as supplied by publisher] (Source: The Anatolian Journal of Cardiology)

[Smoking in affective psychosis: review about nicotine use in bipolar and schizoaffective disorders.]

The objective here is to carry out a review of the relation between nicotine use and psychiatric disorders considered as affective psychoses at the epidemiological, clinical, prognostic and treatment levels. We review studies published in the PubMed database that include the keywords smoking, tobacco, nicotine and schizoaffective or bipolar disorder. Comorbidity of bipolar and schizoaffective disorder with nicotine consumption is 66-82.5 % and 67%, respectively. On the basis of this review it can be concluded that smoking results in poorer prognosis and greater clinical seriousness of bipolar and schizoaffective disorders. Use of other substances, psychiatric diagnosis, clinical seriousness and caffeine consumption are risk factors for nicotine use. The most effective treatment approach is...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Actavis South Atlantic LLC]

Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pharmacotherapy for Smoking Cessation: Present and Future.

Authors: Aubin HJ, Karila L, Reynaud M Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medication...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Do painkillers ??stop Prozac working???

Conclusion This predominantly animal research found that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen reduce the increase in p11 (a marker for depression) when mice are treated with SSRIs, which are a commonly used class of antidepressant. Furthermore, anti-inflammatories and other painkillers have been shown to reduce antidepressant behaviour in mice. The researchers followed up this study by looking at patient data. However, although they found some associations between use of anti-inflammatories and other classes of painkiller and a reduced remission rate in patients taking a particular SSRI drug (citalopram), they point out that they cannot say whether the painkillers caused this effect. They go on to say that to evaluate fully the effects of anti-inflammatories and...

Pramipexole/ropinirole: Compulsive behaviours treated with bupropion: 3 case reports

(Source: Reactions)

Review: Varenicline is better than placebo or bupropion, but not clearly different from the nicotine patch, for smoking abstinence.

Authors: PMID: 21502642 [PubMed - in process] (Source: Annals of Internal Medicine)

BUPROPION HYDROCHLORIDEtablet, Extended Release [American Health Packaging]

Updated Date: Apr 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [American Health Packaging]

Updated Date: Apr 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia

Conclusions&nbsp;&nbsp;The results of this study indicate the efficacy and feasibility of this CM intervention for reducing smoking in individuals with schizophrenia. Content Type Journal ArticlePages 1-9DOI 10.1007/s00213-011-2282-8Authors Jennifer W. Tidey, Center for Alcohol and Addiction Studies, Brown University, Box S-121-5, Providence, RI 02912, USADamaris J. Rohsenow, Center for Alcohol and Addiction Studies, Brown University, Box S-121-5, Providence, RI 02912, USAGary B. Kaplan, VA Boston Healthcare System, Boston, MA, USARobert M. Swift, Center for Alcohol and Addiction Studies, Brown University, Box S-121-5, Providence, RI 02912, USANetesha Reid, Center for Alcohol and Addiction Studies, Brown University, Box S-121-5, Providence, RI 02912, USA Journal Psychoph...

Treatment of Depression in Patients with Epilepsy

Opinion statement&nbsp;&nbsp;In this article, we review the current best evidence for the treatment of depression in patients with epilepsy. Depression is a common epilepsy comorbidity, but it is often unrecognized. The most important step in appropriately managing mood disorders in this population is making the diagnosis. Clinical vigilance and routine use of a validated screening tool can improve detection and quality of care. As is increasingly the case for the general population, persons with epilepsy are often interested in exploring alternative therapies for chronic conditions, including depression. Unfortunately, the benefit of complementary and alternative therapies for depression currently is largely unproven for persons with a seizure history, although an early study of exe...

Orexigen(R) Therapeutics Presents Additional Contrave(R) Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring

Results Presented at the 60th Annual Scientific Session of the American College of Cardiology NEW ORLEANS, April 4, 2011 (HSMN NewsFeed) -- Orexigen&reg; Therapeutics, Inc. (Nasdaq:OREX ) announced additional data that showed that overweight and obese... BiopharmaceuticalsOrexigen Therapeutics, Contrave, naltrexone, bupropion, obesity (Source: HSMN NewsFeed)

Course of Smoking and Quit Attempts Among Clients With Co-occurring Severe Mental Illness and Substance Use Disorders [Articles]

Conclusions: Although many clients with co-occurring serious mental illness and substance use disorders tried to quit each year, few achieved sustained abstinence and none used evidence-based interventions (nicotine replacement therapy or bupropion). Treatment providers need to administer evidence-based interventions to help people quit successfully. (Psychiatric Services 62:353&ndash;359, 2011) (Source: Psychiatr Serv)

Selective uptake and biological consequences of environmentally relevant antidepressant pharmaceutical exposures on male fathead minnows.

Authors: Schultz MM, Painter MM, Bartell SE, Logue A, Furlong ET, Werner SL, Schoenfuss HL Antidepressant pharmaceuticals have been reported in wastewater effluent at the nanogram to low microgram-per-liter range, and include bupropion (BUP), fluoxetine (FLX), sertraline (SER), and venlafaxine (VEN). To assess the effects of antidepressants on reproductive anatomy, physiology, and behavior, adult male fathead minnows (Pimephales promelas) were exposed for 21 days either to a single concentration of the antidepressants FLX, SER, VEN, or BUP, or to an antidepressant mixture. The data demonstrated that exposure to VEN (305ng/L and 1104ng/L) and SER (5.2ng/L) resulted in mortality. Anatomical alterations were noted within the testes of fish exposed to SER and FLX, both modulators of the ne...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion

Conclusion&nbsp;&nbsp;Enhancement of 5-HT and NE transmissions in hippocampus by prolonged bupropion may account for its effectiveness in major depression. Content Type Journal ArticlePages 1-13DOI 10.1007/s00213-011-2260-1Authors Ramez Ghanbari, Institute of Mental Health Research, University of Ottawa, Room 6411, 1145 Carling Avenue, Ottawa, K1Z 7K4 ON CanadaMostafa El Mansari, Institute of Mental Health Research, University of Ottawa, Room 6411, 1145 Carling Avenue, Ottawa, K1Z 7K4 ON CanadaPierre Blier, Institute of Mental Health Research, University of Ottawa, Room 6411, 1145 Carling Avenue, Ottawa, K1Z 7K4 ON Canada Journal PsychopharmacologyOnline ISSN 1432-2072Print ISSN 0033-3158 (Source: Psychopharmacology)

Assessment of receptor occupancy-over-time of two dopamine transporter inhibitors by [(11)C]CIT and target controlled infusion.

Conclusions. The proposed model can be used for assessment of in-vivo occupancy-over-time of DAT ligands by use of target controlled infusion of [(11)C]CIT. The concept of assessing drug-receptor interactions by studying perturbations of a PET tracer from a pseudo steady state can be transferred to other CNS systems. PMID: 21443419 [PubMed - as supplied by publisher] (Source: Upsala Journal of Medical Sciences)

A real-life study of the effectiveness of different pharmacological approaches to the treatment of smoking cessation: re-discussing the predictors of success

CONCLUSION: Satisfactory success rates were obtained in a teaching hospital. Factors such as age, daily cigarette consumption, number of pack-years and dependency score were not reliable markers of abstinence. The combination nortriptyline+NRT was independently associated with higher abstinence rates. (Source: Clinics)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [UDL Laboratories, Inc.]

Updated Date: Mar 21, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Drug Interaction Study between Bupropion and Ticlopidine in Male CF-1 Mice.

In this study we investigated the potential pharmacokinetic (PK) drug interaction between bupropion and ticlopidine in mice. Using a destructive sampling design, male CF-1 mice were administered ticlopidine 1.0 mg/kg daily for 5 d, followed by single-dose bupropion 50 mg/kg. Bupropion and hydroxybupropion levels were measured by HPLC-UV in plasma and brain tissues at 30, 60, 90, 120 and 180 min post-dose, and compared between treatment groups. There was a strong trend in both plasma and brain data towards greater bupropion levels and smaller hydroxybupropion levels in ticlopidine treated mice. Analysis of variance indicated statistical differences (p&lt;0.05) at many time points. The variance associated with the area under the curve was calculated using Bailer's method and significant diff...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [UDL Laboratories, Inc.]

Updated Date: Mar 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion treatment doesn't improve smoking cessation success in ACS patients

Source: Arch Internal Med Area: News Adding bupropion to intensive nurse-led counselling support did not improve smoking quit rates in patients admitted to hospital with acute coronary syndrome (ACS) in a controlled trial. &nbsp; Smoking is a significant risk factor for myocardial infarction (MI), and persistent smoking after MI increases the risk of death within 2 years by 50%. Interventions to improve quit rates are highly cost-effective in these patients. Intensive nurse-led counselling is effective in hospitalised patients, while addition of nicotine replacement therapy has little extra benefit. Only one previous study has examined whether bupropion improved quit rates in ACS patients, and this study was intended to build on the evidence. Participants were hospitalised patients wi...

Bupropion not likely to help folks kick the habit

In a new study on smoking cessation published in the Archives of Internal Medicine, researchers sought to assess the safety and efficacy of bupropion, the active ingredient in the antidepressant Wellbutrin and the smoking cessation aid Zyban. (Source: Health Facts and Fears)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Rebel Distributors Corp.]

Updated Date: Mar 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome [Original Investigation]

Conclusion&nbsp; In hospitalized patients with ACS who received continuous, intensive nurse counseling about smoking cessation, bupropion did not increase the rates of smoking abstinence. (Source: Archives of Internal Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Prediction of Individual Long?term Outcomes in Smoking Cessation Trials Using Frailty Models

Summary In smoking cessation clinical trials, subjects commonly receive treatment and report daily cigarette consumption over a period of several weeks. Although the outcome at the end of this period is an important indicator of treatment success, substantial uncertainty remains on how an individual's smoking behavior will evolve over time. Therefore it is of interest to predict long?term smoking cessation success based on short?term clinical observations. We develop a Bayesian method for prediction, based on a cure?mixture frailty model we proposed earlier, that describes the process of transition between abstinence and smoking. Specifically we propose a two?stage prediction algorithm that first uses importance sampling to generate subject?specific frailties from their posterior...

Prescribing of smoking cessation medication in England since the introduction of varenicline

Conclusions?? Soon after being introduced in England, varenicline was widely prescribed; after NRT it was the most commonly prescribed cessation medication. However, this not to appear to have increased overall rates of prescribing for smoking cessation medication. (Source: Addiction)

Evaluation of a student-run smoking cessation clinic for a medically underserved population

Conclusions: Our medical student-run smoking cessation clinic provided an effective and safe experience for medically underserved patients who might not otherwise have access to conventional smoking cessation programs because of high cost, lack of insurance, or other disparities. Similar medical student initiatives focusing on healthy lifestyles may be feasible and beneficial for individuals with limited access to healthcare resources. (Source: BMC Research Notes)

[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in Primary Care.]

CONCLUSION: One year-follow up results suggest that varenicline is an appropriate alternative compared with bupropion and NRT on smoking cessation in the PC setting. PMID: 21382649 [PubMed - as supplied by publisher] (Source: Atencion Primaria)

Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion

Abstract: Background: Quit attempts may have different outcomes based on menstrual cycle phase on quit day. This is the first preliminary study examining whether smoking cessation outcomes vary by menstrual cycle phase of quit date in women receiving a 6-week open trial of sustained release (SR) bupropion.Methods: Thirty-three treatment-seeking premenopausal women were studied. Abstinence outcomes were compared for women quitting during the luteal versus follicular phase.Results: Women receiving bupropion SR whose self-selected quit date occurred in the luteal phase had significantly higher rates of point prevalence abstinence during the final week of a 6-week post-quit treatment period than women quitting in the follicular phase (62.5% versus 29.4%; p (Source: Drug and Alcohol Dependence)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies

Conclusions: Both varenicline and combination pharmacotherapy were effective and did not increase psychological distress for up to 6 months in smokers with co-morbidities treated at a specialty clinic. (Source: Drug and Alcohol Dependence)

FDA's Request May Signal End for Contrave

The Food and Drug Administration has informed the manufacturer of the weight-loss medicine combination naltrexone/bupropion that it cannot approve the drug without a new large-scale trial to establish its cardiovascular safety. (Source: Cardiology News)

Brain illness and creativity: mechanisms and treatment risks.

Authors: Flaherty AW Brain diseases and their treatment may help or hurt creativity in ways that shape quality of life. Increased creative drive is associated with bipolar disorder, depression, psychosis, temporal lobe epilepsy, frontotemporal dementia, Parkinson disease treatments, and autism. Creativity depends on goal-driven approach motivation from midbrain dopaminergic systems. Fear-driven avoidance motivation is of less aid to creativity. When serotonin and norepinephrine lower motivation and flexible behaviour, they can inhibit creativity. Hemispheric lateralization and frontotemporal connections must interact to create new ideas and conceptual schemes. The right brain and temporal lobe contribute skill in novelty detection, while the left brain and frontal lobe foster approach ...

Effects of bupropion on the reinstatement of nicotine-induced conditioned place preference by drug priming in rats.

Authors: Budzy?ska B, Bia?a G Nicotine is one of the most widely consumed psychoactive drugs, and its consumption is currently associated with other drugs of abuse, such as opioids. The aim of the present study was to evaluate the efficacy of the atypical antidepressant drug bupropion (5, 10 and 20 mg/kg, ip) in blocking the reinstatement of nicotine-induced conditioned place preference (CPP) provoked by nicotine and morphine. It was shown that nicotine produced a place preference to the initially less-preferred compartment paired with its injections during conditioning (0.175 mg/kg, ip, free base, three drug sessions). Once established, nicotine-induced CPP was extinguished by repeated testing. Following this extinction phase, the reinstatement of CPP was investigated. Nicotine-expe...

Aphthous ulcers associated with bupropion in a female adolescent: a case verified by rechallenge

This article describes a female adolescent with depression who developed aphthous ulcers while on high-dose bupropion with positive rechallenge. This is the first case report indicating the incidence of aphthous ulcers associated with bupropion treatment. (Source: General Hospital Psychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion overdose: Refractory hypotension and metabolic acidosis in an infant: case report

(Source: Reactions)

A simple and sensitive LC-ESI-MS (ion trap) method for the determination of bupropion and its major metabolite, hydroxybupropion in rat plasma and brain microdialysates.

Authors: Yeniceli D, Sener E, Korkmaz OT, Do?rukol-Ak D, Tuncel N A specific and highly sensitive liquid chromatography-electrospray mass spectrometry (LC-ESI-MS) method for the direct determination of bupropion (BUP) and its main metabolite hydroxybupropion (HBUP) in rat plasma and brain microdialysate has been developed and validated. The analysis was performed on a Bonus RP C18 (100mm?2.1mm i.d., 3.5μm particles) column using gradient elution with the mobile phase consisting of acetonitrile and ammonium formate buffer (10mM, pH 4). Plasma samples were analyzed after a simple, one-step protein precipitation clean-up with trichloroacetic acid (TCA), however clean-up for microdialysis samples was not necessary, enabling direct injection of the samples into the LC-ESI-MS system. Sign...

Smoking cessation in primary care ?? a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention

Conclusion: Our findings suggest that established smoking cessation treatments are effective when applied by non?specialist primary care physicians. Our data supports a structured, multimodal treatment structure as core ingredient of successful smoking cessation in primary care. Copyright © 2011 John Wiley & Sons, Ltd. (Source: International Journal of Methods in Psychiatric Research)

Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study

A significant number of patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) report sexual dysfunction. SSRI-induced sexual dysfunction adversely affects quality of life and patient adherence to and compliance with treatment regimens. This trial examined the efficacy and safety of adjunctive bupropion in the treatment of SSRI-induced female sexual dysfunction. Sexual function was assessed by using the sexual function domains of the Female Sexual Function Index (primary efficacy outcome measure) and the Clinical Global Impression Scale adapted for sexual function (secondary efficacy outcome measure). End point treatment satisfaction was assessed using a Visual Analog Scale. A total of 218 women (25&ndash;45 years old) with SSRI-induced sexual dysfunction were r...

Bupropion, an atypical antidepressant, induces endoplasmic reticulum stress and caspase-dependent cytotoxicity in SH-SY5Y cells.

In this study, we evaluated the cytotoxicity of bupropion using SH-SY5Y human catecholaminergic cells as the in vitro model. Exposure of the cells to bupropion for 24h reduced their viability in a concentration-dependent manner. Treatment of the cells with a toxic concentration of bupropion (100μg/mL) induced the phosphorylation of eukaryotic initiation factor alpha (EIF-2α), c-JUN N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) within 1h, which later declined to baseline levels. However, bupropion failed to splice X-box binding protein 1 (XBP1) mRNA. Bupropion caused mitochondrial cytochrome c release and activated caspases 9, 8, and 3 in a time-dependent manner. The reduction in cell viability was significantly inhibited by a caspase 3 inhibitor. Bupropion also...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion Improves Sexual Function in Type 2 Diabetes

Patients with type 2 diabetes who are treated with bupiron for major depressive disorder show significant improvement in sexual function, according to a study published in the February issue of Diabetes Care. (Source: Modern Medicine)

BUPROPION HYDROCHLORIDEtablet [McKesson Packaging Services Business Unit Of McKesson Corporation]

Updated Date: Feb 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

A Prospective Single-arm Open-label Study of Baclofen and Bupropion SR Combination Therapy for Smoking Cessation

Conclusions: Combination of baclofen and bupropion SR seems safe and well tolerated with preliminary efficacy for smoking cessation comparing favorably with current first-line smoking cessation aids. The combination of baclofen and bupropion SR may provide an additional treatment option to varenicline or bupropion SR monotherapy. (Health Canada Clinical Trial Registration Control number: 105226). (C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)

Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys.

The effectiveness of methadone as a treatment for opioid abuse and nicotine preparations as treatments for tobacco smoking has led to an interest in developing a similar strategy for treating psychostimulant abuse. The current study investigated the effects of three such potential therapies on intravenous methamphetamine self-administration (1 ?? 30 μg/kg/injection) in rhesus monkeys. When given as a presession intramuscular injection, a high dose of methamphetamine (1.0 mg/kg) decreased intravenous methamphetamine self-administration but did not affect responding for a food reinforcer during the same sessions. However, the dose of intramuscular methamphetamine required to reduce intravenous methamphetamine self-administration exceeded the cumulative amount taken during a typical self-ad...

Contingency management for behavior change: Applications to promote brief smoking cessation among opioid-maintained patients.

Cigarette smoking is highly prevalent among patients who are being treated for opioid-dependence, yet there have been limited scientific efforts to promote smoking cessation in this population. Contingency management (CM) is a behavioral treatment that provides monetary incentives contingent upon biochemical evidence of drug abstinence. This paper discusses the results of two studies that utilized CM to promote brief smoking cessation among opioid-maintained patients. Participants in a pilot study were randomly assigned for a 2-week period to a Contingent group that earned monetary vouchers for providing biochemical samples that met criteria for smoking abstinence, or a Noncontingent group that earned monetary vouchers independent of smoking status (Dunn et al., 2008). Results showed Conti...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

APLENZIN (Bupropion Hydrobromide ) Tablet, Extended Release [STAT RX USA LLC]

Updated Date: Feb 11, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Influence of Traditional Tobacco Use on Smoking Cessation among American Indians

Conclusions?? American Indians appear to show low levels of awareness of effective pharmacotherapies to aid smoking cessation but those who use ??traditional tobacco?? report somewhat longer periods of abstinence from past quit attempts. (Source: Addiction)

FDA issues CRL for Contrave

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Modern Medicine)

FDA issues CRL for obesity treatment

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Drug Topics - Top News)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: Feb 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Feb 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

FDA Update: Week of January 31, 2011

FDA Decides To Pass On Obesity Drug &mdash; For Now Orexigen and Takeda received a full response letter from the FDA regarding their new drug application for Contrave (naltrexone/bupropion) tablets for the treatment of obesity. (Source: Pharmaceutical Online News)

FDA rejects Contrave obesity drug, requesting more CV research

The FDA has sent a complete response letter, rejecting Orexigen Therapeutics and Takeda Pharmaceutical Company Limited??s new drug application for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Cardiovascular Business News)

BUPROBAN (Bupropion Hydrochloride) Tablet, Extended Release [TEVA Pharmaceuticals USA Inc]

Updated Date: Feb 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUDEPRION (Bupropion Hydrochloride) Tablet, Extended Release [TEVA Pharmaceuticals USA Inc]

Updated Date: Feb 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Breaking news: FDA issues CRL for obesity treatment

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Drug Topics - Top News)

US FDA rejects combination product naltrexone with bupropion for obesity

Source: BioSpace.com Area: News According to a report by BioSpace.com, the US Food and Drug Administration has issued a "Complete Response" letter in which they request a further randomised, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese patients treated with combination product naltrexone with bupropion does not adversely affect the drug's benefit-risk profile. (Source: NeLM - News)

Breaking news: FDA issues CRL for obesity treatment

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Modern Medicine)

Breaking News: FDA issues CRL for obesity treatment due to concerns about cardiovascular safety

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Modern Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Breaking news: FDA issues CRL for obesity treatment

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Drug Topics - Pharmacy News)

FDA issues CRL for obesity treatment

FDA has issued a complete response letter for Orexigen?s and Takeda?s Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss. (Source: Drug Topics - Pharmacy News)

FDA Declines Approval for Contrave Diet Drug; Asks for CVD Outcomes Studies

The drug, a combination of naltrexone and bupropion HCL, had been given a positive decision by the majority of members on an FDA advisory group panel in December. Heartwire (Source: Medscape Today Headlines)

Lightlake Therapeutics: Lightlake Therapeutics Takes Safer Approach to Obesity

LONDON, ENGLAND (MARKET WIRE) Lightlake Therapeautics (&quot;Lightlake&quot;) (OTCBB: LLTP) After the recent FDA decision concerning Orexigen's obesity medicine, Contrave(TM) (naltrexone plus bupropion) Lightlake would like to clarify that they do not anticipate the same cardiovascular problems with their treatment of binge eating disorder with naloxone alone. (Source: Market Wire - Pharmaceuticals and Biotech)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA Says No to Weight-Loss Combo Drug

(MedPage Today) -- A pill combining bupropion and naltrexone for weight loss (Contrave) won't receive the FDA's approval until its manufacturer, Orexigen, conducts a new clinical trial evaluating its cardiovascular risks, the company said. (Source: MedPage Today Pediatrics)

FDA declines approval for Contrave diet drug; asks for CVD outcomes studies

UPDATED WITH COMMENTARY // The drug, a combination of naltrexone and bupropion HCL, had been given a positive decision by the majority of members on an FDA advisory group panel in December. For complete story visit theheart.org. (Source: theHeart.org)

FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity

SAN DIEGO and OSAKA, Japan, Feb. 1, 2011 (HSMN NewsFeed) -- Orexigen&reg; Therapeutics, Inc. (Nasdaq:OREX ) and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502.to ) announced today that the United States Food and Drug Administration (FDA) has is... Biopharmaceuticals, FDAOrexigen Therapeutics, Takeda Pharmaceutical, Contrave, naltrexone, bupropion (Source: HSMN NewsFeed)

Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion.

CONCLUSIONS Insufficient SF is prevalent and may be suspected in patients with MDD and type 2 diabetes. BU treatment of MDD had few sexual side effects and was associated with significant improvements in SF. PMID: 21270190 [PubMed - in process] (Source: Diabetes Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA's Requirements May Signal End for Contrave

The Food and Drug Administration has informed the manufacturer of the weight-loss drug combination naltrexone/bupropion that it cannot approve the drug without a new large-scale trial to establish its cardiovascular safety. (Source: Clinical Endocrinology News)

Bupropion: Psychosis: case report

(Source: Reactions)

BUDEPRION (Bupropion Hydrochloride) Tablet, Extended Release [TEVA Pharmaceuticals USA Inc]

Updated Date: Jan 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

APPBUTAMONE-D (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

Updated Date: Jan 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: Evidence in the Literature

Conclusion.?? There has been tremendous progress over the past 50 years in understanding the role of monoamines in sexual function and the effect of pharmacologic agents which stimulate or antagonize monoaminergic receptors on sexual dysfunction. Nevertheless, large, double?blind, placebo?controlled studies evaluating the efficacy of currently available agents in populations without comorbid disorders are limited, preventing adequate interpretation of data. Continued research on sexual function and specific receptor subtypes will result in the development of more selective pharmacologic agents with the goal of increasing efficacy without the dose?limiting side effects of nonselective agents. Moll JL and Brown CS. Treatment of sexual dysfunction: Evidence in the literature. J Sex Med...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Approach to Smoking Cessation in the Patient With Vascular Disease

Opinion statement&nbsp;&nbsp;In the patient with vascular disease, cigarette smoking is particularly perilous; the benefits of smoking cessation greatly exceed any risks associated with pharmacologic treatment. The patient with claudication is often uniquely motivated to quit smoking because 1) there is a chance that the leg pain will improve and 2) smoking cessation may prevent disease progression and thus invasive procedures. The first step toward success is a systematic approach with focus on the 5 A??s (Ask, Advise, Assess, Assist, and Arrange). Multiple clinical trials have demonstrated the efficacy of pharmacologic therapy for smoking cessation. The most effective medications available are bupropion and varenicline. If the patient is ready to quit, varenicline is typically fir...

The effects of nicotine and cigarette smoke on the monoamine transporters

AbstractCigarette smoking is the leading cause of preventable illness worldwide; however, smoking addiction remains poorly understood and cessation therapies based on nicotine replacement have limited success. The monoamine transporters are the primary mechanism for regulating the levels of dopamine, serotonin and norepinephrine in the synapse, and have been implicated in addiction and associated behaviours. Furthermore, the non nicotinic smoking cessation therapy bupropion acts at least in part by blocking the dopamine and norepinephrine transporters. Despite this, little work has been conducted into the effects of nicotine and cigarette smoke on the monoamine transporters. This review will outline research that has been conducted to date on cigarette smoke, nicotine and the monoamine tra...

Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5?A3?B4) predict severity of nicotine addiction and response to smoking cessation therapy

AbstractStopping smoking is difficult even with treatment. Many patients prescribed pharmacologic treatments for smoking cessation experience side effects or lack of efficacy. We performed a pharmacogenetic study of the efficacy and tolerability of bupropion and transdermal nicotine (TN), two treatments for smoking cessation. Samples were drawn from two studies. In the first study (Maintenance 1, MT1), 301 smokers received bupropion plus TN for 11 weeks, followed by 14 weeks of placebo or bupropion. In the second study (MT2), 276 smokers received bupropion and TN for 8 weeks. We focused on eight SNPs in the 15q24 region, which contains the genes for the nicotinic cholinergic receptor subunits CHRNA5, CHRNA3, and CHRNB4, and has previously been implicated in nicotine addiction and smoking c...

The effect of five smoking cessation pharmacotherapies on smoking cessation milestones.

Conclusions: These findings demonstrate that medications are effective at aiding initial abstinence and decreasing lapse risk but that they generally do not decrease relapse risk following a lapse. The analysis of cessation milestones sheds light on important impediments to long-term smoking abstinence, suggests potential mechanisms of action of smoking cessation pharmacotherapies, and identifies targets for future treatment development. (PsycINFO Database Record (c) 2010 APA, all rights reserved) (Source: Journal of Consulting and Clinical Psychology)

Bupropion, Varenicline May Decrease Brain Reactivity to Smoking Cues

Two brain imaging studies show smoking cessation medications bupropion and varenicline may change the way the brain reacts to smoking cues, making it easier to curb cravings. Medscape Medical News (Source: Medscape Today Headlines)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Amantadine/bupropion: Cranial myoclonus: 2 case reports

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Watson Laboratories, Inc.]

Updated Date: Jan 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Pharmacotherapeutic treatment strategies for smoking cessation.]

Authors: Vasic N, Wolf RC, Wolf N, Connemann BJ, Sosic-Vasic Z Regular tobacco smoking occurs in about 35% of the male and 25% of the female German population. Individual attempts to independently quit smoking and to remain abstinent for 1 year have been shown to be successful in less than 5% of cases. This rate can be doubled by means of individual consulting and cognitive-behavioral interventions and additional pharmacological treatment might increase abstinence rates up to 25%. Apart from nicotine substitution (e.g. transdermal, oral and inhalative applications) and bupropion, recent studies have shown beneficial effects of varenicline for smoking cessation and abstinence. Varenicline, a selective partial nicotinergic agonist, has been specifically developed for the purpose of smoki...

Brain imaging studies examine how anti-smoking medications may curb cravings

The smoking cessation medications bupropion and varenicline may both be associated with changes in the way the brain reacts to smoking cues, making it easier for patients to resist cravings, according to two new reports. (Source: ScienceDaily Headlines)

Study: fMRI visualizes allaying of cravings by anti-smoking meds

Treatment with the anti-smoking medications bupropion and varenicline was associated with diminished cravings, weakened withdrawal symptoms and reduced activation in regions of the brain associated with cravings and withdrawals from smoking, according to a pair of studies published online Jan. 3 in the Archives of General Psychiatry. (Source: Health Imaging News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Extended Release [Eon Labs, Inc.]

Updated Date: Jan 3, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Brain imaging studies examine how anti-smoking medications may curb cravings

(JAMA and Archives Journals) The smoking cessation medications bupropion and varenicline may both be associated with changes in the way the brain reacts to smoking cues, making it easier for patients to resist cravings, according to two reports posted online today that will appear in the May print issue of Archives of General Psychiatry, one of the JAMA/Archives journals. (Source: EurekAlert! - Social and Behavioral Science)

Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers [Original Article]

Conclusions&nbsp; Treatment with bupropion is associated with improved ability to resist cue-induced craving and a reduction in cue-induced activation of limbic and prefrontal brain regions, while a reduction in craving, regardless of treatment type, is associated with reduced activation in prefrontal brain regions. (Source: Archives of General Psychiatry)

Counselors' knowledge of the adoption of tobacco cessation medications in substance abuse treatment programs.

This study assessed counselors' knowledge of the adoption of evidence-based tobacco cessation medications (TCMs)--varenicline, bupropion, and five nicotine replacement therapies (NRTs)--and predictors of adoption in diverse substance abuse treatment settings. We used Managing Effective Relationships in Treatment Services (MERITS I) data from 658 counselors working in 26 programs. Adoption of varenicline was reported by 16% of counselors, bupropion by 11%, and NRTs by 27%. Knowledge of the adoption of all types of TCMs was more likely to be reported by counselors who worked in treatment programs that adhered less to a 12-step orientation and restricted outdoor smoking for employees. Several additional unique predictors of varenicline and NRTs were identified.?? PMID: 21175921 [PubMed -...

Panel Supports Combination for Weight Loss

SILVER SPRING, MD. ?? More than half of a Food and Drug Administration advisory panel supported approval of a weight-loss agent that combines naltrexone and bupropion, despite concerns about associated effects on blood pressure and heart rate. (Source: Rheumatology News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA Panel Supports Combination for Weight Loss

SILVER SPRING, MD. ?? More than half of a Food and Drug Administration advisory panel supported approval of a weight-loss agent that combines naltrexone and bupropion, despite concerns about associated effects on blood pressure and heart rate. (Source: Cardiology News)

Frequency of False Positive Amphetamine Screens due to Bupropion Using the Syva Emit II Immunoassay.

Authors: Casey ER, Scott MG, Tang S, Mullins ME Bupropion is a commonly prescribed, monocyclic antidepressant often used as an aid for smoking cessation. Several case reports have described false positive amphetamine urine drug screens (UDS) associated with bupropion. We sought to determine whether false positive amphetamine UDS due to the use of bupropion would be a frequent occurrence. We conducted an IRB-approved, retrospective chart review of all emergency department patients who underwent UDS between 1 January 2006 and 31 July 2007. All urine samples were screened using Syva EMIT II Plus immunoassay reagents. All positive screens underwent confirmation by gas chromatography (GC). We reviewed the records of patients with positive amphetamine UDS. We documented prescription use of b...

bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban

Title: bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, ZybanCategory: MedicationsCreated: 12/31/1997Last Editorial Review: 12/29/2010 (Source: MedicineNet Lungs General)

BUPROBAN (Bupropion Hydrochloride) Tablet, Extended Release [TEVA Pharmaceuticals USA Inc]

Updated Date: Dec 22, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUDEPRION (Bupropion Hydrochloride) Tablet, Extended Release [TEVA Pharmaceuticals USA Inc]

Updated Date: Dec 22, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Editorial] New obesity pill: new hopes, old fears

On Dec 7, 2010, the US Food and Drug Administration ( FDA) Endocrinologic and Metabolic Drugs Advisory Committee gave a positive recommendation for the use of Contrave in the treatment of obesity and weight management, signalling a potentially major shift in attitude towards the disorder. Contrave, if finally approved by the FDA on Jan 31, 2011, will be the first new weight-loss drug to be approved for 10 years. The drug is a combination of bupropion, an antidepressant used to help patients to quit smoking, and naltrexone, an opioid antagonist prescribed for alcohol and drug addiction, thought to affect the reward pathway (system in which behaviour is regulated by induction of pleasure). (Source: LANCET)

The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects.

Authors: Dell'osso B, Palazzo MC, Oldani L, Altamura AC Even though noradrenaline has been recognized as one of the key neurotransmitters in the pathophysiology of major depression (MD), noradrenergic compounds have been less extensively utilized in clinical practice, compared to selective serotonin reuptake inhibitors (SSRIs). The development of the first selective noradrenergic reuptake inhibitor (NRI), Reboxetine, has not substantially changed the state of the art. In addition, Atomoxetine, a relatively pure NRI used for the treatment of ADHD, has shown mixed results when administered in augmentation to depressed subjects. Through a Medline search from 2000 to 2010, the present article provides an updated overview of the main pharmacological and clinical aspects of antidepressant cl...

FDA committee considers benefits of Contrave® (naltrexone/bupropion sustained release) outweigh potential risks in patients with obesity

Source: BioSpace Area: News According to BioSpace, the US FDA's Endocrinologic and Metabolic Drugs Advisory Committee has voted 13 to 7 that the available data for Contrave® (naltrexone/bupropion sustained release) adequately demonstrate that its potential benefits outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.&nbsp; The Committee additionally voted that a study to examine the drug's effect on risk for major adverse cardiac events should be conducted as a post-approval rather than a pre-approval requirement. (Source: NeLM - News)

Bupropion abates dopamine agonist?mediated compulsive behaviors in Parkinson's disease

(Source: Movement Disorders)

FDA panel recommends approval of weight-loss drug

An FDA panel has recommended that the agency approve Orexigen Therapeutics? and Takeda?s obesity drug Contrave (naltrexone SR/bupropion SR). This makes the drug the first in a group of competitors to receive this recommendation, the Associated Press reported. (Source: Drug Topics - Clinical News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Table of Contents

AbstractModest Benefits of Adjunctive Risperidone in Partial Responders to ClozapineQuetiapine Monotherapy and Olanzapine?Fluoxetine Effective for Bipolar DepressionPharmacokinetic Interaction Between Bupropion and VenlafaxineGreater Vigilance Needed in Prescribing Anxiety MedicationsAdjunctive Aripiprazole for Risperidone?Induced HyperprolactinemiaAntipsychotics and Venous ThromboembolismVenlafaxine vs. Methylphenidate in Pediatric ADHDHigher Duloxetine Starting Dose Found Safe for Severe DepressionLamotrigine Toxicity May Induce Brugada?Like ECG PatternSafety Labeling ChangesNew ApprovalsWarnings on OTC Chelation Products (Source: The Brown University Psychopharmacology Update)

FDA panel recommends approval of weight-loss drug

An FDA panel has recommended that the agency approve Orexigen Therapeutics? and Takeda?s obesity drug Contrave (naltrexone SR/bupropion SR). This makes the drug the first in a group of competitors to receive this recommendation, the Associated Press reported. (Source: Drug Topics - Pharmacy News)

Late breaking news: FDA panel recommends approval of weight-loss drug

An FDA panel has recommended that the agency approve Orexigen Therapeutics' and Takeda's obesity drug Contrave (naltrexone SR/bupropion SR). This makes the drug the first in a group of competitors to receive this recommendation, the Associated Press reported. (Source: Modern Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Most FDA Advisors Say Likely Benefits of Contrave Diet Drug Outweigh Its Cardiovascular Risks

In all, 13 panel members voted "yes" to the question of whether the potential benefits of naltrexone/bupropion outweigh its potential risks if used long term, while seven voted "no." On a separate question, eight voted to recommend that a cardiovascular outcomes study be conducted prior to drug approval, while 11 voted that such a study could happen postapproval. Heartwire (Source: Medscape Today Headlines)

Obesity Drug, Contrave Gets Green Light From FDA Advisory Panel

Experimental drug Contrave(R) (naltrexone SR/bupropion SR) for the treatment of obesity has been recommended for approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee. The Committee (Panel) voted 13 to 7 in favor of approving Contrave for long-term use among certain obese and overweight patients. The Panel's recommendation is not binding for the FDA (Food and Drug Administration) when it makes its final NDA (New Drug Application) decision. However, it usually goes along with what the Panel advises... (Source: Health News from Medical News Today)

APPBUTAMONE-D (Bupropion) Tablet [Physician Therapeutics LLC]

Updated Date: Dec 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Watson Laboratories, Inc.]

Updated Date: Dec 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Weight-loss drug cleared by FDA panel

Advisors recommend the approval of Contrave despite concerns about its safety &#8212; particularly its impact on blood pressure &#8212; and effectiveness.An advisory panel to the Food and Drug Administration set aside lingering concerns about the safety and marginal effectiveness of the latest weight-loss drug to come before it, voting 13 to 7 on Tuesday to recommend the approval of Contrave, a combination of two medications available since the mid-1980s &#8212; the antidepressant and smoking cessation drug bupropion and the anti- addiction medication naltrexone. (Source: Los Angeles Times - Science)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Panel Endorses Weight-Loss Drug

(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee has voted 13-7 that the modest weight-loss benefits of an investigational combination of naltrexone and bupropion (Contrave) outweigh the drug's blood pressure risk. (Source: MedPage Today State Required CME)

Most FDA advisors say likely benefits of Contrave diet drug outweigh its cardiovascular risks

In all, 13 panel members voted "yes" to the question of whether the potential benefits of naltrexone/bupropion outweigh its potential risks if used long term, while seven voted "no." On a separate... For complete story visit theheart.org. (Source: theHeart.org)

FDA advisors give nod to Orexigen obesity pill, Contrave

Advisers on the FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 13-7, that the benefits of the fixed-dose combination obesity drug Contrave (a combination of naltrexone and bupropion, Orexigen Therapeutics), outweigh its risk. (Source: Cardiovascular Business News)

FDA advisers give nod to Orexigen obesity pill, Contrave

Advisers on the FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 13-7, that the benefits of the fixed-dose combination obesity drug Contrave (a combination of naltrexone and bupropion, Orexigen Therapeutics), outweigh its risk. (Source: Cardiovascular Business News)

Bupropion overdose: Serotonin syndrome: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA says Contrave diet drug demonstrated efficacy, but BP increases of concern

Briefing documents posted online in advance of an FDA advisory meeting next week suggest that the clinical-trial program for Contrave (extended-release naltrexone/bupropion) met one of the two... For complete story visit theheart.org. (Source: theHeart.org)

FDA Staff Questions Slim Data on Weight-Loss Drug

WASHINGTON (MedPage Today) -- An investigational diet drug combining naltrexone and bupropion (Contrave) comes with an increased risk of high blood pressure, and more studies on its safety may be needed, FDA staff reviewers said. (Source: MedPage Today Public Health)

The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine

AbstractAn important step in the development of new drugs is to evaluate the extent of their metabolism during absorption in the small intestine. Reliable in vitro systems to do this can expediate the development process, but the current systems are often unsuitable because they lack the appropriate metabolic enzymes (e.g. Caco?2 cell monolayers) or are not representative of the physiological conditions present in the intact intestinal cells (e.g. isolated microsomes). The aim of this study was to validate the use of isolated intestinal epithelial cells (enterocytes), equivalent to hepatocytes, to evaluate Phase I drug metabolism. A method was developed to prepare enterocytes from rat and pig (as metabolically closer to man) that maintained good viability and activity for up to 90??min ...

Are Circulating Metabolites Important in Drug-Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency.

In conclusion, cytochrome P450 (CYP) inhibitors often have circulating metabolites that contribute to clinically observed CYP inhibition. PMID: 21124313 [PubMed - as supplied by publisher] (Source: Clinical Pharmacology and Therapeutics)

Cover Picture: Electrophoresis 23?24'2010

AbstractIssue no. 23??24 is a regular issue with an ??Emphasis on Proteomics? and comprises 20 contributions assembled into 5 distinct parts. Part I is on innovation in proteomics and has 9 research articles describing novel proteomics methodologies and applications. Part II is on innovative assays and applications, and contains 5 full research articles on in?capillary CE assay, electrophoretically mediated microanalysis, genotyping, SNP, STR and CE of polyphenols. Two research articles on preconcentration of peptides and melamine are included in Part III. Part IV has two articles on enantioseparations of amino acids by ligand exchange CE and on sensitized phosphorescence in the chiral separation of bupropion by CE. Part V is on open tubular CEC with 2 articles describing novel wall ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Primary Lifelong Delayed Ejaculation: Characteristics and Response to Bupropion

Conclusions.?? Lifelong DE is mainly associated with higher and idiosyncratic masturbatory activity, lower night emissions, infertility, longer IELT, lower orgasmic, and intercourse satisfaction domains of IIEF, higher anxiety and depression scores. Bupropion?SR in a daily dosage of 150??mg seemed to be of limited benefit in lifelong DE. Abdel?Hamid IA and Saleh E. Primary lifelong delayed ejaculation: Characteristics and response to bupropion. J Sex Med **;**:**??**. (Source: The Journal of Sexual Medicine)

Impact of Genetic Variability in Nicotinic Acetylcholine Receptors on Nicotine Addiction and Smoking Cessation Treatment.

Authors: Russo P, Cesario A, Rutella S, Veronesi G, Spaggiari L, Galetta D, Margaritora S, Granone P, Greenberg DS Nicotine dependence (ND) is one of the world's leading causes of preventable death. Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the world. Evidence for a genetic influence on smoking behaviour and ND has prompted a search for susceptibility genes. Evidence has recently accumulated that single nucleotide polymorphisms (SNPs) in the genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with smoking and ND. Brain nAChR are a heterogeneous family of ion channels expressed in the various parts of the brain. A number of studies suggest that brain nAChR are ...

Bupropion abuse: Generalised seizures: case report

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Nov 22, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Apotex Corp]

Updated Date: Nov 19, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Using policy to increase prescribing of smoking cessation medications in the VA healthcare system

Conclusion The results provide strong support for the efficacy of these policies and illustrate how healthcare systems can successfully employ multiple strategies to increase evidence-based smoking-cessation treatment. (Source: Tobacco Control)

Sensitized phosphorescence as detection method for the enantioseparation of bupropion by capillary electrophoresis

AbstractA new CE detection method was developed for the chiral drug bupropion (a second?generation antidepressant), based on phosphorescence both in the direct and in the sensitized mode using pulsed laser excitation at 266??nm. Electrokinetic chromatography using 5??mM sulfated?α?CD as chiral selector in 25??mM phosphate buffer at pH 3 allowed the separation of bupropion enantiomers with a high chiral resolution (Rs&gt;3). In the sensitized phosphorescence detection mode, excitation energy is transferred from the analyte to an acceptor (1?bromo?4?napthhalenesulfonic acid or biacetyl) followed by time?resolved phosphorescence detection under deoxygenated buffer conditions. Using 2?10??4??M biacetyl as the acceptor an LOD of 2?10??7??M was obtained for each enantiome...

Bupropion: Visual hallucinations and delirium: case report

(Source: Reactions)

Bupropion Plus Naltrexone for Weight Loss?

The combination of bupropion and naltrexone is being studied for possible weight-loss effects through its synergistic action on appetite signaling and the mesolimbic reward system. Journal Watch (Source: Medscape Today Headlines)

Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo?controlled trial

Conclusions?? NNS is effective when given in primary care. The benefit was lower than in a specialist clinic but similar to that with the nicotine patch in primary care. Unlike most other NRT formulations, bupropion or varenicline, NNS was especially helpful for more dependent smokers. Continuing treatment of those initially failing was not beneficial. An initial 1?week prescription to those more dependent on nicotine is likely to be the most cost?effective NNS treatment protocol. These results should offer support to the effectiveness of the other NRT formulations untested in this setting. (Source: Addiction)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Efficacy of Bupropion for Irritable Bowel Syndrome [LETTERS TO THE EDITOR]

(No abstract is available for this citation) (Source: Psychosomatics)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Sandoz Inc.]

Updated Date: Nov 3, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion: Acute toxic hepatitis: case report

(Source: Reactions)

Bupropion: Mixed-type dyskinesia: case report

(Source: Reactions)

Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.

Conclusion: This patient with relapsing-remitting MS experienced improvements in chronic fatigue (as measured by FSS) after treatment with bupropion, but properly designed, randomized, active- and placebo-controlled clinical trials are needed to evaluate the efficacy and safety of bupropion in more patients with MS and fatigue. PMID: 21118738 [PubMed - in process] (Source: Clinical Therapeutics)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Digest

AbstractAnxiety and depressionAntidepressant weight gain Anti ? depressants are another class of drugs associated with weight gain but a new meta?analysis of 116 studies identifies some that carry the greatest risk (J Clin Psychiatry 2010;71:1259?72). Amitriptyline, mirtazapine and paroxetine were associated with the highest risk of weight gain whereas bupropion and acute use of fluoxetine were associated with weight loss. Evidence for other agents was inconclusive.Anxiolytic abuse Drugs for anxiety have abuse potential and, say US investigators, there is a link between prescribing and abuse (Am J Psychiatry 2010;167:1247?53). Using national survey data from 34 653 adults, they found that the prescription of anxiety medication was associated with a 90 per cent increased risk of non...

Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice.

In this study, chronic bupropion pretreatment intraperitoneally (i.p.) for 14days in a dose of 5mg/kg reduced the ED(50) (i.e. the dose protecting 50% of mice against electroconvulsions) of lamotrigine, topiramate, and felbamate from 4.58, 60.95, and 48.79 (antiepileptic+vehicle) to 3.01, 41.68, and 37.28mg/kg (antiepileptic+bupropion), respectively, against maximal electroshock-induced seizures in mice. Bupropion significantly increased the plasma and brain concentrations of lamotrigine. Plasma concentration of topiramate was elevated, however, the brain concentration of the drug was not affected. Neither plasma nor brain concentrations of felbamate were elevated by bupropion administration. Bupropion did not exacerbate motor coordination impairment caused by the antiepileptic drugs in th...

Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia

(No abstract is available for this citation) (Source: Evidence-Based Mental Health)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

Updated Date: Oct 26, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Mental health stability in veterans with posttraumatic stress disorder receiving varenicline.

Conclusion Varenicline appeared to have destabilizing effects on MH in veterans with PTSD. PMID: 20966147 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

[Department of Error] Department of Error

Greenway FL, Fujioka K, Plodkowski RA, et al, for the COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595??605??In this Article (Aug 21), the third sentence of the second paragraph of the Methods section should have read: ??Additional exclusion criteria included history of seizures or serious psychiatric illness, treatment with bupropion or naltrexone in the previous 12 months, and history of drug or alcohol misuse in the previous 12 months?. (Source: LANCET)

State medicaid coverage for tobacco-dependence treatments --- United States, 2009.

Authors: Medicaid enrollees have nearly twice the smoking rates (37%) of the general adult population (21%), and smoking-related medical costs are responsible for 11% of Medicaid expenditures. In 2008, the Public Health Service released clinical practice guidelines recommending comprehensive coverage of effective tobacco-dependence medications and counseling by health insurers. Healthy People 2010 established a clear objective for Medicaid programs to cover all Food and Drug Administration--approved medications and counseling for tobacco cessation. To monitor progress toward that objective, the Center for Health and Public Policy Studies at the University of California, Berkeley, in collaboration with CDC, surveyed Medicaid programs in the 50 states and the District of Columbia (DC) ...

Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina

Conclusions: Most of the interventions selected were cost-saving or very cost-effective. This study aims to inform policy makers on resource-allocation decisions to reduce the burden of CVD in Argentina. (Source: BMC Public Health - Latest articles)

BUPROPION HYDROCHLORIDE EXTENDED RELEASE SR (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Oct 15, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [McKesson Packaging Services Business Unit Of McKesson Corporation]

Updated Date: Oct 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Reboxetine: meta-analysis including unpublished data suggests lack of efficacy in acute depression

Source: BMJ Area: News A meta-analysis that included unpublished trial data concludes that reboxetine (Edronax®) has not been shown to be more effective than placebo but causes greater harms. &nbsp; Reboxetine is a selective noradrenaline reuptake inhibitor (SNRI) and has been in use as an antidepressive drug in Europe for over a decade. Licensing in the US was refused by the FDA, however, and a recent meta-analysis of published trial data suggested that it might be less effective than other anti-depressive drugs. The German Agency for health technology assessment has carried out health technology assessments of reboxetine, mirtazapine, and bupropion, comparing their benefits and harms against placebo, and using published and unpublished data. This paper reports their assessment of r...

Intravenous lipid emulsion and amiodarone

3.5 out of 5 stars Intravenous Lipid Emulsion Sequesters Amiodarone in Plasma and Eliminates Its Hypotensive Action in Pigs. Niiya T et al. Ann Emerg Med October 2010;56:402-408. Abstract Multiple animal studies and limited clinical experience have suggested that administering IV lipid emulsion has a beneficial effect on outcomes in acute overdose of lipophilic drugs, including bupivacaine, propranolol, verapamil, clomipramine, bupropion, and amitriptyline. The exact mechanism responsible for this effect has not been fully determined. Does the lipid infusion provide a &#8220;sink&#8221; that sequesters fat-soluble drugs? Or do the lipids primarily provide fuel for the myocardium and improve cardiac function? The main objective of this animal study was to determine how extensively IV-admini...

BUPROPION HYDROCHLORIDE EXTENDED RELEASE SR (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Oct 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion SR and contingency management for adolescent smoking cessation

Abstract: There is a significant need for evidence-based treatments for adolescent smoking cessation. Prior research, although limited, has suggested potential roles for bupropion sustained-release (SR) and contingency management (CM), but no previous studies have assessed their combined effect. In a double-blind, placebo-controlled design, 134 adolescent smokers were randomized to receive a 6-week course of bupropion SR + CM, bupropion SR + non-CM, placebo + CM, or placebo + non-CM, with final follow-up at 12 weeks. The primary outcome was 7-day cotinine-verified point prevalence abstinence, allowing for a 2-week grace period. Combined bupropion SR + CM treatment yielded significantly superior abstinence rates during active treatment when compared with placebo + non-CM treatment. In addit...

Hypothalamic opioid??Melanocortin appetitive balance and addictive craving

Summary: Whilst the parallels between drug and food craving are receiving increasing attention, the recently elucidated complex physiology of the hypothalamic appetite regulatory centres has been largely overlooked in the efforts to understand drug craving which is one of the most refractory and problematic aspects of drug and behavioural addictions. Important conceptual gains could be made by researchers from both appetite and addiction neuroscience if they were to have an improved understanding of each others?? disciplines. It is well known in addiction medicine that the use of many substances is elevated in opiate dependency. There is voluminous evidence of very high rates of drug use in opiate agonist maintained patients, and the real possibility exists that opiate agonist therapy the...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Oct 4, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Comparing the effectiveness of different treatment modalities on the smoking cessation rates.]

Authors: Onen ZP, Sen E, Eri? Gülbay B, Oztürk A, Akkoca Yıldız O, Acıcan T, Saryal S, Karabıyıko?lu G The social patterns of smoking have changed significantly in the past two decades but smoking is still as prevalent in the lowest socioeconomic groups as it was widespread. For the solution of this enormous problem many kinds of treatment modalities have been proposed but there is no single successful method for quitting. To determine the smoking cessation rates with behavioural treatment, behavioural + pharmacological treatments and compare the differences between each approaches. 371 smokers were prospectively evaluated between 2004 and 2008. At the beginning subjects were classified into two groups: behavioral treatment group (I) and pharmacological + behavioural treatment...

Predictors of alternative antidepressant agent initiation among U.S. veterans diagnosed with depression

We examined predictors of antidepressant choice among US Veterans Administration (VA) patients treated for depression. Methods: Retrospective cohort study of VA patients with depression diagnoses and a new start of one of the&nbsp;7 most commonly prescribed antidepressant agents between 1 Apr 1999 and 30 Sep 2004 (n? =? 502,?179).&nbsp; We examined the relationship between patient and facility characteristics and new starts of bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline and venlafaxine. &nbsp;We also examined factors associated with new starts only among patients starting selective serotonin reuptake inhibitors (SSRIs). Results: 33%&nbsp;of patients starting mirtazapine had at least three outpatient mental health visits in the prior year, compared ... (Source...

Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms

Abstract&nbsp;&nbsp;Current data suggest that monoamines, acetylcholine, amino acids, cortisol, thyroid hormones, and melatonin may be involved in the pathophysiology of bipolar disorder (BPD). Any neuropsychological or pharmacologic factor causing a disturbance in these neurochemicals may trigger manic/hypomanic switching. Antidepressants, stimulants, anticholinergics, steroids, and thyroid hormone have been reported to cause treatment-emergent mania (TEM) in BPD, but only recently have the traditional antidepressants been systematically studied. Paroxetine, 20&nbsp;mg/d, monotherapy in treatment of acute, relatively ??pure? bipolar I and II depression, and fluoxetine monotherapy in bipolar II depression conferred a similar risk as placebo for TEM. Paroxetine or bupropion adjuncti...

Bupropion: Stevens-Johnson syndrome and acute exacerbation of psoriasis: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [STAT RX USA LLC]

Updated Date: Sep 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

Updated Date: Sep 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

CADTH review: Pharmacological strategies for smoking cessation

Source: CADTH Area: News The Canadian Agency for Drugs and Technologies in Health (CADTH) has published a review comparing the clinical effectiveness and cost-effectiveness of pharmacological agents, with or without behavioural support programs, for smoking cessation. &nbsp; The following are some of the conclusions made with respect to cost-effectiveness in the Canadian population: .&nbsp;All pharmacotherapies reviewed are effective in helping the general population quit smoking, with varenicline being superior to bupropion and conventional use of nicotine patch. .&nbsp;For the general population, bupropion and varenicline were more cost-effective than nicotine gum, patch, lozenge, and inhaler. .&nbsp;Adding behavioural support to drug therapy did not have a strong impact on s...

Bupropion: Premature ejaculation: 2 case reports

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion/venlafaxine interaction: CNS disorders, and increased serum venlafaxine concentrations: 3 case reports

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Rebel Distributors Corp]

Updated Date: Sep 21, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Sandoz Inc.]

Updated Date: Sep 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Recent progress and novel perspectives on obesity pharmacotherapy

This article aims to present recent data on clinical trials of novel weight-loss drugs with short perspective to enter the market, if approved by the regulatory agencies. This review will discuss the efficacy and safety of these compounds, which include lorcaserin (selective serotonin 5-HT2c agonist), tesofensine (triple monoamine reuptake inhibitor), liraglutide (GLP-1 analogue) and cetilistat (gastrointestinal lipase inhibitor), as well as the combination therapies of bupropion/naltrexone, bupropion/zonisamide, phentermine/topiramate and pramlintide/metreleptin. (Source: Arquivos Brasileiros de Endocrinologia e Metabologia)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Sep 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone??bupropion combination?

(Source: International Journal of Clinical Practice)

Naltrexone, Bupropion Led to More Weight Loss

Major Finding: Patients receiving 32 mg naltrexone and 360 mg bupropion daily for 56 weeks lost 6.1% of their body weight on average compared with 1.3% for patients receiving placebo. (Source: Family Practice News)

Internet-based interventions for smoking cessation.

CONCLUSIONS: Results suggest that some Internet-based interventions can assist smoking cessation, especially if the information is appropriately tailored to the users and frequent automated contacts with the users are ensured, however trials did not show consistent effects. PMID: 20824856 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR)

Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just signed an exclusive partnership for the North American area. The Contrave combination treatment targets the central pathways involved in controlling the balance of both food consumption and metabolism, as well as regulating eating behavior, Orexigen informs... (Source: Health News from Medical News Today)

Orexigen&reg; Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave&reg; in North America

Orexigen&reg; Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced that they have entered into an exclusive partnership to develop and commercialize Contrave&trade; (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico. (Source: Pharmaceutical Online News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Extended Release [Sandoz Inc.]

Updated Date: Sep 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [NCS HealthCare Of KY, Inc Dba Vangard Labs]

Updated Date: Sep 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo

(Source: Addiction)

Significant Weight Loss Seen With Drug Combo

Two different doses of naltrexone in combination with bupropion resulted in significantly more weight loss than did a placebo in a 56-week trial involving 1,742 overweight and obese participants. (Source: Cardiology News)

Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis.

CONCLUSION: About half of the patients in this study did not fill any smoking cessation medication following a rejected varenicline claim. It is important to address this treatment gap in support of patients seeking smoking cessation therapy. PMID: 20873954 [PubMed - in process] (Source: The American Journal of Managed Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Watson Laboratories, Inc.]

Updated Date: Aug 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for Tobacco Dependence

Abstract: The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion 11C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced 11C-raclopride binding potential (BPND) in the ventral caudate/nucleus accumbens (VCD/N...

BUDEPRION XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [NCS HealthCare Of KY, Inc Dba Vangard Labs]

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Global Pharmaceuticals, Division Of Impax Laboratories Inc.]

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Anti-addiction drug combination studied in weight loss

Combination treatment with the anti-addiction drugs naltrexone and bupropion could help tackle obesity, a study suggests. (Source: HealthcareRepublic Independent Nurse News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions

Conclusions: Clinicians should remain cautious about using strong inhibitors and/or inducers of cytochrome 2D6 and 3A4 concomitantly with tamoxifen. Use of natural menopausal supplements and diets rich in isoflavones should not be encouraged in tamoxifen users until more data is available. There are however safe treatments for hot flashes and depression in tamoxifen users. (Source: Maturitas)

Bupropion: Arrhythmia following in utero exposure: case report

(Source: Reactions)

Bupropion: Angioedema: case report

(Source: Reactions)

Bupropion/lorazepam: CNS disorders, heart disorders and respiratory insufficiency: 2 case reports

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Watson Laboratories, Inc.]

Updated Date: Aug 24, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

[Department of Error] Department of Error

Greenway FL, Fujioka K, Plodkowski RA, et al, for the COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595??605??In figure 3A of this Article (Aug 21), in the graph showing weight loss of 5% or more, an asterisk should have been shown above the bar for naltrexone 32 mg plus bupropion, in addition to the dagger. This correction has been made to the online version as of Aug 20, 2010, and also to the printed Article. (Source: LANCET)

[Articles] Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants. (Source: LANCET)

Addition of Bupropion SR to Varenicline Alleviated Depression and Suicidal Ideation: A Case Report.

Authors: Karam-Hage M, Shah KR, Cinciripini PM PMID: 20694132 [PubMed - in process] (Source: Primary Care Companion to the Journal of Clinical Psychiatry)

Naltrexone, bupropion combination helps individuals lose excess weight

Investigational combination treatment with sustained-release (SR) naltrexone and bupropion (Contrave, Orexigen Therapeutics) combined with lifestyle modification, appears effective in helping people lose 5% or more of their excess body weight, according to research published online July 30 in The Lancet and reported by HealthDay News. (Source: Drug Topics - Clinical News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion as the treatment of choice in depression associated with Parkinson??s disease and it??s various treatments

Summary: Parkinson disease (PD) is a chronic progressive degenerative disorder that affects over 6million people worldwide. It is manifested by motor and psychiatric signs. The latter inflicts up to 88% of PD patients. With the prolongation of life expectancy, it is presumed that the prevalence of PD will further rise, together with comorbid depression. As a result, the need for an adequate therapeutic answer for compounded PD with depression is called for urgently.Several theories try to explain the trigger of depression in PD patients by impaired activity in dopamine, norepinephrine and serotonin systems.Various treatment to combat depressive symptoms in PD patients were proposed and are in use, with ambiguous results and disturbing side effects. These anti-depressive modalities include ...

An Effective Regimen for Weight Loss?

Dr. Leslie Citrome reviews a new study in The Lancet suggesting that combination treatment with naltrexone and bupropion is a viable intervention for obesity. Medscape Psychiatry & Mental Health (Source: Medscape Today Headlines)

Commonly prescribed medications and potential false-positive urine drug screens.

Conclusion A number of routinely prescribed medications have been associated with triggering false-positive UDS results. Verification of the test results with a different screening test or additional analytical tests should be performed to avoid adverse consequences for the patients. PMID: 20689123 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction.

Bupropion has been used in the treatment of patients with substance dependence based on its weak inhibition of dopamine and norepinephrine reuptake. We hypothesized that 6 weeks of bupropion sustained release (SR) treatment would decrease craving for Internet game play as well as video game cue-induced brain activity in patients with Internet video game addiction (IAG). Eleven subjects who met criteria for IAG, playing StarCraft (>30 hr/week), and eight healthy comparison subjects (HC) who had experience playing StarCraft ( (Source: Experimental and Clinical Psychopharmacology)

Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion

Conclusion&nbsp;&nbsp;These data demonstrate an important dissociation between the antiallodynic and antidepressant effects in mice when tested in a model of neuropathic pain. Depressive behavior in CCI mice was reversed by bis selenide and amitriptyline but not by the conventional antidepressants fluoxetine and buproprion. Bis selenide was more potent than the other drugs tested for antidepressant-like and antiallodynic effects in mice. Content Type Journal ArticleDOI 10.1007/s00213-010-1977-6Authors Cristiano R. Jesse, Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, CEP 97105-900 Santa Maria, RS BrazilEthel A. Wilhelm, Laboratório de Síntes...

Review: Commonly prescribed medications and potential false-positive urine drug screens

Source: American Journal of Health-System Pharmacy Area: News In this article, the authors conducted a review of the literature for reports of false-positive urine drug (UDS) results in patients receiving commonly prescribed medications, as well as common non-prescription medications. &nbsp; They identified 25 reports of false-positive UDS results involving the following categories of medications, as well as certain non-prescription agents. &nbsp; .&nbsp;Antihistamines .&nbsp;Antidepressants .&nbsp;Antibiotics .&nbsp;Analgesics .&nbsp;Antipsychotics &nbsp; Reports of false-positive results were found for the following clinic formulary and non-prescription medications: brompheniramine, bupropion, chlorpromazine, clomipramine, dextromethorphan, diphenhydramine, doxylamin...

BUPROPION HYDROCHLORIDEtablet, Film Coated [State Of Florida DOH Central Pharmacy]

Updated Date: Aug 5, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Orexigen® Therapeutics COR-BMOD Study Published In The Journal Obesity

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced the online publication of results from its COR-BMOD trial of Contrave® (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification (BMOD) plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients. The addition of Contrave to BMOD delivered significant incremental weight loss and improvements in measures of cardiometabolic risk. Results showed that patients taking Contrave lost 9... (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [TEVA Pharmaceuticals USA Inc]

Updated Date: Aug 4, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combination Naltrexone And Bupropion For Obesity Leads To Substantial Reductions In Bodyweight

Combination treatment for obesity using the drugs naltrexone and bupropion, plus diet and exercise, helps reduce bodyweight by a mean of 5% or more over a year, depending on the dosage used. The findings of the COR-I study are reported in an Article Online First and in an upcoming Lancet, written by Professor Frank L Greenway, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA, and colleagues... (Source: Health News from Medical News Today)

Naltrexone??bupropion combination aids weight loss

Overweight patients taking the combination of extended-release naltrexone and bupropion lose more weight than those taking placebo, shows the randomized COR-I trial. (Source: MedWire News - Lipidology)

Bupropion overdose: Neurological disorders and tonic-clonic seizures: case report

(Source: Reactions)

REVIEW: A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline

(Source: Journal of the American Academy of Nurse Practitioners)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Weight-Loss Combo Appears Effective (CME/CE)

(MedPage Today) -- A sustained-release formulation combining bupropion and naltrexone (Contrave) appears to be an effective treatment for weight loss in obese patients, researchers have found. (Source: MedPage Today Primary Care)

Naltrexone-Bupropion Plus Lifestyle Changes Better Than Lifestyle Changes Alone for Weight Loss

(Source: Physician's First Watch current issue)

Addiction drugs may boost weight loss (BBC News Online, 30 July 2010)

Results from large randomised controlled trial suggest that combination therapy with the anti-addiction drugs naltrexone and bupropion may be beneficial in promoting weight loss when combined with diet and exercise. Full article (Source: Society for Endocrinology)

RCT: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I study)

Source: Lancet Area: News According to the findings of this multicentre, phase III, double-blind, randomised, controlled American trial, a sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity. The researchers note that although obesity is a public health concern and is associated with an increased risk for conditions such as type 2 diabetes, cardiovascular disease, and cancer, there are few safe and effective drug treatments available.&nbsp; They investigated the effect of two different dosages of a sustained release combination of naltrexone and bupropion in overweight and obese people. &nbsp; The trial randomised participants in a 1:1:1 ratio to either: (i) sustained-release naltrexone 32 mg per day plus sustained-r...

Combination Weight Loss Drugs Appear Effective for Obesity

Treatment with two obesity drugs, naltrexone and bupropion, plus lifestyle modification appears effective in helping people lose 5 percent or more of their excess body weight, according to research published online July 30 in The Lancet. (Source: Modern Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Dispatch: What??s Up With All These Drug Combos?

An experimental obesity pill that combines the anti-addiction drug naltrexone and the anti-depressant bupropion has resulted in substantial reductions in body weight among participants in a clinical trial, the Lancet reports. (Source: Health Facts and Fears)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Major Pharmaceuticals]

Updated Date: Jul 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR

In this study, bupropion XR did not demonstrate statistically significant evidence of greater improvement from baseline compared with placebo on week 8 Montgomery Asberg Depression Rating scale scores (primary endpoint) or on secondary endpoints including CGI, HAM-A and responder and remitter analyses. Descriptive statistics for venlafaxine XR indicated separation versus placebo on MADRS total scores at week 8 and other intermediate time points, and on other endpoints including CGI, HAM-A and responder and remitter analyses. Both active treatments elicited improvement on the Sheehan Disability Scale and its subscales and were generally well tolerated at the doses studied. Rates of nausea, dry mouth, dizziness, hyperhidrosis, insomnia, constipation, tremor, anorexia and male sexual dysfunct...

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation

Authors: A M Leventhal, S P David, M Brightman, D Strong, J E McGeary, R A Brown, E E Lloyd-Richardson, M Munaf&#242;, G R Uhl & R Niaura (Source: The Pharmacogenomics Journal)

Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population.

This article describes the pattern of reported antidepressant use around the time of pregnancy in a population-based sample of women who delivered live-born babies without birth defects. Data were used from the National Birth Defects Prevention Study, an ongoing case-control study of risk factors for birth defects covering 10 US states. Mothers of live-born infants without birth defects (controls) born between 1998 and 2005 were randomly selected from each site. Information on the mother's characteristics and exposure to antidepressants was collected via a standardized telephone interview. Among 6582 mothers included in the study, 298 (4.5%) reported use of an antidepressant in the period of 3 months before through the end of pregnancy. Use of selective serotonin-reuptake inhibitors was re...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Actavis Receives Approval Of Bupropion HCl SR 100mg And 200mg In The U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg. Distribution of the product will commence immediately. (Source: Pharmaceutical Online News)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Jul 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Provision of relapse prevention interventions in UK NHS Stop Smoking Services: a survey

Conclusions: Just over half of UK managers of NHS Stop Smoking Services who responded to the questionnaire reported that, in their services, relapse prevention interventions were currently provided for clients, despite, at that time, there being a weak evidence base for their effectiveness. The most commonly provided relapse prevention interventions were those for which there was least evidence. If these interventions are found to be effective, barriers would need to be removed before they would become part of routine care. (Source: BMC Health Services Research)

Predictors of alternative antidepressant agent initiation among U. S. veterans diagnosed with depression

We examined predictors of antidepressant choice among VA patients treated for depression.Retrospective cohort study of VA patients with depression diagnoses and a new start of one of the seven most commonly prescribed antidepressant agents between 1 April 1999 and 30 September 2004 (n = 502 179). We examined the relationship between patient and facility characteristics and new starts of bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and venlafaxine. We also examined factors associated with new starts only among patients starting selective serotonin reuptake inhibitors (SSRIs).Thirty-three percent of patients starting mirtazapine had at least three outpatient mental health visits in the prior year, compared to [le]24% of patients prescribed other antidepressants. Pa...

Infant Heart Defects Linked to Pregnancy Bupropion Use

Maternal use of bupropion during early pregnancy appears to have a modest positive association with left outflow tract heart defects in infants, according to a study published in the July issue of the American Journal of Obstetrics &amp; Gynecology. (Source: Modern Medicine)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparison of Available Treatments for Tobacco Addiction

Abstract&nbsp;&nbsp;Cigarette smoking is a major public health problem that causes more than 5 million deaths annually worldwide. Cigarette smoking is especially common among individuals with psychiatric comorbidity, including individuals with primary psychiatric disorders and other addictions. Effective behavioral and pharmacologic treatments for smoking cessation are available. Behavioral treatments including brief (&lt; 3&nbsp;min) counseling by physicians are effective. Seven first-line pharmacologic treatments are currently available: five nicotine replacement therapies, bupropion, and varenicline. In addition, clonidine and nortriptyline are second-line treatments for smoking cessation. These treatments increase the chances of quitting smoking by two- to threefold, supporting t...

BUPROPION (Bupropion Hydrochloride) Tablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: Jul 9, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs.

Conclusion: These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action. PMID: 20626429 [PubMed - as supplied by publisher] (Source: CNS Neuroscience and Therapeutics)

Smoking Cessation??Recent Advances

Conclusion&nbsp;&nbsp;Further studies are required to address the uncertainty that exists on the most appropriate duration of therapy as well as the effectiveness and safety of combination pharmacotherapy. Post-marketing surveillance continues to play an important role in monitoring the adverse effects events associated with these therapies. Content Type Journal ArticleDOI 10.1007/s10557-010-6246-8Authors John J. McNeil, Monash University Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Alfred Hospital Melbourne Victoria 3004 AustraliaLoretta Piccenna, Monash University Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Alfred Hospital Melbourne Victoria 3004 AustraliaLisa L. Ioannide...

Bupropion overdose: Generalised seizures: 3 case reports

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Off-label treatment for cocaine and methamphetamine addiction

Heidi B. Magyar, MS, ARNP (Source: Pearls)

Bupropion/nortriptyline/tramadol: Seizures, complicated by spinal fracture: case report

(Source: Reactions)

Disorders of Orgasm in Women: A Literature Review of Etiology and Current Treatments

Conclusions. Although more research is needed to better understand and manage disorders of orgasm in women, significant progress is being made. IsHak WW, Bokarius A, Jeffrey JK, Davis MC, and Bakhta Y. Disorders of orgasm in women: A literature review of etiology and current treatments. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)

A positive association was found between bupropion use in early pregnancy and left outflow tract heart defects

(Source: Reactions)

Bupropion: Ataxia, tremor and mental status changes in an elderly patient: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Interventions for smoking cessation and reduction in individuals with schizophrenia.

CONCLUSIONS: Bupropion increases smoking abstinence rates in smokers with schizophrenia, without jeopardising their mental state. Bupropion may also reduce the amount these patients smoke. CR may help this group of patients to quit and reduce smoking. We failed to find convincing evidence that other interventions have a beneficial effect on smoking behaviour in schizophrenia. PMID: 20556777 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors.

Authors: Khokhar JY, Miksys SL, Tyndale RF CYP2B is a drug-metabolizing enzyme expressed in the liver and brain that metabolizes a variety of centrally acting drugs (e.g. propofol, bupropion and nicotine), endogenous neurochemicals (e.g. serotonin and testosterone) and toxins (e.g. chlorpyrifos). Human CYP2B6 is found at higher levels in the brains of smokers, and 7-day nicotine treatment induces rat brain CYP2B while not altering hepatic CYP2B. We characterized the time course of rat brain CYP2B induction by nicotine and determined if nicotinic acetylcholine receptors (nAChRs) mediated this induction. Rats were treated once daily with 1mg/kg nicotine base or saline s.c. for 1 or 7days and sacrificed from 30minutes to 7days after the last injection. One-day nicotine treatment did not i...

A pilot study combining individual-based smoking cessation counseling, pharmacotherapy, and dental hygiene intervention

Conclusions: We explored a new multi-disciplinary approach to smoking cessation, which included medical and dental interventions. Despite the small sample size and non-controlled study design, the observed rate was similar to that found in standard medical care. In terms of acceptability and feasibility, our results support further investigations in this field.Trial Registration number: ISRCTN67470159 (Source: BMC Public Health - Latest articles)

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial.

Authors: Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E This 56-week, randomized, placebo-controlled trial examined the efficacy and safety of naltrexone plus bupropion as an adjunct to intensive behavior modification (BMOD). A total of 793 participants (BMI = 36.5 +/- 4.2 kg/m(2)) was randomly assigned in a 1:3 ratio to: (i) placebo + BMOD (N = 202); or (ii) naltrexone sustained-release (SR, 32 mg/day), combined with bupropion SR (360 mg/day) plus BMOD (i.e., NB32 + BMOD; N = 591). Both groups were prescribed an energy-reduced diet and 28 group BMOD sessions. Co-primary end points were percentage change in weight and the proportion of participants who lost &gt;/=5% weight at week 56. Efficacy a...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [UDL Laboratories, Inc.]

Updated Date: Jun 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae.

This study examined the accumulation and metabolism of a number of drugs and commonly used probes for human cytochrome P450s (CYPs) in zebrafish larvae under conditions relevant to pharmacological and toxicological assays. Studies with cisapride, chlorpromazine, verapamil, testosterone, and dextromethorphan showed that the zebrafish larvae catalyze a range of phase 1 (oxidation, N-demethylation, O-de-ethylation, and N-dealkylation) and phase 2 (sulfation and glucuronidation) reactions. Both similarities and differences in the metabolic pathways were observed in zebrafish larvae when compared to mammals. Metabolism of phenacetin to paracetamol and dextromethorphan to dextrorphan (metabolic reactions catalyzed by CYP 1A2 and 2D6 in humans respectively) were observed in the zebrafish larvae. ...

The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19.

Authors: Chen Y, Liu HF, Liu L, Nguyen K, Jones EB, Fretland AJ The involvement of cytochrome P450 2B6 (CYP2B6) to the in vitro and in vivo metabolism of bupropion has been well studied. In these investigations we performed a detailed in vitro phenotyping study to characterize isoforms other than CYP2B6. A total of nine metabolites were identified (M1-M9) in the incubations with cDNA-expressed P450s (rhCYP) and human liver microsomes (HLM). Incubations in rhCYP identified CYP2B6 as the isoform responsible for the formation of hydroxybupropion (M3). CYP2C19 was involved in bupropion metabolism primarily through alternate hydroxylation pathways (M4-M6) with higher activity at lower substrate concentrations, near 1 microM. The results from HLM inhibition studies using CYP2B6 and CYP2C19 i...

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jun 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals]

Updated Date: Jun 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Jun 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats

We examined its influence on the duration of immobility during the forced swim test in adrenocorticotropic hormone (ACTH)-treated rats and further analyzed the possible role of dopamine receptors in this effect. Additionally, the mechanism by which bupropion acts in this model was explored specifically in relation to the site of action through the use of microinjections into the medial prefrontal cortex and nucleus accumbens. Bupropion significantly decreased the duration of immobility in normal and ACTH-treated rats. This effect was blocked by D2 and D3 receptor antagonists in normal rats. Furthermore, infusions of bupropion into the nucleus accumbens, but not medial prefrontal cortex, decreased the immobility of normal and ACTH-treated rats during the forced swim test. Bupropion tr...

Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

(Source: Evidence-Based Medicine)

Orexigen® Therapeutics Announces FDA Acceptance Of Contrave® New Drug Application For The Treatment Of Obesity

Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients... (Source: Health News from Medical News Today)

Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users.

Authors: Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity. The abuse potential of triple reuptake inhibitors is not yet known, and so this study was undertaken to evaluate the potential abuse-related effects of tesofensine in humans. It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupropion, and atomoxetine (negative/unscheduled controls) in recreational stimulant users (N = 52). Subjective and objective measures were assessed for 48 h after drug administration. The study results show that the effects of D-a...

Orexigen(R) Therapeutics Announces FDA Acceptance of Contrave(R) New Drug Application for the Treatment of Obesity

SAN DIEGO, June 1 (HSMN NewsFeed) -- Orexigen&reg; Therapeutics, Inc. (Nasdaq:OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's ... Biopharmaceuticals, FDAOrexigen Therapeutics, Contrave, naltrexone, bupropion, obesity (Source: HSMN NewsFeed)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Orexigen&reg; Therapeutics Announces FDA Acceptance Of Contrave&reg; New Drug Application For The Treatment Of Obesity

Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients. (Source: Pharmaceutical Online News)

Combo Therapies Were Most Effective in Smoking Cessation

Baltimore ?? Utilizing a nicotine patch or bupropion together with a nicotine lozenge was the most effective of five therapies tested for promoting smoking abstinence and avoiding a lapse or relapse into smoking behaviors, according to a prospective study of 1,504 smokers. (Source: Internal Medicine News)

Combo Therapies Deliver Best Smoking Quit Rates

BALTIMORE ?? Using a nicotine patch or bupropion with a nicotine lozenge was the most effective of five therapies tested for promoting smoking abstinence and avoiding a lapse or relapse into smoking, according to a prospective study of 1,504 smokers. (Source: Clinical Psychiatry News)

An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine

Although the exact mechanism that makes bupropion hydrochloride (Zyban&reg;) effective as a smoking cessation aid has not been fully elucidated, studies have found that bupropion and nicotine share behavioural and neurophysiological properties suggesting that bupropion might serve as a substitute for nicotine. In fact, bupropion prompts nicotine-appropriate responding in operant and Pavlovian drug discrimination studies with rats. A majority of the literature examining this substitution pattern has been done with an operant paradigm. The present research extended this literature by further characterising the behavioural and neuropharmacological properties underlying the substitution for a nicotine conditioned stimulus (CS). Examination of the dose&mdash;effect function and temporal dynamic...

Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion

In conclusion, successfully treated smokers showed attenuated craving and reduced activity in the mesolimbic reward circuit. (Source: Journal of Psychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Aplenzin (Bupropion Hydrobromide Tablet) - updated on RxList

Aplenzin (Bupropion Hydrobromide Tablet) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: May 19, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Dose-Related Reduction in Bupropion Plasma Concentrations by Ritonavir.

Authors: Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, Sutherland SM, Muir KT The effect of repeat oral doses of ritonavir, at high (600 mg twice daily) and low (100 mg twice daily) doses, on the pharmacokinetics of a single dose of bupropion was evaluated in healthy volunteers. Subjects received a single dose of 150 mg of bupropion on day 1 and twice-daily ritonavir from day 8 through day 30. Ritonavir was up-titrated from 300 mg twice daily to 600 mg twice daily in the high-dose ritonavir study, whereas subjects remained on 100 mg twice-daily ritonavir in low-dose ritonavir study. Subjects received a second single dose of bupropion on day 24. Serial blood samples were obtained to evaluate the pharmacokinetics of bupropion and its metabolites on days 1 and 24. Steady...

Review: Psychopharmacological treatment of PTSD in children and adolescents

Source: J Clin Psychiatry Area: News According to a review on the treatment of post-traumatic stress disorder (PTSD) in children and adolescents, selective serotonin reuptake inhibitors (SSRIs) are not generally helpful, although they may have a role in those with co-morbid depression. &nbsp; The authors note that there are currently limited and conflicting data available to guide treatment of paediatric patients with PTSD.&nbsp; The aim of this article was to summarise the available evidence for the treatment of PTSD in this population.&nbsp; Researchers reviewed the literature using the National Library of Medicine (limited to English articles published 1966-2009) and then conducted manual searches of citations and of two leading journals.&nbsp; They discuss the available evidence f...

Smoking cessation in severe mental illness: what works?

Conclusions Treating tobacco dependence is effective in patients with SMI. Treatments that work in the general population work for those with severe mental illness and appear approximately equally effective. Treating tobacco dependence in patients with stable psychiatric conditions does not worsen mental state. (Source: Addiction)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

How it doesn't work: The dogma of the 12 steps

Imagine being diagnosed with cancer, going through a regimen of chemotherapy only to have the cancer return within months, and being told by your doctor that there must be something wrong with you and that he can't treat you unless you let the chemo do its work.Absurd right?12-Step dogmaUnfortunately, if you replace the cancer above with addiction, the chemotherapy with the 12-steps, and the doctor with 12-step dogma, you have what we know as the ________ Anonymous model (fill in your favorite blank). It's even written in what 12-steppers call The Big Book (officially called "Alcoholics Anonymous") and often read as part of the "How it Works" section."Those who do not recover are people who cannot or will not completely give themselves to this simple program, usually men and women who are ...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: May 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: May 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: May 6, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Extended Release [Sandoz Inc]

Updated Date: May 5, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [NCS HealthCare Of KY, Inc Dba Vangard Labs]

Updated Date: May 5, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Validation of The Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications

Evaluation of tobacco policy requires high quality and timely data on smoking cessation behaviour in the general population and in relevant target groups. Electronic primary care databases have the potential to provide a valuable source of data due to their size and continuity, and the availability of demographic and socioeconomic data. We therefore sought to investigate whether The Health Improvement Network (THIN) prescribing data are complete and can therefore be used to monitor trends in the prescribing of smoking cessation medications.The THIN smoking cessation medication prescriptions data for England were compared with smoking cessation medication dispensing data from NHS Prescription Services for January 2004 to December 2005.Throughout the period the rates of prescribing and dispe...

Antidepressant tied to risk of newborn heart defect

NEW YORK (Reuters Health) - Women who use the antidepressant bupropion during early pregnancy may have an increased risk of having a baby with a particular type of heart defect, a new study suggests. (Source: Reuters: Health)

Mylan Receives Approval for Generic Version of Zyban(R)

PITTSBURGH, May 4 (HSMN NewsFeed) -- Mylan Inc. (Nasdaq:MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupr... Biopharmaceuticals, Generics, FDAMylan, Mylan Pharmaceuticals, GlaxoSmithKline, Bupropion, Zyban (Source: HSMN NewsFeed)

Meta-analysis: Bupropion for smoking cessation and reduction in schizophrenia

Source: British Journal of Psychiatry Area: News A systematic review and meta-analysis has found that bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without affecting their mental state. &nbsp; To investigate, the authors conducted a systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia. &nbsp; The following results were noted: .&nbsp;Overall, 21 reports of 7 trials with a total of 260 participants were included. .&nbsp;Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 mont...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion, Bayesian Logic and Serotonin Toxicity.

Authors: Gillman PK PMID: 20440594 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)

Bupropion: Status epilepticus and retrograde amnesia: case report

(Source: Reactions)

Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

(Source: Evidence-Based Nursing)

Combined Pharm Tx Best for Smoking Cessation

BALTIMORE ?? Utilizing a nicotine patch or bupropion together with a nicotine lozenge was the most effective of five therapies tested for promoting smoking abstinence and avoiding a lapse or relapse into smoking, according to a prospective study of 1,504 smokers. (Source: Family Practice News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis [REVIEW ARTICLES]

Conclusions Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state. (Source: The British Journal of Psychiatry)

General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: Impact after 1year of two complex interventions

Conclusion: The program doubled the cessation rates (statistically nonsignificant). Too few participants used the additional bupropion-SR to prove its effectiveness.Practice implications: The protocols can be used for COPD patients in general practice, but expectations should be modest. If quitting is unsuccessful, a stepped care approach should be considered. (Source: Patient Education and Counseling)

Significant Proportion of Abuse Counselors Lack Knowledge of Bupropion for Tobacco Cessation

A new study shows that approximately 40% of substance abuse counselors tested from 2002 to 2004 and from 2007 to 2008 have little knowledge of bupropion and its effectiveness. Medscape Medical News (Source: Medscape Today Headlines)

CADTH: Brief review of bupropion in patients with depression and the associated risk of seizures

Source: CADTH Area: News The Health Technology Inquiry Service* (HTIS) of the Canadian Agency for Drugs and Technologies in Health (CADTH) has produced a report exploring the evidence on the risk of seizures with bupropion in patients with depression, and how this compares to other antidepressants (or placebo).&nbsp;&nbsp; &nbsp; One systematic review (and an associated update) conducted by the Agency for Healthcare Research and Quality (AHRQ) met the inclusion criteria. Two studies evaluating bupropion were included in this review; the seizure rates reported were 0.1% and 0.4% (both authors concluded that this was within the rates seen for other antidepressants).&nbsp; Both studies were rated as low quality, and the HTIS report concludes that "the absence of data from controlled tria...

The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments

Conclusion: Similar to other antidepressants, the reduction of prefrontal QEEG cordance might be helpful in the prediction of the acute outcome of bupropion treatment. (Source: European Neuropsychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Maternal use of bupropion and risk for congenital heart defects

Conclusion: We identified a positive association between early pregnancy bupropion use and left outflow tract heart defects; however, the magnitude of the observed increased risk was small. Nevertheless, further studies are needed to confirm these results. (Source: American Journal of Obstetrics and Gynecology)

Repetitive transcranial magnetic stimulation for tinnitus treatment: No enhancement by the dopamine and noradrenaline reuptake inhibitor bupropion

Conclusions: Our data suggest that 150 mg bupropion administration does not enhance the effect of rTMS in the treatment of tinnitus. (Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation)

Generalized Seizure in Three Adolescents with Bupropion Overdose

Journal of Child and Adolescent Psychopharmacology Apr 2010, Vol. 20, No. 2: 159-160. (Source: Journal of Child and Adolescent Psychopharmacology)

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

Updated Date: Apr 22, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Sun Pharma Global FZE]

Updated Date: Apr 21, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Sertraline versus other antidepressive agents for depression.

CONCLUSIONS: This systematic review and meta-analysis highlighted a trend in favour of sertraline over other antidepressive agents both in terms of efficacy and acceptability, using 95% confidence intervals and a conservative approach, with a random effects analysis. However, the included studies did not report on all the outcomes that were pre-specified in the protocol of this review. Outcomes of clear relevance to patients and clinicians were not reported in any of the included studies. PMID: 20393946 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

Non smoking for successful aging: therapeutic perspectives.

Authors: Nicita-Mauro V, Maltese G, Nicita-Mauro C, Lasco A, Basile G The smoke of cigarettes represents an important accelerator of the aging process, and there is no doubt that smoke is an important risk factor for many diseases, in particular for cardiovascular, neoplastic and respiratory diseases. Smoking plays an important role also in the development of other pathological conditions being particularly frequent in geriatric ages, such as dementia, osteoporosis, diabetes, erectile dysfunction, senile macular degeneration, nuclear cataract and alterations of skin. This means that smoke compromises not only life expectancy, but also the quality of the life, favoring the occurrence of non-autonomy. Non-smokers have a much higher life expectancy than smokers, and the suspension of smok...

BUPROPION HYDROCHLORIDEtablet, Extended Release [Rebel Distributors Corp.]

Updated Date: Apr 15, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Apr 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Sun Pharma Announces USFDA Approval For Generic Wellbutrin SR(R) Extended Release Tablets

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets. These generic Bupropion Hydrochloride Extended Release tablets are equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets and includes three strengths: 100 mg, 150 mg and 200 mg... (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUDEPRION (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [STAT RX USA LLC]

Updated Date: Apr 6, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder

This study demonstrated that the extended-release bupropion is an effective, well-tolerated treatment for major depression in the elderly. (Source: Journal of Psychopharmacology)

Orexigen(R) Therapeutics Submits Contrave(R) New Drug Application To FDA For The Treatment Of Obesity

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients. "The COR program was designed to address all the elements of the FDA guidance for weight loss and weight maintenance in patients with obesity... (Source: Health News from Medical News Today)

Bupropion Plus CBT Help Women Quit Smoking

For women concerned about gaining weight if they quit smoking, the combination of bupropion plus a cognitive-behavioral therapy centered on weight concerns may be more effective at sustaining abstinence than the CBT plus placebo, according to a report in the Archives of Internal Medicine. (Source: Rheumatology News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Orexigen Therapeutics Submits Contrave New Drug Application to FDA for the Treatment of Obesity

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave (naltrexone SR/bupropion SR), its... (Source: Drugs.com - New Drug Applications)

BUPROPION HYDROCHLORIDEtablet, Film Coated [State Of Florida DOH Central Pharmacy]

Updated Date: Mar 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION (Bupropion Hydrochloride) Tablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: Mar 26, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Combination Therapy Improves Abstinence Rates in Weight-Concerned Female Smokers

Bupropion + CBT designed to address concerns about weight gain produce higher rates of abstinence and longer times to relapse than standard CBT + medication or the weight-concerned CBT program alone. Medscape Medical News (Source: Medscape Today Headlines)

Approach May Help Smokers With Weight-Gain Concern

Cognitive behavioral therapy combined with bupropion may be helpful for sustaining smoking abstinence in female smokers concerned about weight gain, according to research published in the March 22 issue of the Archives of Internal Medicine. (Source: Modern Medicine)

Weight counseling plus drug helps women quit smoking

Behavioral therapy with a focus on weight-counseling combined with the smoking-cessation medicine bupropion (Zyban) is more effective ... (Source: USATODAY.com Health)

Acute Psychosis Associated with Dissociated Sleep-Wakefulness State After Mirtazapine Treatment

We describe a 43-year-old Caucasian man with major depressive disorder who started mirtazapine 15 mg at bedtime because he had poor symptom control with other antidepressant drugs. Three days later, vivid dream activity was noted, evolving into realistic nightmares that the patient was not able to distinguish from reality on awakening. Acute paranoia was suspected, and haloperidol was started. The dream activity then ended, and within 3 days the patient was able to identify the dreams as unreality. Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact. A short course of haloperidol restored the patient's reality testing, and mirtazapine was eventually replaced with bupropion. The unusual nocturnal...

Weight Counseling, Bupropion Help Smokers Quit (CME/CE)

Adding bupropion (Wellbutrin, Zyban) to cognitive behavioral therapy intervention that focuses on weight-gain concerns increased smoking cessation rates, researchers said. (Source: MedPage Today Primary Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Combining weight-focused counseling, medication helps women quit smoking

For women smokers worried about their weight, combining cognitive behavioral therapy addressing weight concerns with the medication bupropion appears more effective than counseling alone to help them quit smoking, according to a new study. (Source: ScienceDaily Headlines)

Bupropion-Associated Premature Ejaculation

PharmacopsychiatryDOI: 10.1055/s-0030-1249034© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents  |  Full text (Source: Pharmacopsychiatry)

Bupropion plus cognitive behavioural therapy for smoking cessation in women with weight concerns

Source: Arch Internal Med Area: News Combination of bupropion and cognitive behavioural therapy (CBT) that addressed weight gain concerns was more effective than bupropion or CBT alone for smoking cessation in women concerned about their weight, according to a controlled trial. &nbsp; Women who smoke may wish to quit but are concerned about the weight gain that can accompany quitting. Concurrent use of smoking cessation and weight control interventions is not helpful and may reduce quit rates, so the authors of this trial aimed to determine whether there was benefit in adding CBT that addressed concerns about post-quit weight gain to standard pharmacotherapy for smoking cessation. Participants were adult female smokers who wished to quit but expressed concern about subsequent weight g...

Bupropion and Cognitive Behavioral Therapy for Weight-Concerned Women Smokers [Original Investigation]

Conclusions&nbsp; Weight-concerned women smokers receiving the combination of CONCERNS&nbsp;+&nbsp;B were most likely to sustain abstinence. This effect was not related to differences in postcessation weight gain or changes in weight concerns. Trial Registration&nbsp; clinicaltrials.gov Identifier: NCT00006170 (Source: Archives of Internal Medicine)

Combining weight-focused counseling, medication helps women quit smoking

(JAMA and Archives Journals) For women smokers worried about their weight, combining cognitive behavioral therapy addressing weight concerns with the medication bupropion appears more effective than counseling alone to help them quit smoking, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. (Source: EurekAlert! - Social and Behavioral Science)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Which Xenobiotic(s) Could be Responsible for the Radiologic Findings Below? : Answer: Any proconvulsant xenobiotic, in this case tramadol, bupropion, and nortriptyline.

CONCLUSIONS: Sudden onset of back pain during sleep can be an important clue to a seizure complicated by vertebral compression fractures, even in the absence of trauma. Toxicology consultation in seizures of unclear etiology can help discern drugs that offend even in therapeutic doses. PMID: 20306168 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)

Unintentional Pediatric Bupropion Ingestions

3.5 out of 5 stars The Outcomes of Unintentional Pediatric Bupropion Ingestions: A NPDS Database Review.  Meuhler MC et al.  J Med Toxicol (published online 06 March 2010) (abstract not available online) Bupropion, an atypical antidepressant, inhibits re-uptake of dopamine and norepinephrine.  It is used as an aid to stop smoking as well as an antidepressant.  Major effects of overdose include decreased mental status, coma, and seizures.  This review of data from the National Poison Data System &#8212; covering seven years of cases referred to American poison centers &#8212; identified cases of unintentional, acute, single ingestions of bupropion in children &lt; 6 years old.  The authors found 5,964 cases that met inclusion criteria.  There were no deaths, and seizures occurred in ...

Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats.

This study is an attempt to demonstrate whether bupropion (BP) and diethylpropion (DEP) exert their pharmacological actions by similar neurochemical mechanisms in the dorsal striatum. In this regard, the release of dopamine (DA), glutamate (Glu), and GABA, was determined in the rat dorsal striatum after acute (5min) and chronic (15 consecutive days) treatments, and subsequently correlated with the locomotor activities produced by these drugs. The results from the acute experiments indicate that BP and DEP (40mg/kg) increase locomotor activity, whereas chronic DEP treatment decreases locomotor activity by unspecific mechanisms. Acute BP treatment produces significant DA and Glu, but not GABA, releases. A lesser extent of DA release and tissue content of DA and its metabolites, and consequen...

Can Adults Have ADHD?

Attention deficit disorder is not just a childhood disorder. Adults can be diagnosed with attention deficit disorder (ADHD) as well. Sometimes this is a result of the person&#8217;s childhood ADHD progressing into adulthood (up to 70 percent of children will continue to struggle with ADHD as adults). Other times, an adult can either simply never been diagnosed as a child, or develop the disorder later on in life. Adult attention deficit disorder looks a lot like childhood attention deficit disorder. That shouldn&#8217;t come as a surprise, since the symptoms are largely the same. If you answer &#8220;Yes&#8221; to six or more of the below symptoms, you may have adult ADHD: Often fails to give close attention to details or makes careless mistakes in course work, work, or other activities ...

Bupropion Induced Serotonin Syndrome: A Case Report.

Authors: Thorpe EL, Pizon AF, Lynch MJ, Boyer J Although there are no documented cases of serotonin syndrome (SS) following bupropion ingestion alone in the literature, the ability of bupropion to potentiate serotonin levels and lead to SS is known. A 15-year-old boy was found at home hallucinating. He then developed tonic-clonic activity. Upon arrival in the emergency department, he was confused and restless. On exam, he had tachycardia, hypertension, dilated pupils and dry oral mucosa, normal tone and reflexes in his arms, but rigidity and +4 reflexes in his legs with sustained clonus at his ankles. He was admitted and treated with intravenous fluids and lorazepam for his agitation. A urine drug screen (via gas chromatography/mass spectrometry) was positive only for naproxen and bupr...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage

Conclusions: The strength of EVITA appears to lie in its speedy assessment of the potential therapeutic advantage of a new drug for a given indication. At the same time, this approach draws attention to the typical deficits of data used for drug approval. EVITA is not intended to replace classical health technology assessment reports but rather serves as a screening tool in the sense of horizon scanning. (Source: BioMed Central)

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study

Source: American Journal of Psychiatry Area: Evidence > Medicines Management > References > 2010 - March > 16 Various classes of antidepressant medications generally induce remission of major depressive disorder in only about one-third of patients. In a previous study using mirtazapine or paroxetine alone or in combination from treatment initiation, the rate of patients who remitted within a 6-week period was twice that of patients using either drug alone. In this double-blind study, the authors sought to produce evidence for the superiority of different combinations of antidepressant drugs from treatment initiation. Patients (n = 105) meeting DSM-IV criteria for major depressive disorder were randomly assigned to receive, from treatment initiation, either fluoxetine monotherapy (20 mg/da...

The Outcome of Unintentional Pediatric Bupropion Ingestions: A NPDS Database Review. - Beuhler MC, Spiller HA, Sasser HC.

Unintentional bupropion pediatric exposures uncommonly report severe clinical effects such as seizures. We sought to determine the clinical effects and case outcomes for unintentional bupropion ingestions in children age ... (Source: SafetyLit: All (Unduplicated))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Watson Laboratories, Inc.]

Updated Date: Mar 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Contract Pharmacy Services-PA]

Updated Date: Mar 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

Updated Date: Mar 9, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Outcome of Unintentional Pediatric Bupropion Ingestions: A NPDS Database Review.

Authors: Beuhler MC, Spiller HA, Sasser HC Unintentional bupropion pediatric exposures uncommonly report severe clinical effects such as seizures. We sought to determine the clinical effects and case outcomes for unintentional bupropion ingestions in children age &lt;/=6 years. The National Poison Data System was queried for unintentional, acute, single substance bupropion ingestions in children age &lt;/=6 years for the time period January 1, 2000 to February 27, 2007 for cases followed to a known outcome. If exposure amount was reported, a mg/kg dose was determined; when weight was absent, it was interpolated from the available data set. An adverse neurological effect (ANE) was defined as seizure (single, multi/discrete, and status) or coma. For analysis, the outcomes of no effect an...

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

Updated Date: Mar 5, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals]

Updated Date: Mar 4, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study [Articles]

Conclusions The combination treatments were as well tolerated as fluoxetine monotherapy and more clinically effective. The study results, which add to a growing body of evidence, suggest that use of antidepressant combinations from treatment initiation may double the likelihood of remission compared with use of a single medication. (Source: Am J Psychiatry)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Parkinsonism and dystonia in an elderly patient: case report

(Source: Reactions)

Use PDE-5 Inhibitors for Antidepressant Side Effects

SANTA FE, N.M. ?? Skip the yohimbe. Don't switch your patients to bupropion. Do you really want to tell them to stop taking their antidepressants before the weekend? Men and women who develop sexual dysfunction while on serotonin reuptake inhibitors (SRIs) should be treated with phosphodiesterase-5 (PDE-5) inhibitors, Dr. H. George Nurnberg told attendees at an annual psychiatric symposium sponsored by the University of Arizona. He dismissed as ??clinical folklore? virtually all the commonly used remedies for sexual dysfunction associated with SRIs. (Source: Clinical Psychiatry News)

Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

CONCLUSIONS: STEP-BD yielded numerous clinical and systems observations that provide fresh direction for research and treatment of BD, including setting new benchmarks for outcome and demonstrating the viability of large BD networks. PMID: 20370963 [PubMed - in process] (Source: Canadian Journal of Psychiatry)

Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT(3) receptor antagonist, in animal models of depression.

In conclusion, this behavioral study describes an antidepressant-like effect of QCF-3 in rodent behavioral models of depression. PMID: 20508279 [PubMed - in process] (Source: Pharmacological Reports)

Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects

CONCLUSIONS These results indicate that woohwangcheongsimwon suspension has a negligible effect on the disposition of a single dose of bupropion in vivo. As a result, temporary co-administration with woohwangcheongsimwon suspension does not seem to require a dosage adjustment of bupropion. (Source: British Journal of Clinical Pharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

A randomized, double?blind, placebo?controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women

(Source: BJU International)

Buproprion Shows Benefits for Women With Hypoactive Sexual Desire Disorder

The antidepressant bupropion (Wellbutrin) may hold promise for improving symptoms in younger women with hypoactive sexual desire disorder (HSDD), a small study suggests. Reuters Health Information (Source: Medscape Medical News Headlines)

Effectiveness of Pharmacotherapy and Behavioral Interventions for Smoking Cessation in Actual Clinical Practice

This study looked at the effectiveness of behavioral interventions in combination with bupropion SR for smoking cessation. Therapeutic Advances in Respiratory Disease (Source: Medscape Today Headlines)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Contract Pharmacy Services-PA]

Updated Date: Feb 26, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Antidepressant shows benefits for low sex drive

NEW YORK (Reuters Health) - The antidepressant bupropion may hold promise for improving symptoms in younger women diagnosed with so-called hypoactive sexual desire disorder, a small study suggests. (Source: Reuters: Health)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antidepressant Shows Benefits for Low Sex Drive

The antidepressant bupropion may hold promise for improving symptoms in younger women diagnosed with so-called hypoactive sexual desire disorder, a small study suggests.Source: Reuters Health Related MedlinePlus Pages: Antidepressants, Sexual Health, Women's Health (Source: MedlinePlus Health News)

Bupropion for the Treatment of Neuropathic Pain.

Authors: Shah TH, Moradimehr A Neuropathic pain is a common problem in clinical practice, affecting patients physically, emotionally, financially, and socially. Current treatment includes antidepressants, antiepileptics, and opioid analgesics. Bupropion is a specific inhibitor of neuronal noradrenaline reuptake and a weak inhibitor of dopamine reuptake, which shows some promise in the treatment of neuropathic pain. PMID: 20185402 [PubMed - as supplied by publisher] (Source: The American Journal of Hospice and Palliative Care)

Efficacy of psychostimulant drugs for cocaine dependence.

CONCLUSIONS: This review found mixed results, therefore evidence of the efficacy of psychostimulants for cocaine dependence is inconclusive. Nevertheless promising results exist for methadone maintained dual heroin-cocaine addicts and for some specific drugs such as dexamphetamine and bupropion. PMID: 20166094 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.

Prevalence of cigarette smoking among opioid-maintained patients is more than threefold that of the general population and associated with increased morbidity and mortality. Relatively few studies have evaluated smoking interventions in this population. The purpose of the present study was to examine the efficacy of contingency management for promoting initial smoking abstinence. Forty methadone- or buprenorphine-maintained cigarette smokers were randomly assigned to a contingent (n = 20) or noncontingent (n = 20) experimental group and visited the clinic for 14 consecutive days. Contingent participants received vouchers based on breath carbon monoxide levels during Study Days 1 to 5 and urinary cotinine levels during Days 6 to 14. Voucher earnings began at $9.00 and increased by $1.50 wit...

Bupropion-Induced Status Epilepticus and Retrograde Amnesia [LETTERS TO THE EDITOR]

(Source: J Neuropsychiatry Clin Neurosci)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation

Journal of Medicinal Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of Medicinal Chemistry)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

Updated Date: Feb 16, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective ...

Urology and Nephrology Research Center, Shahid Beheshti University (MC), Tehran, Iran. (Source: UroToday)

Pharmacologically Induced/Exacerbated Restless Legs Syndrome, Periodic Limb Movements of Sleep, and REM Behavior Disorder/REM Sleep Without Atonia: Literature Review, Qualitative Scoring, and Comparative Analysis

Conclusion: Based on scores &ge; 10 and trials of medication reduction/cessation, the strongest evidence available for drug induced RLS are for the following drugs: escitalopram; fluoxetine; L-dopa/carbidopa and pergolide; L-thyroxine; mianserin; mirtazapine; olanzapine; and tramadol. Since none of the PLMS articles assessed PLMI in trials of medication reduction/cessation, the strongest evidence based on scores &ge; 10 are for the following drugs: bupropion, citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine. Based on scores &ge; 10 and/or trials of medication cessation, the strongest evidence for drug induced RBD/RSWA is for the following drugs: clomipramine, selegiline, and phenelzine. Keywords: Pharmacologically induced, periodic limb movements of sleep, rapid eye movemen...

BUPROPION HYDROCHLORIDEtablet, Film Coated [UDL Laboratories, Inc.]

Updated Date: Feb 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Extended Release [GlaxoSmithKline LLC]

Updated Date: Feb 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [KAISER FOUNDATION HOSPITALS]

Updated Date: Feb 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Paxil May Raise Death Risk for Those Taking Tamoxefin

Breast cancer patients who are taking Tamoxefin to prevent a recurrence of the disease should not take the antidepressant Paxil (paroxetine), a new study suggests. Women in the study who took both drugs together had a greater than average risk of dying from breast cancer. The study looked at medical records for 2,430 breast cancer patients who had been taking tamoxefin. About 1 out 4 of these women had also taken Paxil; and, on average, about 41% of the time that the women were taking tamoxefin they were also taking Paxil. The researchers found that there was about one extra death from breast cancer for every 20 women who had taken the two drugs together. The researchers believe that the risk of death from breast cancer was increased because Paxil interferes with the cancer-preventing a...

A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To compare the efficacy of sustained-release (SR) bupropion to placebo in treating hypoactive sexual desire disorder (HSDD) in ovulating women. After a 1-week, placebo lead-in phase, 232 treatment-seeking women with regular menstrual cycles were randomly assigned to bupropion SR 150 mg/daily (116) or placebo (116) for 12 weeks under double-blind conditions. Efficacy was assessed with the Brief Index of Sexual Functioning for Women (BISF-W), the Personal Distress Scale (PDS), the global efficacy question (GEQ; 'Did the treatment you received during the 12-week improve meaningful your sexual desire?') and overall patient satisfaction question ('Are you satisfied with the efficacy of your treatment?'). The mean (sd) composite score on the B...

Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons

This study was designed to investigate the effects of co-administration of bupropion with escitalopram on the firing rate of 5-HT and norepinephrine (NE) neurons in anesthetized rats. Escitalopram (10 mg/kg/day x 2 days), given via subcutaneously (s.c.) implanted minipumps, decreased the firing of 5-HT and NE neurons by 70% and 55%, respectively. The firing of 5-HT neurons, unlike that of NE neurons, recovered after the 14-day escitalopram regimen. Bupropion, injected once daily (30 mg/kg/day, s.c. x 2 days), did not increase 5-HT firing but decreased that of NE by 55%. After 14 days of repeated bupropion administration, 5-HT firing was increased by 50%, and NE firing was back to baseline. Co-administration of escitalopram and bupropion doubled 5-HT firing after 2 and 14 days, whereas NE n...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Medical interventions for addictions in the primary care setting.

This article summarizes a presentation made by R. Douglas Bruce, MD, MA, MSc, at the 12th Annual Clinical Conference for the Ryan White HIV/AIDS Program held in October 2009 in Dallas, Texas. The original presentation is available as a Webcast at www.iasusa.org. PMID: 20305310 [PubMed - in process] (Source: Topics in HIV Medicine)

Pharmacological approaches to methamphetamine dependence: a focused review

Methamphetamine dependence is a serious worldwide public health problem with major medical, psychiatric, socioeconomic and legal consequences. Various neuronal mechanisms implicated in methamphetamine dependence have suggested several pharmacological approaches. A literature search from a range of electronic databases (PubMed, EMBASE, PsycInfo, the NIDA research monograph index and the reference list of clinicaltrials.gov) was conducted for the period from January 1985 to October 2009. There were no restrictions on the identification or inclusion of studies in terms of publication status, language and design type. A variety of medications have failed to show efficacy in clinical trials, including a dopamine partial agonist (aripiprazole), GABAergic agents (gabapentin) and serotonergic agen...

The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double?blind placebo?controlled and randomized study

(Source: BJU International)

Use of Enantiomeric Bupropion and Hydroxybupropion to Assess CYP2B6 Activity in Glomerular Kidney Diseases.

Authors: Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED There are limited data describing the influence of chronic kidney diseases on the cytochrome P450 2B6 pathway. The purpose of this study was to evaluate the pharmacokinetics of enantiomeric bupropion and hydroxybupropion in patients with glomerulonephritis. Ten patients with biopsy-confirmed lupus nephritis or antineutrophil-associated vasculitis were enrolled for CYP2B6 phenotyping with oral bupropion. Blood and urine were collected over 72 hours for pharmacokinetic analysis. R- and S-bupropion and (R,R) and (S,S) hydroxybupropion were analyzed by high-performance liquid chromatography tandem mass spectrometry. Statistics included paired t tests or nonparametric equivalent. Bupropion (2329 +/- 953 mug*h/L vs 1240 +...

Biovail Comments On Proposed Generic Wellbutrin XL(R) Trial

Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail's FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva's generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009... (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion metabolism by human placenta.

Authors: Wang X, Abdelrahman DR, Zharikova OL, Patrikeeva SL, Hankins GD, Ahmed MS, Nanovskaya TN Smoking during pregnancy is the largest modifiable risk factor for pregnancy-related morbidity and mortality. The success of bupropion for smoking cessation warrants its investigation for treatment of pregnant patients. Nevertheless, the use of bupropion for the treatment of pregnant smokers requires additional data on its biodisposition during pregnancy. Therefore, the aim of this investigation was to determine the metabolism of bupropion in placentas obtained from nonsmoking and smoking women, identify metabolites formed and the enzymes catalyzing their formation, as well as the kinetics of the reaction. Data obtained revealed that human placentas metabolized bupropion to hydroxybupropio...

Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial

TORONTO--(HSMN NewsFeed)--Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse event... Biopharmaceuticals, GenericsBiovail, Wellbutrin, Teva Pharmaceutical, bupropion (Source: HSMN NewsFeed)

Statistics on NHS Stop Smoking Services: England, April 2009 to September 2009

Source: NHS Information Centre Area: News This quarterly report presents provisional results from the monitoring of the NHS Stop Smoking Services in England from 1 April 2009 to 30 September 2009. Key facts on treatments include the following, though these data should not be used to assess or compare the clinical effectiveness of the various pharmacotherapies: &nbsp; .&nbsp;The majority of those setting a quit date received Nicotine Replacement Therapy (NRT) only (65%), 23% varenicline, 1% bupropion, 1% both NRT and varenicline and &lt; 1% received both NRT and bupropion, whilst 5% did not receive any pharmacotherapy. &nbsp; .&nbsp;Of those who used varenicline 59% successfully quit, compared with 50% who received bupropion only, and 48% who received NRT only, whilst 42% of people...

A bupropion smoking cessation clinical trial for cancer patients

Conclusions&nbsp;&nbsp;For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients. Content Type Journal ArticleCategory Original paperDOI 10.1007/s10552-010-9507-8Authors Robert A. Schnoll, University of Pennsylvania Department of Psychiatry 3535 Market Street, 4th Floor Philadelphia PA 19104 USAElisa Martinez, Fox Chase Cancer Center 333 Cottman Avenue Philadelphia PA 19111 USAKristina L. Tatum,...

Design, recruitment, and retention of African-American smokers in a pharmacokinetic study

Conclusions: Although recruitment of African-American smokers into a non-treatment, pharmacokinetic study poses challenges, retention is feasible. The results provide valuable information for investigators embarking on non-treatment laboratory-based studies among minority populations. (Source: BioMed Central)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Modeling smoking cessation data with alternating states and a cure fraction using frailty models

We propose a flexible parametric model to describe alternating states recurrent-event data where there is a possibility of cure with each type of event. We begin by introducing a novel cure model in which a common frailty influences both the cure probability and the hazard function given not cured. We then extend our model to data with recurring events of two alternating types. We assume that each type of event has a gamma frailty, and we link the frailties by a Clayton copula. We illustrate the model with an analysis of data from two smoking cessation trials comparing bupropion and placebo, in which each subject potentially experienced a series of lapse and recovery events. Our analysis suggests that bupropion increases the probability of permanent cure and decreases the hazard of lapse, ...

BUPROPION HYDROCHLORIDEtablet, Extended Release [KAISER FOUNDATION HOSPITALS]

Updated Date: Jan 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Amitriptyline/bupropion/fluspirilene interaction: First report of an interaction, leading to tonic-clonic seizure in a sleep-deprived patient: case report

(Source: Reactions)

Bupropion: Neck and shoulder pain in an elderly patient: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined. The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI. The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks. Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfac...

Answers to your questions about SSRIs.

Authors: White C, Wigle PR, Albert LG, Eichel E, Udorn L Avoid prescribing a highly activating SSRI, such as fluoxetine, for patients for whom agitation is a presenting symptom. Consider citalopram and escitalopram, which have less potential for drug interactions and less complex dose titration compared with other SSRIs, as first-line agents for depressed patients with complex medication profiles. For patients with sexual side effects caused by SSRIs, consider augmentation therapy with bupropion or mirtazapine; for male sexual dysfunction, a trial of a phosphodiesterase inhibitor is another alternative. PMID: 20074497 [PubMed - in process] (Source: The Journal of Family Practice)

The Relationship between Antidepressant Use and Smoking Cessation in Pregnant Women in Treatment for Substance Abuse.

Conclusions: Trend for greater decrease in smoking for the bupropion vs. citalopram/escitalopram group [-6.4 vs. -.4 cigarettes/day (p = .276)], although the bupropion decrease was similar to that seen in the no antidepressant group [-5.3 cigarettes/day]. Scientific Significance: Data support continued study of bupropion in depressed pregnant substance-dependent smokers. PMID: 20141396 [PubMed - in process] (Source: The American Journal of Drug and Alcohol Abuse)

Bupropion Plus Naltrexone Improves Weight Loss in Obese Patients

Bupropion plus naltrexone led to greater weight loss than monotherapy or placebo in a preliminary study in obese patients. Reuters Health Information (Source: Medscape Today Headlines)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Watson Laboratories, Inc.]

Updated Date: Dec 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals]

Updated Date: Dec 24, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Combination Antidepressant Therapy More Effective for MDD Than Fluoxetine Alone

The combinations of mirtazapine with fluoxetine, venlafaxine, or bupropion from treatment initiation are more clinically effective when treating MDD than fluoxetine alone. Medscape Medical News (Source: Medscape Today Headlines)

Combination Antidepressant Therapy May Be More Effective for Major Depression Than Monotherapy

Initial treatment with mirtazapine in combination with fluoxetine, venlafaxine, or bupropion is more effective in the treatment of MDD than fluoxetine alone. Medscape Medical News (Source: Medscape Psychiatry Headlines)

Mirtazapine and Bupropion Combined Treatment in Treatment-resistant Depression

We present a case of treatment-resistant depression with fu ...more (Source: Tzu Chi Medical Journal)

Antidepressant Pharmacotherapy in Adults with Type 2 Diabetes: Rates and Predictors of Initial Response.

Conclusions: In patients with type 2 diabetes, poor initial response to antidepressant medication is predicted by multiple factors. Auxiliary treatment of pain and impairment may be required to achieve better outcomes. PMID: 20032276 [PubMed - as supplied by publisher] (Source: Diabetes Care)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia

This study provides preliminary evidence of how polymorphisms in the serotonin transporter can be informative in predicting individual responses to smoking reduction therapy. (Source: Psychiatry Research)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Watson Laboratories, Inc.]

Updated Date: Dec 22, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Journal Scan: Comparative Effectiveness of 5 Smoking Cessation Pharmacotherapies in Primary Care Clinics (Arch Intern Med 2009;169:2148-2155.)

A total of 1,346 primary care patients attending routine appointments were recruited by medical assistants in 12 primary care clinics. Patients were randomly assigned to five active pharmacotherapies: three monotherapies (nicotine patch, nicotine lozenge, and bupropion hydrochloride sustained releas. . . (Source: Cardiosource)

A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment

Conclusions&nbsp;&nbsp;Efficacy of rolipram but not antipsychotics to reverse the effects of bupropion suggests novel cAMP-dependent and D2 receptor-independent mechanisms of the bupropion-induced LI deficit. Further detailed biochemical analysis of bupropion-induced LI deficit might be a fruitful approach in developing new antipsychotics. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1749-3Authors Tatiana Lipina, Mount Sinai Hospital Samuel Lunenfeld Research Institute 600 University Avenue Toronto ON Canada M5G 1X5John Roder, Mount Sinai Hospital Samuel Lunenfeld Research Institute 600 University Avenue Toronto ON Canada M5G 1X5 Journal PsychopharmacologyOnline ISSN 1432-2072Print ISSN 0033-3158 (Source: Psychopharmacology)

In practice, anti-smoking drug combinations give greater smoking quit rates than monotherapy

This study aimed to determine what proportion of smokers visiting a primary care clinic for routine appointments will make a quit attempt when pharmacotherapy is available at no charge, and which of a range of treatments was most effective. Participants were adults smoking 10 or more cigarettes daily who were suitable for treatment with the study medications recruited at a visit to their primary care clinic. They were randomised to receive one of five open-label interventions, three monotherapy and two combinations: nicotine patch, bupropion SR, nicotine lozenge, bupropion SR + lozenge, and patch + ... (Source: NeLM - News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Comparative Effectiveness of 5 Smoking Cessation Pharmacotherapies in Primary Care Clinics [Original Investigation]

Conclusions&nbsp; One in 5 smokers attending a routine primary care appointment was willing to make a serious quit attempt that included evidence-based counseling and medication. In this comparative effectiveness study of 5 tobacco dependence treatments, combination pharmacotherapy significantly increased abstinence compared with monotherapies. Provision of free cessation medications plus quit line counseling arranged in the primary care setting holds promise for assisting large numbers of smokers to quit. Trial Registration&nbsp; clinicaltrials.gov Identifier: NCT00296647 (Source: Archives of Internal Medicine)

Bupropion, a brief history of seizure risk

I was recently having a discussion with a child psychiatry colleague of mine, regarding bulimia nervosa (BN), comorbid depression, and their treatment. We spoke about selective serotonin receptor inhibitors (SSRIs), and then I suggested bupropion perhaps if there was an anergic depression. She stated, ??no, there is an absolute contraindication of bupropion with bulimia. It reduces seizure threshold.? I tried to clarify, ??you mean just immediate release, right, the kind no one uses anymore.? She replied, ??no, I mean bupropion generally, it's in the literature?? (Source: General Hospital Psychiatry)

Bupropion for Depression in Schizophrenia: A Case Report

PharmacopsychiatryDOI: 10.1055/s-0029-1242818© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents  |  Full text (Source: Pharmacopsychiatry)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

Updated Date: Dec 11, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics

Abstract&nbsp;&nbsp;Monoamine neurotransmission is efficiently terminated through synaptic reuptake of released neurotransmitters by high-affinity Na+- and Cl??-dependent neuronal monoamine transporters of the SLC6A family located in the plasma membrane of presynaptic nerve terminals. Recently, a low-affinity, high-capacity Na+- and Cl??-independent plasma membrane monoamine transporter (PMAT) belonging to the SLC29 solute carrier family has been cloned. PMAT was shown to transport monoamine neurotransmitters as well as organic cations such as 1-phenyl-4-methyl-pyridinium (MPP+). Thus, the PMAT which is highly expressed in the human brain may be involved in the modulation of central monoaminergic neurotransmission and it may be a target for drugs used to treat depression and schizoph...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

BUPROPION HYDROCHLORIDEtablet, Film Coated [TEVA Pharmaceuticals USA Inc]

Updated Date: Dec 8, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Blockade of dopamine, but not noradrenaline, transporters produces hyperthermia in rats that lack serotonin transporters.

Authors: Olivier JD, Cools AR, Deen PM, Olivier B, Ellenbroek BA To investigate whether life-long disturbed serotonin neurotransmission may result in adaptive changes of dopaminergic and noradrenergic systems, effects of drugs on stress-induced hyperthermia were studied in serotonin transporter knockout rats. The noradrenalin transporter blocker atomoxetine was more effective in reducing stress-induced hyperthermia, induced by an injection, in serotonin transporter (SERT) knockout (SERT(-/-)) rats compared to SERT(+/+) rats. The dopamine transporter blocker GBR12909 increased the core body temperature in SERT(-/-) rats, and had no effect on the SERT(+/+) rats. Finally, the noradrenalin transporter together with dopamine transporter blocker bupropion was more effective in decreasing the...

Effects of antidepressant treatment on heart rate variability in major depression: a quantitative review

Source: DARE Area: Evidence > Medication Safety CRD Summary: This review concluded that the use of tricyclic antidepressants in patients diagnosed with major depressive disorder lead to changes in heart rate variability that were associated with an increased risk of mortality. The authors' conclusions appeared to reflect the evidence but, given the methodological limitations, these conclusions should be interpreted with caution as they may not be reliable. [Of the included studies, tricyclic antidepressants included amitriptyline, imipramine and doxepin. Selective serotonin reuptake inhibitor medications included fluvoxamine, paroxetine and fluoxetine. Other drugs included bupropion, mirtazapine, nefazodone and reboxetine. ] CRD Commentary: This review addressed a clear question in t...

Wellbutrin alternative didn't help

Is there anything new on the generic version of Wellbutrin XL? My wife had done well on the brand name and then the Watson generic bupropion for several years. She was abruptly switched to Teva's Budeprion last spring. Her depression returned. (Source: L.A. Times - Health)

Antidepressants: Benefit Of Reboxetine Not Proven

There is no scientific proof that people suffering from depression can benefit from taking reboxetine. However, clinical trials do provide proof of benefit of bupropion XL and mirtazapine: both agents can alleviate symptoms. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care (IQWiG) published on 24 November 2009. (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Benefit of Reboxetine Antidepressant not Proven

There is no scientific proof that people suffering from depression can benefit from taking reboxetine. However, clinical trials do provide proof of benefit of bupropion XL and mirtazapine: both agents can alleviate symptoms. (Source: Disabled World)

Antidepressants: Benefit of reboxetine not proven

(Institute for Quality and Efficiency in Health Care) There is no scientific proof that people suffering from depression can benefit from taking reboxetine. However, clinical trials do provide proof of benefit of bupropion XL and mirtazapine. This is the conclusion of the final report of the Institute for Quality and Efficiency in Health Care published on Nov. 24, 2009. The final evaluation of reboxetine and mirtazapine was only possible after manufacturers disclosed data that had previously been concealed. (Source: EurekAlert! - Social and Behavioral Science)

Gemfibrozil-Induced Myositis in a Patient with Normal Renal Function (January).

CONCLUSIONS: Although the risk of myositis appears to be low with gemfibrozil monotherapy, clinicians should be aware of the potential for this adverse event. For patients taking gemfibrozil monotherapy who present with myalgia, discontinuation of the medication may be necessary for the alleviation of pain. PMID: 19934390 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Bupropion: Delirium in a patient with bipolar disorder: case report

(Source: Reactions)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Incidence and onset of delayed seizures after overdoses of extended-release bupropion. - Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S.

This study systematically evaluates the frequency and timing of seizures and an association between other toxic effects (ie, agitation, tremors, and hallucin... (Source: SafetyLit: All (Unduplicated))

The Cost-Effectiveness of an Extended Course (12&nbsp;+&nbsp;12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO Model

Conclusions: A total of 12 weeks of varenicline followed by a further 12-week course for successful quitters is a highly cost-effective alternative compared with currently available smoking cessation options. (Source: Value in Health)

BUPROPION (Bupropion Hydrochloride) Tablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: Nov 10, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Repeated medication-assisted smoking cessation may be effective

Source: Arch Internal Med Area: News A case series report suggests that smokers who fail to quit after one cycle of pharmacotherapy may benefit from repeated cycles. &nbsp; The authors note that while controlled trials show benefit in improving quit rates in smokers using cessation therapy, many will not be successful on the first attempt and there is little published information on the outcome of subsequent attempts. They therefore followed a cohort of smokers who were offered up to four courses of pharmacotherapy for smoking cessation over a two year period. &nbsp; The cohort was recruited from rural primary care clinics in Kansas USA; there were 726 initially and they were offered pharmacotherapy to help quitting at six month intervals. Options offered were nicotine replacement...

Addition of psychotherapy to medication in patients with inadequate response to antidepressants no better than optimisation of pharmacotherapy?

Source: Arch Gen Psychiatry Area: News The results of a study (REVAMP trial) designed to evaluate the effects of adding psychotherapy to medication in patients with chronic depression not responding adequately to a trial of antidepressants has been published in the Archives of General Psychiatry.&nbsp; &nbsp; The trial included chronically depressed patients with a major depressive episode (according to DSM-IV criteria) who had persistent depressive symptoms for more than two years.&nbsp; There were two 12-week phases.&nbsp; During phase 1 (n=808), patients were assigned to receive an antidepressant according to an algorithm, based on their previous response to treatment (choices were escitalopram, sertraline, bupropion SR, venlafaxine SR, or mirtazapine).&nbsp; Patients achieving les...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Nicotine patch plus lozenge best for smoking cessation?

Source: Arch Gen Psychiatry Area: News The results of a randomised, placebo-controlled trial evaluating the relative efficacies of nicotine lozenges, nicotine patches, bupropion, nicotine patches plus nicotine lozenges, and bupropion plus nicotine lozenges in smoking cessation has been published in the Archives of General Psychiatry. &nbsp; A total of 1,504 adult smokers were recruited into this US study; all smoked an average of ?10 cigarettes per day for at least the past 6 months and were motivated to quit smoking.&nbsp; Those using any other form of tobacco, currently taking bupropion, or with a current psychosis or schizophrenia diagnosis were excluded from the study.&nbsp; Participants were randomised in a double-blind fashion to one of the following, in addition to individual c...

ORIGINAL ARTICLE: A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies

Conclusion&nbsp; While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those reported in previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation. (Source: Archives of General Psychiatry)

A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies [Original Article]

Conclusion&nbsp; While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those reported in previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation. (Source: Archives of General Psychiatry)

Combination Smoking Cessation Therapy Increases Abstinence Rates in Teens

The first study of combination therapy of bupropion SR and contingency management for smoking cessation in adolescents suggests that a combination of the 2 is superior to either treatment alone. Medscape Medical News (Source: Medscape Today Headlines)

Treatment for SRI-Linked Sex Problems Studied

SANTA FE, N.M. ?? Skip the yohimbe. Don't switch your patients to bupropion, and don't tell them to stop taking their antidepressants before the weekend. Men and women who develop sexual dysfunction while on serotonin reuptake inhibitors (SRIs) should be treated with phosphodiesterase-5 (PDE-5) inhibitors, Dr. H. George Nurnberg told attendees at an annual psychiatric symposium sponsored by the University of Arizona. He dismissed as ??clinical folklore? virtually all the commonly used remedies for sexual dysfunction associated with SRIs. (Source: Ob.Gyn. News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Use and reimbursement costs of smoking cessation medication under the Quebec public drug insurance plan.

CONCLUSION: The reimbursement provisions put in place in Quebec in 2000 were successful in reaching financially disadvantaged smokers, at a cost that was comparable with other effective smoking cessation services. PMID: 20209733 [PubMed - in process] (Source: Canadian Journal of Public Health)

The Roles of Dopamine Transport Inhibition and Dopamine Release Facilitation in Wake Enhancement and Rebound Hypersomnolence Induced by Dopaminergic Agents

Conclusions: All DA releasing agents tested, and some DAT-inhibiting agents, produced RHS at equal wake-promoting doses. Thus amphetamine-like DA release appears sufficient for inducing RHS, but additional properties (pharmacologic and/or pharmacokinetic) evidently underlie RHS of other DAT inhibitors. Enhancing wake while mitigating RHS can be achieved by combining DAT-inhibiting and DA-releasing agents. Keywords: Sleep/wake, dopamine transporter, amphetamine, hypersomnolence, pharmacokinetic, rat (Source: Sleep)

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.

Authors: Wilcox CS, Oskooilar N, Erickson JS, Billes SK, Katz BB, Tollefson G, Dunayevich E A combination of sustained release (SR) naltrexone (32mg/day) and bupropion SR (360mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain. Thirty overweight or obese nicotine-dependent subjects were enrolled in a 24-week, open-label study; 85% and 63% completed 12 and 24weeks, respectively. The target quit date was Week 4. Week 4-12 continuous abstinence rate was 48%, 78% of subjects achieved CO&lt;/=10ppm, serum cotinine decreased from 185 to 48mug/L, and tobacco use decreased from 129 to 14 cigarettes/week. Similar results were seen at Week 24. Body weight was essentially unchanged (Week 12: -0.1%; Week 24: ...

Gestational Exposure to Antidepressants and the Risk of Spontaneous Abortion: A Review.

Conclusions. This review suggests that gestational exposure to antidepressants, especially paroxetine and venlafaxine, can lead to spontaneous abortion. PMID: 19863482 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)

Effects of Treatment for Tobacco Dependence on Resting Cerebral Glucose Metabolism

Authors: Matthew R Costello, Mark A Mandelkern, Stephen Shoptaw, Stephanie Shulenberger, Stephanie K Baker, Anna L Abrams, Catherine Xia, Edythe D London & Arthur L Brody Keywords: tobacco dependence, nicotine, cigarette, 18F-fluorodeoxyglucose&#8211;positron emission tomography (FDG&#8211;PET), statistical parametric mapping, bupropion HCl (Source: Neuropsychopharmacology)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

A randomised trial of glucose tablets to aid smoking cessation

Conclusions&nbsp;&nbsp;No significant effect of glucose tablets over and above sweet tasting tablets could be detected overall, but the possibility of an effect as an adjunct to NRT or bupropion merits further investigation. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1692-3Authors Robert West, University College London Cancer Research UK Health Behaviour Research Centre, Department of Epidemiology and Public Health London WC1E 6BT UKSylvia May, University College London Health Behaviour Research Centre London UKAndy McEwen, University College London Health Behaviour Research Centre London UKHayden McRobbie, University of Auckland Clinical Trials Research Unit Auckland New ZealandPeter Hajek, Barts and the London, Queen Mary??s School of Med...

BUPROPION (Bupropion Hydrochloride) Tablet, Extended Release [Physicians Total Care, Inc.]

Updated Date: Oct 26, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Contract Pharmacy Services-PA]

Updated Date: Oct 22, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo.

Conclusions: NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates. Further study is needed to demonstrate long-term efficacy and safety of NB. PMID: 19846734 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

Updated Date: Oct 20, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Cocaine Addiction

Journal of Medicinal Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of Medicinal Chemistry)

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. - Gunnell D, Irvine D, Wise L, Davies C, Martin RM.

OBJECTIVE: To determine whether varenicline, a recently licensed smoking cessation product, is associated with an increased risk of suicide and suicidal behaviour compared with alternative treatments bupropion and nicotine replacement therapy. DESIGN: Coho... (Source: SafetyLit: All (Unduplicated))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [SmithKline Beecham Corporation]

Updated Date: Oct 9, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Intravenous Lipid Emulsion as Antidote (review)

CONCLUSION: Available data, though limited,  suggest that ILE may be beneficial in treating life-threatening cardiotoxicity induced by highly lipophilic drugs.  Physicians managing these cases should follow established guidelines and consult at an early stage with a poison center. (66 references) COMMENT:  This thoughtful review is well worth reading. Although ILE is not yet ready for routine use in the early stages of resuscitation, many toxicologists would recommend it as a last-ditch effort when a lipophilic drug has caused cardiovascular collapse not improved by standard treatment.  The strongest statement to this effect has been by Jeffrey Brent in a recent editorial: &#8220;It is fair to say that based on what we know so far, no patient dying of cadiotoxic drug poisoning should d...

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database

Source: BMJ Area: News According to the authors of a cohort study published early online in the British Medical Journal, an increased risk of self-harm with varenicline cannot be ruled out.&nbsp; They do note however that their results 'provide some reassurance concerning its association with suicidal behaviour'. &nbsp; The MHRA issued a warning in December 2007, after reports of depression and suicidal thoughts among people prescribed varenicline; further warnings were issued in July and November 2008.&nbsp; Similar warnings have been issued by regulatory authorities worldwide, and the US FDA recently required the manufacturers of both varenicline and bupropion to add a new "boxed warning" to the product labelling based on the continued review of post-marketing adverse event reports....<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Chantix-Suicide Link Questioned

Earlier this year, the FDA ordered a "black box" warning be added to the drugs Chantix (varenicline) and Zyban (bupropion), which are both used as aids in quitting smoking. ... (Source: About.com Depression)

Smoking Cessation Strategies Now Numerous: Try nicotine replacement therapy plus bupropion or high-dose NRT plus nicotine gum or lozenges.

ESTES PARK, COLO. ?? Three major drug classes with diverse mechanisms of action are now approved for smoking cessation, providing an unprecedented array of options in terms of sequential and combination therapies. (Source: Clinical Psychiatry News)

Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries

Conclusions: Although all INMBs were positive, there were significant differences across countries. These were primarily related to choice of discount rate and epidemiology of diseases. (Source: Value in Health)

Incidence and onset of delayed seizures after overdoses of extended-release bupropion

Conclusion: Delayed seizure onset suggests a minimum observation period of 24 hours after bupropion XL overdose. Although patients experiencing agitation or tremors may be at greater risk, seizures can occur without preceding central nervous system toxicity. (Source: The American Journal of Emergency Medicine)

Efficacy of pharmacotherapies for short-term smoking abstinence: A systematic review and meta-analysis.

Background: Smoking cessation has important immediate health benefits. The comparative short-term effectiveness of smoking cessation interventions is not well known. We aimed to determine the relative effectiveness of nicotine replacement therapy (NRT), bupropion and varenicline at 4 weeks post-target quit date. Methods: We searched 10 electronic medical databases (inception to October 2008). We selected randomized clinical trials [RCTs] evaluating interventions for our primary outcome of abstinence from smoking at at-least 4 weeks post-target quit date, with biochemical confirmation. We conducted random-effects odds ratio (OR) meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and calculated indirect comparisons. Results: We com...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats

Conclusion&nbsp;&nbsp;The reinforcement enhancing effects of nicotine and bupropion increased over time and repeated treatments suggesting a shared mechanism of action. However, the reinforcement enhancing effects of nicotine are mediated by nicotinic acetylcholine receptors, whereas the reinforcement enhancing effects of bupropion were mediated by alpha noradrenergic receptors. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1666-5Authors Matthew I. Palmatier, Kansas State University Department of Psychology 469 Bluemont Hall Manhattan KS 66502 USAMelissa E. Levin, University of Pittsburgh Department of Psychology Pittsburgh PA 15260 USAKara L. Mays, University of Pittsburgh Department of Neuroscience Pittsburgh PA 15260 USAEric C. Donny, Unive...

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This generally well-conducted review assessed the efficacy and safety of treatments for attention-deficit hyperactivity disorder in adults. The authors concluded that the use of immediate release methylphenidate as a first-line treatment was supported. The questionable quality of many of the included studies and some concerns over the appropriateness of the synthesis may mean these conclusions were overstated. [Studies of the following treatments were eligible: amphetamine mixture, dextroamphetamine sulphate, methylphenidate HCl, dexmethylphenidate HCl, modafinil, atomoxetine HCl and bupropion HCl. ] CRD Commentary: The review question and inclusion criteria were clearly specified. The authors searched a number of rele...

Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables

Abstract: Although some individuals who abuse methamphetamine have considerable cognitive deficits, no prior studies have examined whether neurocognitive functioning is associated with outcome of treatment for methamphetamine dependence. In an outpatient clinical trial of bupropion combined with cognitive behavioral therapy and contingency management (Shoptaw, S., Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W., 2008. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 96, 222-232.), 60 methamphetamine-dependent adults completed three tests of reaction time and working memory at baseline. Other variables that were collected at baseline included measures of ...

[Care Results in a Specialist Stop-Smoking Unit.]

CONCLUSIONS: A stop-smoking clinic that is designed according to SEPAR Recommendations is effective and has a good cost/effective ratio. PMID: 19758742 [PubMed - as supplied by publisher] (Source: Archivos de Bronconeumologia)

Bupropion decreases resting motor threshold: A case report

Conclusions: Bupropion 300 mg/d increased cortical excitability as demonstrated by decreased RMT. This finding emphasizes the importance of assessing RMT regularly during rTMS treatment, especially in the context of new or changed doses of medications. (Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

UCLA researchers develop biomarker for rapid relief of major depression

It is a long, slow slog to treat major depression. Many antidepressant medications are available, but no single biomarker or diagnostic test exists to predict which one is right for an individual. As a result, for more than half of all patients, the first drug prescribed doesn't work, and it can take months to figure out what does. Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary. The study, called the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression, or BRITE-...

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Psychother Psychosom 2009;78:391-393 (DOI:10.1159/000235985) (Source: Karger Publishers)

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder

We examined the Antidepressant Treatment Response (ATR) index as a predictor of differential response and remission to escitalopram, bupropion, or a combination of the two medications, in subjects with major depressive disorder (MDD). Three hundred seventy-five subjects had a baseline quantitative electroencephalographic (QEEG) study preceding 1 week of treatment with escitalopram, 10 mg, after which a second QEEG was performed and the ATR index was calculated. Subjects then were randomized to continue escitalopram, switch to bupropion, or receive a combination of the two. Clinical response was assessed using the 17-item Hamilton Depression Rating Scale at 49 days of treatment. Accuracy of ATR in predicting response and remission was calculated. There were no significant differences betwe...

Bupropion-Induced Neck and Shoulder Pain

Pharmacopsychiatry 2009; 42: 203-204DOI: 10.1055/s-0029-1220934© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents  |  Full text (Source: Pharmacopsychiatry)

Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation: A BENESCO Markov Cost-Effectiveness Analysis

(Source: Clinical Drug Investigation)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Recalls and Safety Alerts: Warning on Neuropsychiatric Effects from Smoking Cessation Drugs

FDA is requiring that two drugs used to help people stop smoking carry new warnings about the risk of serious neuropsychiatric effects. The drugs are Chantix (varenicline) and Zyban (bupropion). The same warnings will be required for other bupropio... (Source: Food and Drug Adminstration (FDA): Patient Safety News)

Significant Weight Loss Shown With Naltrexone/Bupropion Combo

NEW ORLEANS ?? An investigational oral agent that combines naltrexone and bupropion produced clinically meaningful weight loss at 56 weeks, results from a multicenter phase III trial showed. (Source: Cardiology News)

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [SmithKline Beecham Corporation]

Updated Date: Aug 31, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6.

Authors: Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF CYP2B6 is mainly expressed in the liver that has been thought historically to play an insignificant role in human drug metabolism. However, increased interest in this enzyme has been stimulated by the discovery of polymorphic and ethnic differences in CYP2B6 expression, identification of additional substrates for CYP2B6, and evidence for co-regulation with CYP3A4. This paper updates our knowledge about the structure, function, regulation and polymorphism of CYP2B6. CYP2B6 can metabolise approximately 8% of clinically used drugs (n &gt; 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol. CYP2B6 is one of the CYP enzymes that bioactivate sever...

Table of Contents

Transdermal Methylphenidate Absorption Differs Based on Patch's Application SiteBipolar Youths Receiving Mood Stabilizers Show Some Cognitive Impairments in StudyMethylphenidate Side Effects in Childhood Cancer SurvivorsQuetiapine Equal to Placebo for Teen Bipolar DepressionADHD Treatment: Duration of Action of LisdexamfetamineAripiprazole Assessed for Bipolar Disorder Comorbid With ADHDControlled Atomoxetine Trial for ADHD Children in RussiaPregabalin for Treating Dysautonomic CrisisAripiprazole for Psychosis in a Child With Arachnoid CystBlack Box Warnings for Bupropion and VareniclineAtomoxetine Safety Labeling Changes (Source: The Brown University Child & Adolescent Psychopharmacology Update)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Saudi bans anti-smoking drugs

Saudi Arabia&#039;s Ministry of Health has banned two popular smoking cessation drugs as their side-effects include suicidal tendencies, the Saudi Gazette has reported. The drugs containing varenicline, with the trade name of Champix from Pfizer, and Bupropion were banned after the US Food and Drugs Administration (FDA) had issued a black box warning, the toughest warning on risks associated with a medicine, on serious mental health risks of the drugs. (Source: Healthcare)

Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder

AbstractStudies so far have provided contradictory results on immune system markers during use of antidepressants. There are no data on changes in immune parameters after treatment augmentation. The present study aimed to clarify whether the addition of bupropion in escitalopram-resistant patients with major depression causes changes in the immune system and whether treatment response could be predicted by baseline levels of cytokines. We recruited 28 depressive patients (11 men and 17 women) who did not respond to 12-week treatment with escitalopram (20&nbsp;mg/d) for an augmentation trial with bupropion (150&ndash;300&nbsp;mg/day). The levels of soluble interleukin-2 receptor, interleukin-8 (IL-8) and tumor-necrosis factor- were measured before and 6&nbsp;weeks after addition of bupropio...

Use Generic Zyban to Quit Unhealthy Habit of Smoking

Generic Zyban is the smoking cessation drug that helps the smokers to quit the unhealthy habit of smoking. Generic Zyban contains Bupropion as an active constituent that helps the person to overcome the unhealthy habit of smoking. It reduces the person urge to smoke. The habit of smoking is hard to... (Source: Networks Talk)

Sexual side-effects of contemporary antidepressants: review.

Authors: Schweitzer I, Maguire K, Ng C The aim of the present study was to review the sexual side-effects of contemporary antidepressants in Australia, comparing the selective serotonin re-uptake inhibitors (SSRIs) with venlafaxine, reboxetine, mirtazepine, duloxetine, bupropion, desvenlafaxine and agomelatine. Double-blind, randomized comparative studies of these antidepressants that included assessment of sexual dysfunction with validated rating scales in patients with major depressive disorder were identified from the literature using MEDLINE, EMBASE and PsychINFO databases. Bupropion and duloxetine caused significantly less sexual dysfunction than the SSRIs in short-term studies and reboxetine significantly less in both short- and longer term studies. Bupropion and agomelatine caus...

Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States

Conclusion&nbsp;&nbsp;Regardless of the treatment used, minority smokers in the US have lower smoking abstinence after treatment for tobacco dependence. Future research should focus on the improvement in treatment strategies for minority smokers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10389-009-0277-2Authors Ivana T. Croghan, Mayo Clinic College of Medicine 200 First Street SW Rochester MN 55905 USARichard D. Hurt, Mayo Clinic College of Medicine 200 First Street SW Rochester MN 55905 USAJon O. Ebbert, Mayo Clinic College of Medicine 200 First Street SW Rochester MN 55905 USAGary A. Croghan, Mayo Clinic College of Medicine 200 First Street SW Rochester MN 55905 USAOctavius D. Polk, Howard University Cancer Center 2041 Georgia Avenue, N.W. Washington DC ...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Table of Contents

Lithium Fails to Show Efficacy for Mild Alzheimer's DiseaseStudy Finds Important Differences Between Young and Old Bipolar Manic PatientsMirtazapine-Induced HyponatremiaIncreased Dementia Risk Linked to Long-Term Benzodiazepine UseAcetylcholinesterase Inhibitors Studied in a Real-World SettingEditorial Weighs in on Lithium and Alzheimer'sCombination Cilostazol and Donepezil Treatment for ADAdjunctive Valproate and Pleural EffusionBlack Box Warnings for Bupropion and VareniclineAtomoxetine Safety Labeling Changes (Source: The Brown University Geriatric Psychopharmacology Update)

Use Generic Zyban to Quit Unhealthy Habit of Smoking

Generic Zyban is the smoking cessation drug that helps the smokers to quit the unhealthy habit of smoking. Generic Zyban contains Bupropion as an active constituent that helps the person to overcome the unhealthy habit of smoking. It reduces the person urge to smoke. The habit of smoking is hard to... (Source: Networks Talk)

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [SmithKline Beecham Corporation]

Updated Date: Aug 3, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Smoking Cessation Drugs Get Boxed Warning

Accumulating reports of serious neuropsychiatric symptoms associated with the smoking cessation medications varenicline and bupropion have prompted the Food and Drug Administration to require new boxed warnings for the drugs. (Source: Internal Medicine News)

News from the FDA

Accumulating reports of serious neuropsychiatric symptoms associated with the smoking cessation medications varenicline and bupropion prompted the Food and Drug Administration to require new boxed warnings for the drugs. (Source: Family Practice News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Smoking Cessation Drugs Get Boxed Warning

Accumulating reports of serious neuropsychiatric symptoms associated with the smoking cessation medications varenicline and bupropion have prompted the Food and Drug Administration to require new boxed warnings for the drugs. (Source: Clinical Psychiatry News)

Smoking cessation pharmacotherapy

Cigarette smoking remains an important risk factor for premature cardiovascular disease and its many complications. There are clear benefits from treating tobacco dependence on the rate of clinical outcomes. In addition to behavioral therapies, various pharmacologic strategies have been developed to help achieve this goal. First-line therapies include nicotine replacement, bupropion and varenicline, a partial nicotine antagonist. Second-line treatments include clonidine and nortriptyline. Additional treatment strategies with less proven efficacy include monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, opioid receptor antagonists, bromocriptine, anti-anxiety drugs, nicotinic receptor antagonists (e.g. mecamylamine) and glucose tablets. Various approaches under investig...

Bupropion/escitalopram: Skin disorders: 2 case reports

(Source: Reactions)

Zyban (Bupropion Hcl) - updated on RxList

Zyban (Bupropion Hcl) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Wellbutrin SR (Bupropion Hydrochloride Sustained-Release) - updated on RxList

Wellbutrin SR (Bupropion Hydrochloride Sustained-Release) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia

Abstract: Background: Patients with schizophrenia have higher rates of smoking (58??88%) than in the general population (?22%), and are more refractory to smoking cessation. These patients also exhibit numerous neurocognitive deficits, some of which may be ameliorated by cigarette smoking. The neurocognitive benefits derived from nicotine may, in turn, contribute to elevated rates of smoking and smoking persistence in schizophrenia. The present study examined the relationship between neurocognitive function and smoking cessation in schizophrenia.Methods: Treatment-seeking smokers with schizophrenia (N=58) participated in a 10-week placebo-controlled trial of sustained-release (SR) bupropion plus transdermal nicotine patch. Neuropsychological performance was evaluated in a subset of pati...

The Novel Nicotinic Receptor Antagonist, N,N'-Dodecane-1,12-diyl-bis not-3-picolinium Dibromide (bPiDDB), Inhibits Nicotine-evoked [(3)H]Norepinephrine Overflow from Rat Hippocampal Slices.

Authors: Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP Smoking is a significant health concern and strongly correlated with clinical depression. Depression is associated with decreased extracellular NE concentrations in brain. Smokers may be self-medicating and alleviating their depression through nicotine stimulated norepinephrine (NE) release. Several antidepressants inhibit NE transporter (NET) function, thereby augmenting extracellular NE concentrations. Antidepressants, such as bupropion, also inhibit nicotinic receptor (nAChR) function. The current study determined if a recently discovered novel nAChR antagonist, N,N'-dodecane-1,12-diyl-bis not-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked NE release from superfused rat hippocampal slices. Previou...

Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment.

Beliefs about medication are associated with treatment adherence and outcome. This is a secondary analysis of the role of beliefs and attitudes about bupropion in treatment adherence and smoking cessation outcomes using data from a smoking cessation trial of open-label sustained-release (SR) bupropion therapy reported previously (Toll et al., 2007). Positive beliefs and attitudes were positively correlated with intentions, desire, confidence, and motivation to quit smoking; expectation of quitting success; perceived benefits of quitting; and perceived disadvantages of smoking. Positive beliefs were also associated with greater medication adherence, an increased likelihood of completing treatment and being continuously abstinent, and a delayed latency to smoking lapse. These findings provid...

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [SmithKline Beecham Corporation]

Updated Date: Jul 9, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Mylan Pharmaceuticals Inc.]

Updated Date: Jul 9, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [SmithKline Beecham Corporation]

Updated Date: Jul 9, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

FDA: Boxed Warning On Serious Mental Health Events To Be Required For Chantix And Zyban

The U.S. Food and Drug Administration announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs. (Source: Health News from Medical News Today)

Warnings for smoking-cessation drugs varenicline, bupropion

Smoking-cessation drugs varenicline and bupropion must carry a boxed warning in their labeling stating that use of the drugs has been associated with serious mental-health events, the US FDA has announced. (Source: theHeart.org)

Chantix and Zyban to Receive Boxed Warnings for Serious Neuropsychiatric Symptoms

Varenicline and bupropion are receiving boxed warnings regarding the risks for changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. Medscape Medical News (Source: Medscape Today Headlines)

Popular Stop-Smoking Drugs to Carry Mental Health Risk Warnings

WASHINGTON (MedPage Today) -- The FDA announced that it will require the labels of varenicline (Chantix) and bupropion (Zyban, Wellbutrin, and generics) to carry boxed warnings on the risk of serious neuropsychiatric symptoms starting today. (Source: MedPage Today Campaign '08)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

FDA: Boxed Warning on Serious Mental Health Events to be Required for Chantix and Zyban

The U.S. Food and Drug Administration today announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs. (Source: Food and Drug Administration)

Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)

FDA requires new Boxed Warnings and patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms (Source: FDA MedWatch)

Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes.

Authors: Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR The ability to quit smoking successfully displays substantial heritability in classical and molecular genetic studies. Twin studies suggest that some of the genetics for the ability to quit overlap with genetic components of nicotine dependence, but many do not. Genome-wide association (GWA) studies have demonstrated haplotypes that distinguish successful quitters from individuals who were not able to quit smoking in: i) clinical trials that employed nicotine replacement; ii) clinical trials that employed bupropion; and iii) community quitter samples. We now report novel GWA results from participants in a clinical trial that document the efficacy of adjunctive use of denicotinized cigarettes. These results buttress data...

Drug Combo Leads to Significant Weight Loss

NEW ORLEANS ?? An investigational oral agent that combines naltrexone and bupropion produced clinically meaningful weight loss at 56 weeks, results from a multicenter phase III trial showed. (Source: Clinical Endocrinology News)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

HIV & smoking in India.

Authors: Kumar SR, Swaminathan S, Flanigan T, Mayer KH, Niaura R There are approximately 2.5 million people living with HIV/AIDS (PLWHA) in India - the young being particularly vulnerable. The prevalence of smoking has increased in India especially among rural, lower socio-economic and illiterate men. Studies have shown that HIV-infected smokers may be at additional risk for several infectious and non-infectious complications, including malignancies and cardiovascular events. Smoking alters immunological mechanisms and suppresses host defenses in the alveolar environment. HIV-infected smokers have also been found to have a poorer response to antiretroviral therapy and a higher risk of death. HIV-infected individuals who smoke could be at a greater risk for developing TB and subsequentl...

Selective serotonin-reuptake inhibitor and norepinephrine dopamine reuptake inhibitor antidepressants do not affect natural killer cell activity in vitro

CONCLUSIONS: PBMCs dead cells occurred in both groups and in proportion to all pharmacological concentrations. Nevertheless, the NKA was not affected, even with the reduction in the number of effective cells.OBJETIVO: Avaliar o efeito citotóxico de dois antidepressivos comumente utilizados na prática, a paroxetina e a bupropriona. Além disso, buscou-se avaliar a atividade natural killer (ANK) após a incubação dos linfócitos com esses fármacos. M?TODOS: Sangue venoso de 15 participantes foi coletado e as células mononucleares (PBMCs) foram separadas e incubadas por 24h com (ou sem = grupo-controle) concentrações de paroxetina e bupropiona em 30, 100 e 1.000 ng/ml. Após a incubação, a quantidade das células mortas foi contada utilizando-se o método trypan blue. Posteriorment...

The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs Through the Skin for Smoking Cessation.

Authors: Escobar-Ch&#xE1;vez JJ, Merino-Sanju&#xE1;n V, L&#xF3;pez-Cervantes M, Rodr&#xED;guez-Cruz IM, Quintanar-Guerrero D, Ganem-Quintanar A Cigarette smoking is the primary cause of lung cancer, cardiovascular diseases, reproductive disorders and delayed wound healing all over the world; as such, the goals of smoking cessation are both to reduce health risks and to improve quality of life. The development of novel and more effective medications for smoking cessation is crucial in the treatment of nicotine dependence. Currently, first-line smoking cessation therapies include nicotine replacement products and bupropion. The partial nicotinic receptor agonist, varenicline, has recently been approved by the FDA for smoking cessation. A newer product seeking approval by the FDA is nicot...

Bupropion: Tonic-clonic seizures: case report.

Page: 12 (Source: Reactions Weekly)

BUPROPION HYDROCHLORIDE EXTENDED-RELEASE (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

Updated Date: Jun 26, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion is to be funded in New Zealand for smoking cessation

(Source: PharmacoEconomics and Outcomes News)

The impact of smoking cessation on patient quality of life

CONCLUSIONS: Our findings illustrate that smoking abstinence is related to better HRQoL, especially in aspects of mental health.OBJETIVO: Avaliar alterações na qualidade de vida relacionada à saúde (QVRS) doze meses após a cessação tabágica. M?TODOS: Estudo prospectivo para avaliar a efetividade de um programa de tratamento de fumantes, em relação à qualidade de vida, com 60 pacientes atendidos em um hospital público no período de agosto de 2006 a dezembro de 2007. O programa consistiu de sessões em grupo semanais com 2 h de duração durante o primeiro mês e quinzenais até o sexto mês, seguidas por telefonema mensal durante mais seis meses. O tratamento foi baseado na mudança comportamental e no uso de bupropiona associada à terapia de reposição nicotínica. A abstin...

Bupropion: Tonic-clonic seizures: case report

(Source: Reactions)

Artemisinin-a possible CYP2B6 probe substrate?

Aim. To compare in vitro metabolism rates for artemisinin and the CYP2B6 substrates, bupropion, propofol and efavirenz in human liver microsomes.Methods. Rate constants of artemisinin, bupropion, propofol and efavirenz metabolism by human liver microsomes from a panel of 12 donors, with different levels of CYP2B6 activity, were estimated in WinNonlin. Correlations between the metabolic rate constant for artemisinin and the other CYP2B6 substrates were examined.Results. Artemisinin and propofol depletion data in human liver microsomes were described by first order kinetic models. For bupropion and efavirenz, metabolite formation data were incorporated in the model. Rate constants varied considerably for all substrates. There was a high degree of correlation of rate constants between substra...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Actavis South Atlantic LLC]

Updated Date: Jun 23, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Factors associated with the use of aids to cessation in English smokers

Conclusions In England, half of all attempts to quit smoking are aided by some form of pharmacological or behavioural treatment. However, the use of the most effective treatment option (the NHS-SSS) is low, despite it being free of charge. Factors associated with an increased use of aids to cessation were female sex, older age, more cigarettes smoked per day and planning a quit attempt. Research is needed into how to increase utilization rates, particularly among males and younger smokers. (Source: Addiction)

Bupropion: SIADH and altered consciousness: case report

(Source: Reactions)

Bupropion is to be funded in New Zealand for smoking cessation,.

Page: 11 (Source: PharmacoEconomics & Outcomes News)

Bupropion: SIADH and altered consciousness: case report.

Page: 11 (Source: Reactions Weekly)

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR

AbstractThe efficacy, safety and tolerability of bupropion XR and venlafaxine XR was assessed and compared with placebo in adult outpatients with major depressive disorder (MDD). Adults meeting DSM-IV criteria for MDD with a minimum Hamilton Depression Rating Scale (HAMD) 17-Item total score of &ge;18 were randomized to eight weeks of double-blind treatment with either bupropion XR (150&nbsp;mg/day), venlafaxine XR (75 mg/day) or placebo. At the end of the fourth week of treatment, a dosage increase to bupropion XR 300&nbsp;mg/day or venlafaxine XR 150&nbsp;mg/day was allowed if, in the opinion of the investigator, response was inadequate. The primary efficacy endpoint was mean change from baseline at week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score last observat...<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Antidepressants: Preliminary Report Published

Benefit of bupropion proven - Benefit of reboxetine not proven: manufacturer conceals study data On 10 June 2009, the Institute for Quality and Efficiency in Health Care (IQWiG) presented the preliminary results of its benefit assessment of certain newer antidepressants. (Source: Health News from Medical News Today)

Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice

Conclusion&nbsp;&nbsp;The augmentation effects of aripiprazole, in the present study, are in agreement with clinical evidence suggesting that aripiprazole may enhance the efficacy of therapeutic effect of SSRIs and SNRIs but not of NRI. These results suggest that augmentation effect of aripiprazole only appears when 5-HT system is activated and might implicate complex regulation between dopamine and 5-HT1A and 5-HT2A receptors. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1583-7Authors Michel Bourin, Faculté de Médecine 1 EA 3256 Neurobiologie de l??anxiété et de la dépression rue Gaston Veil BP 53508 44035 Nantes cedex 01 FranceFranck Chenu, Faculté de Médecine 1 EA 3256 Neurobiologie de l??anxiété et de la dépression rue Gaston...

Preliminary report on antidepressants published

(Institute for Quality and Efficiency in Health Care) The IQWiG has presented the preliminary results of its benefit assessment of the agents reboxetine, mirtazapine and bupropion XL in the treatment of adult patients with depression. According to this report, the benefit of bupropion is proven. However, this does not apply to reboxetine, as a large amount of study data is not accessible. Interested parties and institutions may submit written comments on the preliminary report up until July 9. (Source: EurekAlert! - Social and Behavioral Science)

Bupropion: Unmasking of psychosis: case report

(Source: Reactions)

A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)

Conclusion: ATX and LAS are the most likely drugs to be used as monotherapy. Factors predicting combination use were similar for months in which ATX was used and for months in which LAS was used except that a hyperactive component to ADHD predicted increased combination use for ATX but not for LAS. (Source: BMC Health Services Research)<div id="medworm"><p><b><i>MedWorm Sponsor Message:</i></b> Find the best <a href="http://www.thejanuarysales.com/">Christmas Sales</a>, <a href="http://www.thejanuarysales.com/">Boxing Day Sales</a> and <a href="http://www.thejanuarysales.com/">January Sales</a> <a href="http://www.thejanuarysales.com/">here</a>.</p></div>

Bupropion: Unmasking of psychosis: case report.

Page: 11 (Source: Reactions Weekly)

Weight loss combination shows efficacy in phase 3 trial

A combination of naltrexone and bupropion produces a significant, 4.7% greater weight loss than placebo when combined with behavior modification, according to phase 3 study results. (Source: Modern Medicine)

Would You Like to Record Your Side Effects for later use? It is Free and Easy. >> Start Today

Spread the word: Share, Email, Print



How Effective was Bupropion for You? Share Your Positive and Negative Experiences.

blog comments powered by Disqus
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.


Thank you for visiting Patientsville.com.